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ABSTRACT 
SYSTEMS BIOLOGY OF BLOOD COAGULATION AND PLATELET 
ACTIVATION 
Manash Shankar Chatterjee 
Supervisor: Scott L. Diamond 
 
Blood clotting is a highly conserved physiological response that prevents 
excessive blood loss following vessel injury. It involves a sequence of plasma reactions 
leading to the formation of thromin (the coagulation cascade) as well as tightly controlled 
intracellular reactions mediating platelet activation. These two events are inextricably 
coupled, with the active platelet surface serving as a cofactor for coagulation factor 
assembly and thrombin serving as a potent platelet agonist.  Using the technologies of 
automated liquid handling, high throughput experimental systems were developed that 
allowed individual exploration of these two components of the thrombotic response under 
diverse initial conditions. Based on this high dimensional experimental exploration, a 
“bottom-up” mechanism based Ordinary Differential Equation (ODE) description of 
thrombin generation kinetics and a “top-down” data driven Neural Network model of 
platelet activation were developed. In the first study, “contact activation” (and not 
“blood-borne TF” alone) despite the best available inhibitor to prevent it, was found build 
up enough autocatalytic strength to trigger coagulation in the absence of exogenous tissue 
factor, particularly upon activated platelets. Further, the “Platelet-Plasma model” 
successfully predicted the stability of blood under multiple perturbations with active 
enzymes at various physiologically realizable conditions. In the second study, “Pairwise 
 v
Agonist Scanning” (PAS), a strategy that trains a Neural Network model based on 
measurements of cellular responses to individual and all pairwise combinations of input 
signals is described. PAS was used to predict calcium signaling responses of human 
platelets in EDTA-treated plasma to six different agonists (ADP, Convulxin, U46619, 
SFLLRN, AYPGKF and PGE2). The model predicted responses to sequentially added 
agonists, to ternary combinations of agonists and to 45 different combinations of four to 
six agonists (R=0.88). Furthermore, PAS was used to distinguish between the phenotypic 
responses of platelets from healthy human donors. Taken together, these two studies lay 
the groundwork for integration of coagulation reaction kinetics and donor specific 
descriptions of platelet function with models of convection and diffusion to simulate 
thrombosis under flow. 
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Chapter 1 
Introduction 
1.1 Thrombus formation 
Thrombus formation is an efficient mechanism to prevent excessive blood loss 
following vascular damage. Upon vessel wall damage the continuous lining of the 
endothelium is broken and flowing blood is exposed to the connective tissue matrix of the 
subendothelium. Tissue Factor (TF) at the site of vascular damage binds to minute 
quantities of the circulating form of activated factor VII. This triggers the coagulation 
cascade, involving a series of reactions happening either in solution or upon the catalytic 
surface provided by nearby activated platelets. This cascade culminates in the formation 
of the master enzyme thrombin, which once formed can activate platelets, as well as 
participate in its own production and destruction. Platelets are the primary cells involved 
in mediating the thrombotic response. In addition to thrombin formed downstream of the 
coagulation cascade, platelets are efficiently activated by collagen exposed at the site of 
injury.  Moreover, platelets can self activate via released ADP or thromboxane. 
Mediators like prostacyclin (PGI2) or Nitric Oxide (NO) from the intact endothelium can 
down- regulate platelet activation and keep them quiescent. But once the platelets 
encounter a net activating stimulus as a function of the concentration of all of these 
simultaneous signals they proceed via a sequence of signaling steps (one amongst which 
is the elevation of cytosolic calcium concentration) to become fully activated platelets. 
These platelets make up the body of the clot and are held in place by a meshwork of 
 2
polymerized fibrinogen formed downstream of thrombin in the coagulation cascade. This 
process is schematically represented in Figure 1.1-1 and the two individual mechanisms 
that are critical for the formation of the stable platelet plug (platelet activation and the 
cascade of reactions leading to thrombin production) are introduced below. 
 
Figure 1.1-1 Coagulation and platelet activation pathways during thrombosis. 
Haemostasis system involves a delicate balance of mechanisms that maintain fluidity of 
blood under physiological conditions, yet allowing the body to mount a robust response 
to limit blood loss following vascular injury. The coagulation stimulus at the site of 
injury leads to two interlinked responses. First: the exposure of Tissue Factor (TF) at the 
sub-endothelium triggers the coagulation cascade leading to the formation of thrombin. 
Second: platelets are activated according to the prevailing local concentrations of 
thrombin, collagen, ADP, TXA2 and adhere to the growing clot. NO and prostacyclin 
(PGI2) from the intact endothelium downregulate activation and keep platelets quiescent. 
Once the platelet encounters a net activating stimulus there it activates via an elevation of 
cytosolic calcium concentrations. The active platelet surface in turn serves as cofactor for 
several of the enzymatic reactions of the coagulation cascade. 
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1.2 Platelet activation 
The signaling machinery of circulating platelets makes it possible for them to be 
rapidly captured at the site of vascular damage and be transformed into a tight layer that 
stems uncontrolled blood loss. The sequence of events underlying platelet activation can 
broadly be divided into three stages: initial adhesion to a collagen surface, growth of 
thrombus via autocatalytic signaling, and stabilization of the platelet aggregate [1] . 
1.2.1 Initiation of platelet activation on collagen surfaces 
Under static conditions, collagen alone at the exposed injury is able to capture and 
activate platelets. However, under conditions of high shear that exist in the arterial 
circulation, platelet capture also requires the presence of VWF [2]. Two of the collagen 
receptors (α2β1 and GPVI) bind to collagen directly. Of these GPVI is the most potent in 
terms of generating an activating signal. Collagen binding causes GPVI clustering, 
leading to phosphorylation of the Fc receptor γ chain (associated with this receptor) by 
tyrosine kinases of the Src family. Such phospho-tyrosine residues are recognized by Syk 
[3], and the association and activation of Syk activates PLCγ2. PLCγ2 (like other forms of 
PLC) converts phosphatidylinositol (PI)-4, 5 P2 to 1,4,5- IP3and diacyclglycerol (DAG). 
IP3 opens Ca2+ channels in the platelet dense tubular system, and causes rapid store 
operated calcium entry (SOCE), thus quickly raising cytosolic Ca2+ concentrations [4]. 
DAG activates Protein Kinase C (PKC) in platelets, which in turn governs several of the 
serine/ threonine phosphorylation events occurring downstream. PKC activation can 
cause integrin activation, aggregation and secretion independently of Ca2+ [5].  GP1B, 
α2β1 and αIIbβ3, present in abundance on the platelet surface, bind to collagen via 
multimeric VWF (complexed with collagen) under high shear, thus increasing the 
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probability of collagen mediated signaling via GPVI by bringing the ligand and receptor 
in close proximity [6]. 
1.2.2 Growth of the platelet aggregate via autocatalytic signaling  
Beyond the first monolayer of platelets adherent to collagen/ VWF, the addition 
of subsequent layers of platelets to the growing thrombus is strongly potentiated by the 
activity of locally released agonist like thromboxane (TxA2) and ADP, as well as by the 
activity of locally formed thrombin. All 3 of these agonists act signal through specific G-
Protein Coupled Receptors on the platelet surface (GPCRs). 
GPCRs are composed of α, β and γ subunits. The binding of an agonist to its 
receptor causes an exchange of GTP for GDP on the α subunit, and dissociation of the α 
and βγ subunits. Both these units in turn interact with secondary effectors including 
PLCβ and Adenyl Cyclase. Human platelets express at least 10 forms of Gα (including 
members of the Gq , Gi , G12 , and Gs families) [7]. 
Thrombin, ADP, and TXA2 activate PLCβ via Gq. PLCβ generates IP3 from 
membrane PIP2. IP3 triggers Ca2+ release from the intracellular stores and SOCE, thus 
increasing intracellular Ca2+ concentrations from ~100 nM to ~ 1 µM. Rising Ca2+ levels 
activate the Ras family member, Rap1B via Cal-DAG GEF.  Rap1B activation is a 
precursor to αIIbβ3 activation, and allows the platelets to form aggregates with other 
platelets through fibrinogen bridges [8]. 
In addition to integrin activation, shape change is another event that occurs 
downstream of agonist induced platelet activation. There is a Ca2+ dependent activation 
of myosin light chain kinase (Gq driven), and activation of GTP binding proteins of the 
Rho family (GI2 driven) [9]. Rho activation in turn activates kinases like p160ROCK and 
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LIM-kinase, which phosphorylate myosin light chain kinase and cofilin [10, 11], thus 
regulating actin dependent cytoskeletal shape. Shape change is mediated via Gqα for ADP 
and GI3α for thrombin and TXA2. 
Prostacyclin (PGI2) synthesized by the endothelium causes Gsα mediated increase 
in adenyl cyclase activity. Also NO from the endothelium can inhibit the hydrolysis of 
cAMP by intracellular phosphodiesterases [12]. Taken together these mechanisms elevate 
intracellular cAMP levels, which strongly downregulates platelet signaling. Agonists 
coupled to Gi family members inhibit cAMP production in platelets, thus allowing 
activation to proceed unhindered [13]. Additionally the βγ subunits of these receptors can 
activate PLCβ and the γ isoform of PI3K. The effectors for PI3K include Rap1b and Akt 
[14]. Signaling downstream of Akt is not completely understood, but deletion of Akt2 in 
platelets impairs thrombus formation, stability and platelet secretion [15]. 
ADP is stored in platelet dense granules and is released upon activation. P2Y1 and 
P2Y12 are the primary receptors for this agonist [16]. P2Y1 is Gq coupled and signaling 
through this receptor causes Ca2+ mobilization, shape change and thromboxane 
generation. P2Y12 is the target of the commonly used anti-platelet drug Plavix [17], and is 
a Gi2 coupled receptor that inhibits cAMP production in platelets. A third receptor P2X1 is 
an ATP gated channel that allows Ca2+ influx across the plasma membrane [18]. 
Thrombin is a potent platelet agonist that causes fast mobilization of intracellular 
Ca2+, and activation of phospholipase A2 and subsequent thromboxane generation (all 
mediated by Gqα) [19]. Also, thrombin can trigger Rho dependent signaling pathways in 
platelets (mediated by GI3α) [20], that contribute to actin modeling and shape change. 
Thrombin signals through the protease-activated receptor (PAR) family of GPCRs. PARs 
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1 and 4 are expressed on human platelets, while PARs 3 and 4 are expressed on mouse 
platelets. Thrombin cleaves the N-terminus of these receptors, exposing a new N-
terminus that serves as a tethered ligand for these receptors. Synthetic peptides are able to 
selectively activate these receptors and mimic the actions of thrombin (SFLLRN for 
PAR1, and AYPGKF for PAR4) [21]. Kinetic studies have shown that the human platelet 
response to thrombin is biphasic and involves first signaling through PAR1 and 
subsequent signaling through PAR4 [22, 23]. In mouse platelets signaling occurs 
primarily via PAR4, and is facilitated by PAR3. Conflicting evidence exists Gi signaling 
in platelets downstream of thrombin can occur independently of thrombin. In addition to 
the PAR receptors, GP1bα has high affinity for thrombin. Absence of this receptor 
reduces responses to low doses of thrombin and diminishes PAR1 signaling, suggesting 
that this receptor facilitates signaling through the PARs [24, 25]. 
Ca2+ mobilization activates phospholipase A2 (PLA2), which in turn converts 
membrane phospholipids to Arachidonic Acid. TXA2 is produced from membrane 
arachidonate by the aspirin sensitive cyclooxygenase (COX-1) enzyme [26].  TXA2 
causes Ca2+ mobilization, aggregation, secretion, phosphoinositide hydrolysis and protein 
phosphorylation. TXA2 can diffuse across the membrane and activate nearby platelets, 
but its activity is limited by the molecule’s short half life (~30sec). Its effects in vitro can 
be studied using the stable analog U46619. This agonist signals through the TP receptors 
(α and β forms) [26] that signal through Gqα (Ca2+ mobilization) [19] and GI3α (shape 
change) [20]. No Gi mediated inhibition of cAMP formation is caused via TP signaling. 
  The signaling events involved in the initial accumulation of platelets and the 
extension of the platelet aggregate are schematically represented in Figure 1.2-1. 
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Figure 1.2-1 Platelet signaling during development and growth of the thrombus. 
Platelet activation during thrombosis is governed by several simultaneous activating 
signals. Activation by collagen happens predominantly via the receptor tyrosine kinase 
GPVI. Subsequent activation involves signaling through the GPCRs P2Y1 and P2Y12 
(ADP), PAR1 and PAR4 (thrombin), TP (TXA2) and IP (PGI2). Receptors involved are 
shown in red. Under conditions of high shear, VWF allows the platelet to adhere to 
collagen via the GP1b receptor. 
 8
1.2.3 Stabilization of the platelet aggregate 
Because of the close proximity of individual platelets, several close contacts are 
formed between the surface molecules of individual cells in the growing aggregate. This 
sets of additional waves of signaling in the platelets as well and supplies an additional 
source of adhesive force between the cells. Further, interactions between the intracellular 
domains of αIIbβ3 (bound to its ligands fibrinogen and VWF) and the platelet’s 
actin/myosin machinery causes the aggregate to retract upon itself [27], and thus prevent 
complete occlusion of the vessel. 
Outside-in signaling occurs downstream of the formation of fibrinogen bridges 
that link activated platelets together. Several proteins interact with the cytoplasmic 
domains of αIIbβ3 to either regulate integrin activation or outside in signaling. Some of 
these include talin, myosin, C1B1and the tyrosine kinases Src and Syk. Talin binding is 
one of the final events preceding activation. C1B1 can interact indirectly with actin via 
PAK.  Fibrinogen binding to the extracellular domains of causes a rapid increase in the 
activity of Src family members and Syk. These lead to the phosphorylation of the 
residues Y773 and Y785 on the β3 cytoplasmic domain of the integrin. These events are 
required for full aggregation, spreading and clot retraction. [28] 
Platelet Specific Cell Adhesion Molecule (PECAM-1; CD31) is a cell adhesion 
molecule capable of homotypic interactions. The C-terminal of PECAM-1 is 
phosphorylated at tyrosine residues upon activation and can bind to the phosphatases 
Shp-1/2 [29], bringing these enzymes close to their substrates including the Fcγ chain of 
GPVI. This limits the extent of collagen signaling [30]. 
 9
JAM (Junctional Adhesion Molecule)-A and C are cell adhesion molecules that 
localize to platelet-platelet and platelet-leukocyte contacts and mediate adhesive and 
signaling interactions between these cells. These molecules support heterotypic 
interactions by binding to integrins. Also JAM-A contributes to adhesion by forming 
trans interactions involving the N-terminal Ig domain [31, 32].  ESAM (Endothelial Cell 
Specific Adhesion Molecule) [33] and CD226 [34] two other members of the CTX 
family of immunoglobulin domain containing adhesion molecules detected on active 
platelet surfaces. SLAM (signaling lymphocyte activation molecule) [35] and CD84 [36] 
are members of the CD2 family of homophilic adhesion molecules expressed on platelets, 
and become phosphorylated on activation at platelet-platelet contacts. 
Eph kinases are receptor tyrosine kinases that interact in trans with their cell 
surface ligands called ephrins triggering bidirectional signaling. Blockade of this 
interaction causes reversible platelet aggregation and limits the growth of platelet thrombi 
on collagen surfaces. Signaling downstream of these molecules promotes further integrin 
activation (by activating Rap1B) and integrin signaling (by phosphorylating the β3 
cytoplasmic tail of αIIbβ3) [37]. Similarly growth arrest specific gene - 6 (Gas-6) secreted 
from platelet α granules can serve as a ligand for receptor tyrosine kinases Tyro3, Axl 
and Mer and cause signaling that promotes platelet plug formation and stability [38]. 
Aggregation in Gas-6-/- platelets terminates prematurely, and produces a phenotype 
resistant to thrombosis [39]. 
In addition to the numerous proteins secreted from the platelet granules, platelets 
shed several surface molecules including GP1Bα, GPVI and P-selectin [40, 41]. Such 
shedding has been shown to be mediated by metalloproteases such as ADAM17 and 
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serves to limit signaling [40, 42]. CD40 ligand (CD40L) is a membrane protein that 
appears on the surface of activated platelets, and gradually releases an 18-kDa exodomain 
fragment [43]. The extracellular portion of CD40L can bind to their receptors (CD40) as 
well as integrin. Growth of platelet plugs in CD40L-/- show defective thrombus growth 
over collagen, decreased stability, and delayed occlusion. These effects are presumably 
mediated by integrin since loss of CD40 has no appreciable effect [44].    
1.3 The blood coagulation cascade 
Under normal conditions in vivo, the intact endothelium inhibits platelet activation 
and the chain of plasma reactions known as the coagulation cascade. Upon vascular 
damage, exposed collagen initiates platelet activation, and TF initiates the clotting 
cascade. The cascade involves a series of sequential enzymatic reactions, wherein at 
every step an inactive zymogen is converted into an active enzyme typically by the 
product of the previous step, ultimately leading to the formation of thrombin. With the 
exclusion of thrombin, such newly formed enzymes have low activity, until they bind to 
specific protein cofactors or suitable phospholipid surfaces (typically the active platelet).  
This cascade is traditionally divided into “extrinsic” (or Tissue Factor) pathway 
and “intrinsic” (or contact) pathway leading to the formation of factor Xa. The portion of 
the cascade beyond factor Xa, leading to the formation of thrombin is referred to as the 
“common” pathway. These pathways happen in the presence of plasma inhibitors that 
limit the activity of the active proteases that are formed. These events are schematically 
represented in Figure 1.3-1. Downstream of thrombin, fibrinogen is polymerized during 
the process of fibrin formation, and the fibers of fibrin hold the loose platelet aggregate 
together. The formed fibrin strands are degraded during the process of fibrinolysis.  [45] 
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Figure 1.3-1 The reactions of the coagulation cascade generating thrombin. 
The Coagulation cascade involves multiple sequential plasma reactions that lead to the 
generation of thrombin. Zymogens (red) are converted to active enzymes (green) by the 
products of the preceding reactions in the cascade, aided in some cases by active 
cofactors (light blue). Several plasma inhibitors (red) serve to inhibit the active proteases. 
The cascade is triggered either by the exposure of TF at the site injury (extrinsic cascade) 
or by activation of factor XII adsorbed onto negatively charged surfaces (intrinsic 
cascade). Both pathways ultimately lead to the formation of thrombin. Thrombin formed 
(in addition to other platelet agonists) can activate platelets. The active platelets provide 
catalytic surface for several of these reactions. Contact activation can be minimized in 
vitro by using Corn Trypsin Inhibitor (CTI) to block XIIa. 
 
1.3.1  The extrinsic pathway 
The predominant initiator of the coagulation cascade in vivo is the extrinsic 
system, involving exposure of the molecule Tissue Factor (TF) at the site of vascular 
damage. TF is normally absent from on cells in contact with plasma, but is present on a 
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variety of cells outside the vasculature [46]. TF exposure, allows it to bind to the 
activated form of one of the soluble clotting factors: factor VII. Factor VII is one of a 
group of vitamin K-dependent proteins (including factors IX and X, prothrombin and 
protein C) that is secreted by the hepatocytes and contains a γ-glutamyl carboxyl acid 
(Gla) residue at the N terminal of the molecule. This post-translational modification 
allows these molecules to bind calcium subsequently assemble on a phospholipid surface.  
Once formed, the TF:VIIa complex can activates factor IX via limited proteolysis. 
Alternatively, TF:VIIa can directly activate X and this is the kinetically favored 
mechanism in vitro [47]. Activated factor IX can also activate factor X efficiently 
provided the cofactor activated factor VIII is present. This leads to the formation of the 
“tenase” complex critical for X activation. Absence of factor VIII or IX underlies the 
hemorrhagic symptoms of hemophilia A and B respectively [48]. 
Since all of serine proteases and protein cofactors (excluding TF) in the 
coagulation cascade predominantly circulate in plasma as inactive zymogens, it is 
puzzling how this cascade can be triggered via the assembly of inert precursors. It is 
known that approximately 1 % of total factor VII exists in circulation in the form of VIIa 
[49]. Proportions of the active forms of other enzymes are miniscule in comparison. 
Exposure of TF leads to the formation of both inactive TF:VII and active TF:VIIa 
complexes. Even the minute amounts of TF:VIIa (that can initially exist at circulating 
levels of VIIa) can set up autocatalytic feedback and activate VII bound to TF. 
Furthermore, a variety of enzymes including factors IXa, Xa, XIIa and thrombin have 
been shown to activate VII [50, 51], and this makes the cascade strongly self amplifying.  
 13
1.3.2 The intrinsic pathway 
The “intrinsic” ability of plasma to gel when placed in a glass tube, or more 
accurately “contact” with negative surfaces (glass, clay, kaolin) gives the intrinsic 
pathway its name. 
For many years the contact pathway has been considered physiologically 
irrelevant because severe deficiency in the initiator of this cascade (Factor XII) causes no 
bleeding defect [52]. However recent experiments have revealed that mice deficient in 
Factor XII do indeed have a tendency to form unstable thrombi [53, 54]; suggesting that 
this often overlooked part of the cascade does indeed have an important physiological 
role. 
This pathway is triggered by the activation of the zymogen factor XII upon 
contact with a negative surface. The heavy chain of factor XII binds to surfaces, leading 
to substantial increase in local enzyme concentration, autoactivation and activation of 
XIIa dependent prekallikrein (and its cofactor high molecular weight kininogen, HK) and 
factor XI. Subsequently, factor IX is activated by the novel dimeric serine protease factor 
XIa [55]. 
Kallikrein in turn cleaves HK to release bradykinin, a potent stimulus which links 
the coagulation and inflammatory pathways, and the remaining kinin free kininogen 
(activated HK) binds several fold better than intact HK. This allows more prekallikrein to 
associate with HK setting up a strong autocatalytic loop. Additionally Kallikrein can 
reciprocally activate factor XII [55]. 
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This pathway is also characterized by negative feedbacks. Factor XIa can cleave 
the light chain of HK, which is responsible for the cofactor’s procoagulant activity. This 
in turn liberates XIa from the activating surface [56]. 
1.3.3 The common pathway 
Factor Xa formed by either the extrinsic or intrinsic pathway converts 
prothrombin to thrombin. Prothrombin is another vitamin K dependent zymogen that 
requires calcium to bind to phospholipid surfaces. After cleavage by Xa, the N terminal 
Gla portion of prothrombin is removed and thrombin is formed. Thrombin occupies a 
central portion in the formation of the haemostatic plug and limits both its own formation 
and destruction by acting on multiple substrates including fibrinogen, factors V, VIII, XI, 
platelet receptors, and proteins S and C. The rate of thrombin formation is increased by 
more than 300,000 fold (in comparison to Xa alone) by the action of the prothrombinase 
complex (factors Xa, Va, phospholipid and calcium) on localized prothrombin [57]. 
Activated factor V is possibly supplied by platelet secretion of   α-granule content 
following activation [58]. 
1.3.4 Coagulation inhibition 
Plasma inhibitors serve to limit the extent of both the coagulation and the 
fibrinolytic systems. The major plasma inhibitors are C1 inhibitor, ATIII and TFPI. 
C1inhibitor is the major inhibitor of the contact system, and accounts for 95% of 
the plasma inhibitor capacity of factor XIIa and more than 50% of the inhibitory capacity 
of kallikrein [45]. α1-Antitrypsin is the major plasma inhibitor of XIa [59].  
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Antithrombin (ATIII) is one in a class of general serine protease inhibitors 
(serpins) that limits the action of most active proteases in the coagulation cascade. In 
particular ATIII strongly inhibits the actions of thrombin, factors IXa and Xa. ATIII 
deficiency is associated with a striking increase in the risk of thromboembolism. The 
catalytic site serine of thrombin reacts with an arginine of ATIII to form an inactive 
covalent complex. The affinity of ATIII for thrombin is strongly enhanced, by the 
binding of a basic group in ATIII to heparin (a highly negatively charged sulfated 
polysaccharide that exists on the endothelial surface) [60]. Heparin cofactor II is a serpin 
that selectively inactivates thrombin in the presence of heparin or dermatan sulfate [61]. 
Tissue factor pathway inhibitor (TFPI) is a protein that in association with factor Xa, 
inhibits TF:VIIa [62]. 
α2-Macroglobulin is a secondary inhibitor of several coagulant and fibrinolytic 
enzymes including kallikrein, thrombin and plasmin. Enzymes trapped in the cage 
structure of this inhibitor are protected from other inhibitors [63].  α2-Antiplasmin is the 
primary inhibitor of plasmin and serves to limit the fibrinolytic response till completion 
of wound healing [64]. Protein C inhibitor is also a serpin that can function as a 
procoagulant molecule by inhibiting the action of protein C [65]. 
1.3.5 Fibrin formation 
The formation of fibrin strands stabilizes the loose platelet aggregate at the site of 
injury. Fibrin is formed by the action of thrombin on fibrinogen, a protein present in 
abundance both in plasma and platelet granules. Thrombin binding to the central domain 
of fibrinogen liberates fibrinopeptides A and B, resulting in fibrin monomer and polymer 
formation. Progressive lengthening of the polymer occurs by half overlap, side to side of 
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fibrin monomers, thus forming long, thin, fibrin strands. The degree of lateral 
polymerization regulates the tensile strength of the clot. Factor XIIIa serves to cross link 
these loose fibrin strands and confers resistance to degradation by plasmin [66].  
The fibrin mesh holds platelets together and attaches them to the vessel wall, by 
binding to platelet receptor glycoproteins and by interacting with other adhesive proteins 
like thrombospondin and fibronectin. After binding to platelet binding sites, these 
proteins serve as molecular bridges between plasma proteins and the platelet interior, 
between platelets and the vessel wall, and between plasma fibrin fibers and the 
subendothelial matrix. For instance, fibronectin is crosslinked by XIIIa to fibrin [67], and 
its separate binding site for collagen [68] bridges fibrin and the vessel wall. VWF serves 
as a bridge between platelet membrane and the subendothelium (via platelet membrane 
GP1B and αIIbβ3) [69]. Additionally, platelet αIIbβ3 joins fibrinogen to intracellular actin, 
thereby controlling clot retraction and vessel wall constriction [70]. 
Several mechanisms exist to exist to limit and localize the extent of thrombosis. 
Firstly, the shear forces of blood flow tear away loosely attached clumps of platelets [71]. 
Secondly, thrombin in conjunction with thrombomodulin on the endothelial surface, acts 
as a receptor for protein C. Activated Protein C is a potent inhibitor of factors V and VIII 
[72]. Soluble pro-coagulant molecules like Xa or thrombin that advect away from the site 
of the growing clot are efficiently inhibited by plasma inhibitors like ATIII [60]. 
1.3.6 Fibrinolysis 
Fibrinolysis, along with endothelial cell regrowth and vessel regrowth are repair 
mechanisms set in motion following thrombus formation. Similar to the coagulation 
cascade, fibrinolysis involves zymogen to enzyme conversions, autoactivation and 
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inactivation. The inactive precursor plasminogen is present at high concentrations. 
During the initial process of thrombus formation, activated platelets and endothelial cells 
release plasminogen activator inhibitors that allow fibrin formation to continue 
unhindered. However, once the vessel wall is sufficiently repaired, endothelial cells 
release tissue plasminogen activator, which in turn activates plasminogen to plasmin [73]. 
Plasmin contributes to its own activation by cleaving an activation peptide from 
plasminogen, making it more susceptible to surface binding and activation by 
plasminogen activators. Also plasminogen bound to fibrin, by lysine binding sites on its 
kringle structures has much higher reactivity. The small proportion of plasma fibrinogen 
adhered onto fibrin can lead to clot dissolution [74]. There exists a delicate balance 
dictated by the position and relative abundance of profibrinolytic plasminogen and 
plasminogen activator molecules and antifibrinolytic α2-antiplasmin molecules 
(covalently attached via factor XIIIa action) assembled on the fibrin strands. Soluble 
fibrin degradation products like D-dimers are released into the circulation following 
fibrinolysis and serve as clinical markers of underlying thrombotic activity [75]. Active 
plasmin molecules released into circulation are quickly degraded in solution by α2-
antiplasmin [76], thus limiting fibrinolysis to the site of the thrombus. 
Thus the entire process of clot formation and dissolution is finely regulated by 
numerous plasma clotting factors, cellular components including endothelial cells and 
platelets, thrombus specific and distributed inhibitory mechanisms, as well as 
subendothelial components. This intricate balance of interlinked mechanisms ensures a 
robust response that prevents blood loss following injury, but is one that does not occlude 
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blood flow by uncontrolled thrombus growth. Disruption of any portion of these 
processes can lead to fatal hemorrhagic or thrombotic disorders.  
1.4 Outline 
Previous studies have often looked at individual parts of the thrombotic response 
in isolation. In contrast, this dissertation takes a “systems approach” to thrombosis 
integrating experimental and theoretical studies. This work quantitatively characterizes 
both the coagulation component of the clotting response leading to the formation of 
thrombin via sequential plasma reactions, as well as the cellular component involving 
platelet activation. Fibrinolysis has not been considered.  High throughput experimental 
systems were first developed to efficiently probe the biology of these pathways across 
several dimensions. Models were then developed based on these experimental 
observations. In the second chapter, a study of the kinetics of thrombin formation in 
resting and activated human blood is presented. Thrombin formation is studied in the 
presence of a fluorogenic thrombin substrate (Boc-VPR-MCA), and a mechanism based 
ordinary differential equation (ODE) model is developed based on the framework of the 
Hockin-Mann reaction network. In the third chapter, a study of platelet activation is 
presented. “Pairwise Agonist Scanning” (PAS) was developed to predict higher order 
interactions amongst several simultaneous signals from a high throughput experiment 
sampling of all possible first and second order signals. Data driven Neural Network 
models were trained on PAS datasets to make donor specific predictions of platelet 
signaling. In the final chapter extensions of this work are suggested. 
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Chapter 2 
Kinetics of thrombin generation in resting and activated 
human blood 
2.1 Abstract 
Blood function defines bleeding and clotting risks and dictates approaches for clinical 
intervention. Independent of adding exogenous tissue factor (TF), human blood treated in vitro 
with corn trypsin inhibitor (CTI, to block Factor XIIa) will generate thrombin after an initiation 
time (Ti) of 1 to 2 hr (depending on donor), while activation of platelets with the GPVI-
activator convulxin reduces Ti to ~20 min.  Since current kinetic models fail to generate 
thrombin in the absence of added TF, we implemented a Platelet-Plasma ODE model 
accounting for: the Hockin-Mann protease reaction network, thrombin-dependent display 
of platelet phosphatidylserine, VIIa function on activated platelets, XIIa and XIa 
generation and function, competitive thrombin substrates (fluorogenic detector and 
fibrinogen), and thrombin consumption during fibrin polymerization.  The kinetic model 
consisting of 76 ordinary differential equations (76 species, 57 reactions, 105 kinetic 
parameters) predicted the clotting of resting and convulxin-activated human blood as well 
as predicted Ti of human blood under 50 different initial conditions that titrated increasing 
levels of TF, Xa, Va, XIa, IXa, and VIIa.  Experiments with combined anti-XI and anti-
XII antibodies prevented thrombin production, demonstrating that a leak of XIIa past 
saturating amounts of CTI (and not “blood-borne TF” alone) was responsible for in vitro 
initiation without added TF. Clotting was not blocked by antibodies used individually 
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against TF, VII/VIIa, P-selectin, GPIb, protein disulfide isomerase, cathepsin G nor 
blocked by the ribosome inhibitor puromycin, the Clk1 kinase inhibitor Tg003, or 
inhibited VIIa (VIIai).  This is the first model to predict the observed behavior of CTI-
treated human blood, either resting or stimulated with platelet activators.  CTI-treated 
human blood will clot in vitro due to the combined activity of XIIa and XIa, a process 
enhanced by platelet activators and which proceeds in the absence of any evidence for 
kinetically significant blood borne tissue factor. 
2.2 Introduction 
Blood coagulation is a surface catalyzed protease cascade with autocatalytic 
amplification and multiple modes of inhibition [77]. Clotting in vivo is triggered by 
exposed tissue factor (TF) during vascular injury or plaque rupture.  There is a striking 
sensitivity of  coagulation to picomolar levels of TF [78].  Considerable uncertainty exists 
concerning the relative roles of circulating concentrations of TF [79, 80] and the 
mechanism(s) of platelet display of active TF via synthesis [80, 81], de-encryption [82] 
or changes in membrane composition [83]. Some of these mechanisms are illustrated in 
Figure 2.2-1. The detection of circulating concentrations of activation peptides, such as 
F1.2 and fibrinopeptides A and B, inactivation products such as thrombin-antithrombin 
(TAT) [84-87] and activated factors such as VIIa and activated Protein C (APC) is proof 
of some low level of activated proteases in normal individuals coexisting with flowing 
blood in vivo. Exploring this endogenous “engine-idling” active state of blood ex vivo is 
central to clinical diagnostics.   
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Figure 2.2-1 Triggers of the extrinsic cascade 
Although TF exposure at the site of vascular injury is considered to be the predominant 
trigger of in vivo coagulation (Also see Figure 1.1-1), several other controversial 
explanations have been proposed in existing literature that could account for initiation in 
the absence of exogenous TF. “Bloodborne TF”, “Platelet synthesized TF (either by 
releasing preformed TF molecules or translating new protein from existing mRNA)”, 
“de-encryption” of cryptic TF, and TF independent VIIa activity (using platelet GP1b as 
cofactor) have all been proposed as possible mechanisms. 
 
Once initiated with TF, the coagulation cascade proceeds by sequential enzymatic 
steps to produce thrombin, which in turn polymerizes fibrinogen to fibrin to form the 
protein polymer mesh of the thrombus. Thrombin also has complex regulatory action by 
activating platelets and further enhancing thrombin formation by activating V, VII, VIII, 
and XI.  In vivo, thrombin can limit its own production by binding thrombomodulin and 
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converting protein C to activated protein C (APC), which subsequently inhibits Va and 
VIIIa. Upon activation, platelets express anionic phospholipids on their surface, an event 
that is critical for several surface bound reactions of the cascade [88].  
Given the central role of thrombin in clotting, much effort has focused on 
experimentally detecting the transients of thrombin generation [89]. ‘Calibrated 
Automatic Thrombography’ measures thrombin formation by following the cleavage of  
more than 100 μM  of the thrombin substrate Z-Gly-Gly-Arg-MCA [90].  However, the 
use of this fluorogenic substrate has been shown to interfere with the kinetics of the 
cascade by competitive inhibition of thrombin [91]. Furthermore, inhibitory influences of 
anticoagulants such as citrate may influence conclusions drawn from experiments with 
whole blood [92]. Complications due to artificial material activation of the contact 
pathway in vitro can be minimized by the inhibition of the contact system through the use 
of CTI to inhibit XIIa [93].  
We have built upon the existing Hockin-Mann reaction network of the extrinsic 
coagulation cascade [94] to predict the function of blood studied in vitro with contact 
pathway inhibition. The Hockin-Mann model is a homogenous ordinary differential 
equation (ODE) reaction scheme that assumes a maximally activated platelet at t = 0. The 
Hockin-Mann model predicts accurately the initiation times of blood coagulation at 
picomolar levels of TF, but breaks down at zero or sub-picomolar levels of exogenously 
added TF [95].   Other models have attempted to consider the platelet as a separate entity 
which exists in discrete activation states and contributes binding sites once activated for 
the catalysis of several coagulation reactions [96, 97]. Such approaches have shed light 
on the critical importance of platelet activation mediated changes on the reaction surface 
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area, the fragility of the cascade to thrombin induced activation of the platelet, stochastic 
effects at low molecular counts and experimentally observed variability in the initiation 
of clotting.  However, these models still do not explain why blood drawn into CTI will 
clot without exogenous addition of TF.      
Quantitatively, the systems biology analysis of blood clotting must account for 
strong autocatalytic feedback, nonlinearity of kinetic rates, and extreme sensitivity to 
initial conditions, specifically to help predict system outcomes that lead to insufficient or 
overactive responses (i.e. bleeding or thrombosis). The present study explores the 
stability of normal donor blood (i.e. what tips the balance towards clotting) as indicated 
by prolongation or reduction of the clotting time.  We have developed and validated a 
high throughput assay to measure thrombin production initiation in static blood under 
minimal inhibitory influences of fluorogenic substrate and anticoagulant. We used this 
assay to examine several possibilities in existing literature that could account for 
initiation without exogenous TF and conclude that a leak of XIIa past saturating CTI is 
responsible for such initiation. Further, our studies demonstrated blood’s graded 
sensitivity to exogenously added TF, IXa and XIa; a dramatic switch like response to 
exogenously added Xa; little discernible effect of exogenously added Va; and statistically 
significant VIIa activity (independent of TF) when used above nanomolar concentrations. 
From a systems biology perspective that seeks to accommodate patient-specific 
variations, modeling can help address central questions regarding: (i) the regulation of 
response to perturbation, (ii) the stability of blood in vivo or ex vivo in the face of zero or 
near-zero levels of active TF or active proteases, and the (iii) safe pharmacological 
alteration of blood function. 
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2.3 Materials and methods 
2.3.1 Materials 
  The fluorogenic thrombin substrates Boc-Val-Pro-Arg-methylcoumarinamide 
(Boc-VPR-MCA) and Z-Gly-Gly-Arg methylcoumarinamide (Z-GGR-MCA) were 
obtained from Bachem (King of Prussia, PA). Lipidated recombinant TF (baculovirus 
expressed, amino acids 1-263; 43kDa), monoclonal anti-human FVII/VIIa, and TF 
ELISA kits were obtained from American Diagnostica (Stamford, CT) and used to 
determine the available TF antigen concentration of 18.2 nM. Monoclonal anti human 
FXI and FXII were obtained from Enzyme Research Laboratories (South bend, IN). 
Monoclonal anti human P-selectin was obtained from R&D Systems (Minneapolis, MN). 
Monoclonal anti human Gp1bα was obtained from Lifespan Biosciences (Seattle, WA). 
Polyclonal anti human cathepsin-G was obtained from Molecular Innovations (Novi, MI). 
Monoclonal anti human PDI was obtained from was obtained from Affinity Bioreagants 
(Rockford, IL). Thrombin-antithrombin ELISA kits were obtained from Dade Behring 
(Deerfield, Illinois). Active site inhibited VIIa (VIIai) was gifted by Novo-Nordisk, 
Denmark. Other reagents included: adenosine diphosphate (ADP), benzamidine 
hydrochloride, EDTA, HEPES, NaCl, NaOH, sodium citrate, apyrase,PGE2, Tg003 and 
Puromycin (all from Sigma, St. Louis, MO); corn trypsin inhibitor (CTI), Phe-Pro-Arg-
chloromethylketone (FPRCK), human α-thrombin, polyclonal anti-human TF, Xa, Va, 
VIIa, IXa, XIa , human plasmas deficient in prothrombin  and factors V, VII, XI or XII  
(all from Hematological Technologies, Essex Junction, VT); convulxin (CVX, 
Centerchem, Norwalk, CT); and black 384-well plates (Corning, Corning, NY).  All 
reagents were stored and prepared according to the manufacturers’ recommendations.  
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The buffer used for all dilutions was HEPES buffered saline (HBS, sterile filtered 20 mM 
HEPES and 140 mM NaCl in deionized water adjusted to pH 7.4 with NaOH). 
2.3.2 Blood collection and preparation of washed platelets 
Unless otherwise noted, blood was collected in a syringe containing 1 part sodium 
citrate to 9 parts blood and 50 μg CTI/mL.   To obtain washed platelets for the 
experiments in Figure 2.4-10, blood was first centrifuged at 120g for 12 min to obtain 
platelet rich plasma (PRP). PRP was then treated with 200μM PGE2 and 1unit/ml 
apyrase to prevent activation during subsequent spinning. A platelet pellet was obtained 
by centrifuging PRP at 800g for 10 min and this pellet was resuspended in HBS to yield a 
final concentration of ~3×108 platelets/ml.  
2.3.3 High throughput experimentation 
Prior to phlebotomy, all reagents were prepared in a 384-well plate using a 
Thermo Multidrop and a Perkin-Elmer JANUS workstation. For all experiments, blood 
was added to the whole (or segments) of a well plate using a PerkinElmer Evolution P3. 
To ensure a simultaneous activation time, citrated blood was recalcified in all 384 wells 
simultaneously, yielding a final added calcium concentration of 10 mM. To detect 
thrombin activity with time, we added the fluorogenic substrate (SIIa), Boc-VPR-MCA 
(10 μM) to every well and detected the fluorescence of the released 
aminomethylcoumarin (AMC) with Thermo Fluoroskan fluorimeters preheated to 37 °C. 
Each well was read once per minute for 4 hr.  After 4 hours, 5 U thrombin/well was 
added and then the plate was read again once per minute for 20 minutes to determine the 
maximal signal.  This procedure is illustrated in Figure 2.3-1. 
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Figure 2.3-1 High Throughput Experimental Procedure to study coagulation  
(A) Experimental protocol. Calcium and the fluorogenic thrombin substrate (SIIa) were 
added to the 384-well plate on a Thermo Multidrop. The plate was placed on a Perkin-
Elmer Janus where various concentrations of each individual species were added to each 
well.  After phlebotomy, the plate was moved to a Perkin-Elmer Evolution P3 where the 
blood was added to all wells simultaneously (t = 0).  The plate was read in a Thermo-
Electron Fluoroskan where the fluorescence was measured for 4 hr.  The time from vein 
to first measurement was under 5 min. (B) Initiation Time. The time required to reach 
5% conversion of the fluorogenic substrate was set as the initiation time (Ti). Relative 
prolongation or reductions in Ti were used to quantify coagulation initiation.  (Thanks to 
Bill Denney for his contribution in developing this assay). 
    
27 
 
In experiments to study the effect of fluorogenic substrate concentration, Boc-
VPR-MCA or Z-GGR-MCA were used at final concentrations between 1 and 100 μM. 
All experiments were carried out in 5x diluted whole blood. Fractional conversion of the 
fluorogenic substrate was determined according to:  
          
minmax
min
FF
FFC −
−=                                       (2.3.1) 
where C is the fractional conversion, F is the instantaneous fluorescence at any time, Fmin 
is the minimum fluorescence for that well, and Fmax is the maximum fluorescence in that 
well during either the experiment or after thrombin addition. The initiation time (Ti) was 
set when C rises past 0.05. 
2.3.4 Thrombin-Antithrombin (TAT) immunoassays 
TAT serves as a measure of the cumulative thrombin production. Citrated blood 
was dispensed into all wells of a 384-well plate containing calcium using a PerkinElmer 
Evolution P3 liquid handling station. Reactions were manually stopped in columns of the 
well plate by adding a ‘stop cocktail’ of 50 mM EDTA, 20 mM benzamidine and 100 μM 
Phe-Pro-Arg-chloromoethyl ketone (PPACK) at specific time points [98]. The plate was 
spun at 120g for 12 min to separate out plasma, which was subsequently assayed for TAT 
by ELISA (Dade Behring).  
2.3.5 Simulation 
Simulations were performed in Matlab R2008b (version 7.7.0.471) using the 
Systems Biology Toolbox 2 (SBTOOLBOX2) with the SBPD extension package ODE 
solver with an absolute tolerance of 10-30 and a relative tolerance of 10-7 [99].   
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A function of thrombin concentration was fit with a Hill function to published 
experimental data that quantified ‘Platelet Activation Status’ by reporting surface 
Phosphatidylserine exposure (measured by fold increase in Annexin V binding) in 
response to thrombin (IIa) [100] (Figure 2.3-2): 
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tIIatIIa
tt
= . Since thrombin concentration physiologically starts 
decreasing after monotonically rising to a peak, it was necessary to use the maximum 
transient thrombin concentration )])'(([max
]0['
tIIa
tt
, to ensure that )])(*([ tIIaf  never 
decreases once it has reached its maximum magnitude. )(* tIIa is exactly equivalent to 
[IIa(t)] until [IIa(t)] reaches its peak, whereafter )](*[ tIIa  is constant at that maximum 
value. This ensures that the platelet stays activated even when thrombin declines. 
 
 
 
 
 
 
 
Figure 2.3-2 Definition of εmax for a given thrombin concentration 
Phosphatidylserine exposure measured by fold increase in annexin V binding was 
obtained  from published values [100] and are shown in blue circles. The maximum 
platelet activation state attainable at a given thrombin concentration (εmax) was obtained 
by fitting a hill function to this data (green line). 
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For a given [IIa], we define the maximum platelet activation state, maxε  : 
            ( ) )])(*([1
00 maxmaxmax
tIIaf×−+= εεε      (2.3.3) 
where εmax describes the fractional activation state of the platelet. 
0max
ε  defines the basal 
activation state of the platelet at t=0, and is set to 0.01 in most simulations (assuming a 
basal 1% binding strength of coagulation factors to the resting platelet surface). For full 
activation of platelets at [thrombin] > ~10 nM, maxε  equals 1 and protein dissociation is 
minimized (Figure 2.3-2).  
The instantaneous platelet activation state ε is governed by the differential 
equation 
     ( )εεε −= maxkdt
d       (2.3.4) 
with the initial condition at 01.0,0 == εt ,   this solves to,  
 ( ) )exp(01.0maxmax kt−×−−= εεε  (2.3.5)  
The constant k is inversely proportional to the time scale of platelet activation, and was 
set to 0.005. This is consistent with the fact that it takes ~ 200 s for platelets to mobilize 
calcium from intracellular stores upon stimulation with thrombin or other platelet 
agonists [101]. Such a form of the platelet function (ε) ensures that the platelet achieves 
its maximum attainable activation state (εmax) not instantaneously, but on a 
physiologically relevant timescale.  Transients of ε are shown for values of εmax= 0.25, 
0.5, 0.75 and 1.0 are shown in Figure 2.3-3. 
 To account for changes in the reaction rates with platelet activation, we modified 
the Hockin-Mann model rate constants as follows,  
 kmodified = koriginal × (η / ε) (2.3.6)  
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where η was a parameter that was used to alter the magnitude of the rate constant used in 
the Hockin-Mann model. Many of the Hockin-Mann model parameters were originally 
fitted empirically to global experimental data.  For η = 1 and full platelet activation (ε = 
1), the modified value becomes the original value. For η ≠ 1, the modifications may be 
regarded as further fits to experimental data, consistent with published values of rate 
constants (footnotes to Table 2.4-1). 
 
 
 
 
 
 
 
 
Figure 2.3-3 Representative transients of ε for εmax= 0.25, 0.5, 0.75 and 1.0 
The instantaneous platelet activation status (ε) approaches its maximum attainable value 
(εmax) on a time scale consistent with the time it takes for the platelet to mobilize 
intracellular calcium. Shown are ε transient profiles at various values of εmax. 
  
To estimate the sensitivity of our model’s output to the choice of kinetic 
constants, a global sensitivity analysis of the models output thrombin concentration at 0 
and 10 pM TF concentration was carried out by the method of weighted averaging of 
local sensitivities. The results of this analysis are shown in Figure 2.4-15 A and B; 
Table 2.4-3 and Table 2.4-4. 
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2.4 Results 
We have used a high throughput fluorogenic assay to measure coagulation 
initiation in 384-well plates where 5x-diluted, citrated human blood (CTI treated) was 
recalcified within 5 min of venipuncture (Figure 2.3-1 A). A level of 5% cleavage of the 
fluorogenic substrate Boc-VPR-MCA was used as the coagulation initiation time (Ti). A 
large burst in thrombin production was always detected within minutes after Ti. Relative 
prolongation or reductions in Ti were used to quantify coagulation initiation in response 
to varying conditions (Figure 2.3-1 B). The observed bursts in fluorescence were 
completely abolished by the thrombin inhibitor PPACK, and were not observed in 
prothrombin deficient (platelet supplemented) plasma (not shown), proving that we were 
indeed detecting thrombin and not some other non specific protease mediated cleavage of 
the fluorogenic substrate. 
The Platelet-Plasma model (Figure 2.4-1, Table 2.4-1 and Table 2.4-1) was built 
on the existing framework of the Hockin-Mann model [94] and our experimental 
observations.  During the course of thrombin generation in the well plate, platelets 
become activated and this activation was modeled using a coarse-grained description of 
platelet function by equating platelet activation (ε) to phosphatidylserine (PS) exposure as 
a function of thrombin concentration (Figure 2.3-2 and Figure 2.3-3). The complete 
topology of the model, its constituent reactions, and initial conditions are shown in  
Figure 2.4-1, Table 2.4-1 and Table 2.4-2.  (Also see Supporting Information 
of [102] for full listing of ODEs and reactions). Justifications for alterations to kinetics 
are explained in the footnotes to Table 2.4-1. 
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Figure 2.4-1 Schematic of the Platelet-Plasma model. 
A Wiring diagram of the Platelet-Plasma model is shown above. Blue portions represent 
additions to the Hockin-Mann model [94]. Binding and unbinding equilibriums are 
shown in black. Reactions highlighted in pink occur on the activated platelet, and the 
respective unbinding reaction rates decrease by two orders of magnitude during the 
course of platelet activation. Proteolysis reactions are represented by the green arrows. 
Inhibition reactions are shown in red.  
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Rxn Model Expressions k 1 k -1 
     
    k cat 
(s-1) 
Hockin-Mann 
Model Km or Kd 
(M) 
η 
Platelet-Plasma 
Model   (ε =1) Km or 
Kd (M) 
References 
1 TF + VII ↔ TF=VII 
3.2 x 106  
M-1 s-1 
3.1 x 10-3 
s-1 
  9.6 x 10-10  10 9.6 x10-9 [103, 104] 
2 TF + VIIa ↔ TF=VIIa  
2.3 x 107 
M-1 s-1 
3.1 x 10-3 
s-1 
  1.3 x 10-10 0.01 1.3 x10-12 [105] 
3 TF=VIIa + VII → TF=VIIa + VIIa 
4.4 x 105 
M-1 s-1 
         
4 Xa + VII → Xa + VIIa  
1.3 x 107 
M-1 s-1 
         
5 IIa + VII → IIa + VIIa 
2.3 x 104 
M-1 s-1 
         
6 
TF=VIIa + X ↔ TF=VIIa=X → 
TF=VIIa=Xa 
2.5 x 107 
M-1 s-1 
1.05 s-1 6  2.8 x 10-7 0.01 2.4 x 10-7 [105, 106] 
7 TF=VIIa + Xa ↔ TF=VIIa=Xa 
2.2 x 107 
M-1 s-1 
19 s-1  8.6 x 10-7 1 8.6 x 10-7 [107] 
8 
TF=VIIa + IX ↔ TF=VIIa=IX → 
TF=VIIa + IXa 
1.0 x 107 
M-1 s-1 
2.4 s-1 1.8  4.2 x 10-7 1 4.2 x 10-7 [108] 
9 II + Xa → IIa + Xa 
7.5 x 103 
M-1 s-1 
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10 IIa + VIII → IIa + VIIIa 
2.0 x 107 
M-1 s-1 
         
11 VIIIa + IXa ↔ IXa=VIIIa  
1.0 x 107 
M-1 s-1 
5.0 x 10-3 
s-1 
  5.0 x 10-10 0.02 1.0 x10-11 [109, 110] 
12 
IXa=VIIIa + X ↔ IXa=VIIIa=X → 
IXa=VIIIa + Xa 
1.0 x 108 
M-1 s-1 
1.0 x 10-3 
s-1 
8.2  8.2 x 10-8 0.01 8.2 x 10-8 [111] 
13 VIIIa ↔ VIIIa1•L  + VIIIa2 
6.0 x 10-3 
s-1 
2.2 x 104 
M-1 s-1 
  2.7 x 10-7 0.01 2.7 x10-9 [112, 113] 
14 
IXa=VIIIa=X → VIIIa1•L  + VIIIa2 + X 
+ IXa 
1.0 x 10-3 
s-1 
        
15 IXa=VIIIa → VIIIa1•L + VIIIa2 + IXa 
1.0 x 10-3 
s-1 
        
16 IIa + V → IIa + Va 
2.0 x 107 
M-1 s-1 
         
17 Xa + Va ↔ Xa=Va  
4.0 x 108 
M-1 s-1 
0.2 s-1   5.0 x 10-10 0.04 2.0 x10-11 [114] 
18 
Xa=Va + II ↔ Xa=Va=II → Xa=Va + 
mIIa 
1.0 x 108 
M-1 s-1 
103 s-1 63.5  1.6 x 10-6 0.02 6.5 x 10-7 [115] 
19 Xa=Va + mIIa → Xa=Va + IIa 
1.5 x 107 
M-1 s-1 
         
20 Xa + TFPI ↔ Xa=TFPI  
9.0 x 105 
M-1 s-1 
3.6 x 10-4 
s-1 
  4.0 x 10-10 1 4.0 x10-10 [116] 
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21 
TF=VIIa=Xa + TFPI ↔ 
TF=VIIa=Xa=TFPI 
3.2 x 108 
M-1 s-1 
1.1 x 10-4 
s-1 
  3.4 x 10-13 100 3.4 x10-11 [106] 
22 
TF=VIIa + Xa=TFPI → 
TF=VIIa=Xa=TFPI 
5.0 x 107 
M-1 s-1 
         
23 Xa + ATIII → Xa=ATIII 
1.5 x 103 
M-1 s-1 
         
24 mIIa + ATIII → mIIa=ATIII 
7.1 x 103 
M-1 s-1 
         
25 IXa + ATIII → IXa=ATIII 
4.9 x 102 
M-1 s-1 
         
26 IIa + ATIII → IIa=ATIII 
7.1 x 103 
M-1 s-1 
         
27 TF=VIIa + ATIII → TF=VIIa=ATIII 
2.3 x 102 
M-1 s-1 
         
28 
Boc-VPR-MCA + IIa ↔ Boc-VPR-
MCA-IIa → Boc-VPR + AMC + IIa 
1.0 x 108 
M-1 s-1 
6.1 x 103 
s-1 
53.8  -   6.1 x 10-5  
29 XII → XIIa  
5.0 x 10-4 
s-1 
      
30 XIIa + XII ↔ XIIa=XII → XIIa + XIIa 
1.0 x 
108M-1 s-1    
750 s-1 
3.3 x 
10-2 
- 1 7.5 x 10-6 [117, 118] 
31 XIIa + PK ↔ XIIa=PK → XIIa + K 
1.0 x 
108M-1 s-1 
3.6 x 103 40 - 1 3.7 x 10-5 [117, 119] 
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32 XII + K ↔ XII=K → XIIa + K 
1.0 x 
108M-1 s-1 
45.3 s-1 5.7 - 1 5.1 x 10-7 [117, 120] 
33 PK + K → K + K 
2.7 x 
104M-1 s-1    
  -   [121] 
34 K → K.Inhibited 
1.1 x 10-2 
s-1 
     [122] 
35 XIIa + CTI ↔ XIIa=CTI 
1.0 x 108 
M-1 s-1     
2.4 s-1  - - 2.4 x 10-8 [93] 
36 XIIa + C1inh → XIIa=C1inh 
3.6 x 103 
M-1 s-1 
     [123] 
37 XIIa + ATIII → XIIa=ATIII 
21.6 M-1 
s-1 
     [123] 
38 XI + IIa ↔ XI-IIa→XIa +IIa 
1.0 x 108 
M-1 s-1     
5 s-1 
1.3 x 
10-4  
- - 5.0 x 10-8 [124, 125] 
39 XIIa + XI ↔ XIIa=XI → XIIa + XIa 
1.0 x 108 
M-1 s-1     
200 s-1 
5.7 x 
10-4 
- 1 2.0 x 10-6 [120, 124] 
40 XIa + XI ↔ XIa=XI → XIa + XIa 
3.19 x 
106M-1 s-1    
     [124, 126] 
41 XIa + ATIII → XIa=ATIII 
3.2 x 102 
M-1 s-1 
     [127] 
42 XIa + C1inh → XIa=C1inh 
1.8 x 103 
M-1 s-1 
     [127] 
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43 XIa + α1AT → XIa= α1AT 
1.0 x 102 
M-1 s-1 
     [127] 
44 XIa + α2AP → XIa= α2AP 
4.3 x 103 
M-1 s-1 
     [127] 
45 XIa + IX ↔ XIa-IX→XIa +IXa 
1.0 x 108 
M-1 s-1 
41 s-1 7.7  - 1 4.9 x 10-7 [128, 129] 
46 IXa + X ↔ IXa= X → IXa + Xa 
1.0 x 
108M-1 s-1    
0.64 s-1 
7.0 x 
10-4 
- 1 6.4 x 10-9 
[111, 130, 
131] 
47 Xa + VIII ↔ Xa=VIII → Xa + VIIIa 
1.0 x 108 
M-1 s-1     
2.1 s-1 0.023 - 1 2.1 x 10-8 
[110, 132, 
133] 
48 VIIa + IX ↔ VIIa=IX → VIIa + IXa 
1.0 x 108 
M-1 s-1     
0.9  s-1 
3.6 x 
10-5 
-  9 x 10-9 [134] 
49 VIIa +X ↔ VIIa=X → VIIa + Xa 
1.0 x 108 
M-1 s-1     
210 s-1 
1.6 x 
10-6 
- 1 2.1x 10-6 [134] 
50 
Fbg + IIa ↔ Fbg = IIa → Fbn1 + IIa + 
FPA 
1.0 x 108 
M-1 s-1 
636 s-1 84 -  7.2 x 10-6 [135] 
51 
Fbn1 + IIa ↔ Fbn1 = IIa → Fbn2 + IIa 
+ FPB 
1.0 x 108 
M-1 s-1 
742.6 s-1 7.4 -  7.5 x 10-6 [135] 
52 2Fbn1 ↔ (Fbn1)2 
1.0 x 106 
M-1 s-1 
6.4 x 10-2 
s-1 
    [135] 
53 
(Fbn1)2 + IIa ↔ (Fbn1)2 = IIa → 
(Fbn2)2  + IIa + FPB 
1.0 x 108 
M-1 s-1 
701 s-1 49 -  7.5 x 10-6 [135] 
    
 
38
54 Fbn2 + IIa ↔ Fbn2 = IIa 
1.0 x 108 
M-1 s-1 
1.0 x 103 
s-1 
 -  1.0 x 10-5 [135] 
55 
(Fbn1)2 = IIa + ATIII → (Fbn1)2 = IIa: 
ATIII 
1.6 x 104 
M-1 s-1 
     [135] 
56 Fbn1 = IIa + ATIII → Fbn1 = IIa: ATIII 
1.6 x 104 
M-1 s-1 
     [135] 
57 Fbn2 = IIa + ATIII → Fbn2 = IIa: ATIII 
1.0 x 104 
M-1 s-1 
     [135] 
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Table 2.4-1 Reactions used in the Platelet-Plasma model.  
 
Rxn 1. Bach et al.[103]  report a decrease in KH from 14.9 to 0.58 nM as % 
phosphatidylserine  (PS) increases from 0 to 40.  
O’Brien et al.  [104] report a kassoc of 3.14×105 M-1 s-1 and a kdiss of 6.29×10-4 s-1, 
which yields a Kd of  ~2 nM. With our choice of η, Kd is comparable to this value. 
Rxn 2. Shaw et al.[105] report a decrease in Kd from ~60 pM to ~10 pM as % PS 
increases from 10-40. on TF liposomes and a decrease from ~90 pM to ~10 pM as 
% PS increases from 10-70 on TF nanodiscs.  
Rxn 6. Shaw et al.[105] also report an ~20x decrease in Km from ~400 nM to 20 nM  for 
X activation as % PS increases from   10 to 40. Baugh et al. [106] report an 
experimental Km of 238 nM on 25% PS vescicles. 
Rxn 7. The product inhibition of TF:VIIa by Xa is dependent on local Xa concentrations. 
Given that Xa and X binding to a PSPC bilayer increases hyperbolically with Kds 
of 53.9 and 34.2 nM respectively [107] and that the TF:VIIa:X complex is 
strengthened with increasing PS content (see 6), it is reasonable to assume that the 
TF:VIIa:Xa complex is also strengthened with increasing PS levels. 
Rxn 8. Beals et al. [108] report that the Kd for bovine IX binding to lipid surface at 
optimum [Ca2+] decreases from 4.9 to 1.7 μM as % PS increases from 20 to 50. 
Given that the formation of TF:VIIa is favoured with increasing PS content (See 
2) and analogous to the increased strength of the TF:VIIa:X complex with 
increased PS (see 6), we expect that the formation of TF:VIIa:IX will also 
increase with increasing PS content.    
Rxn 11. Jenkins et al. [109] report a decrease in  Kd from 351 nM to 4 nM on PCPS 
vesicles. Neuenschander and Jesty [110] report a Kd of 74 pM on activated 
platelet surfaces as opposed to 550 pM on equimolar PSPC vesicles. A Kd of 10 
pM on the activated platelet was required to fit the shape of the IXa titration in 
Figure 2.4-11 B.   
Rxn 12. Rawala Sheikh et al. [111] report a decrease in Km from 45μM to 160nM from 
using unactivated to activated platelets respectively.  
    
 40
Rxn 13. Fay et al. [112] report a Kd value of ~260 nM for this interaction at pH 7.4 in the 
absence of phospholipids. Fay et al.  [113] report that this interaction is stabilized 
by the presence of phospholipid. In the Platelet-Plasma model this dissociation 
constant changes from 270 nM to 2.7 nM as the platelet activates. 
Rxn 17. Lindhout et al. [114] report a decrease in Kd from 3.3 nM in solution to 30 pM 
using 10μM 40% PS.   
Rxn 18. Rosing et al. [115] report a decrease in Km from 34.5 to 0.21 μM using 7.5 μM 
phospholipids. 
Rxn 20. Huang et al. [116] report a decrease in Ki from 85.2 to 65.2 pM on using 
phospholipids. 
Rxn 21. Given that the TF:VIIa:Xa (see 7) and the Xa:TFPI (see 20) complexes are 
strengthened on phospholipids, we expect the stabilization of the 
TF:VIIa:Xa:TFPI complex with the exposure of phospholipids as the platelet 
activates. 
 Baugh et al. [106] report an off rate 3.6 × 10-4 s-1 for Xa unbinding Xa:TFPI , and 
on rates experimentally determined to be  9.0 × 105 M-1s-1, or numerically 
estimated to range between 6.8 × 105 and 1.35 × 106 M-1s-1.  Their data imply that 
these constants are comparable to those for the binding of TF:VIIa:Xa to TFPI (ie 
a Kd between 2.66×10-10 and 5.29 × 10-10 M) .  The original constants for this 
reaction in the Hockin-Mann model were fitted empirically, but their choice of 
constants results in a far stronger complex than can be reasonably expected from 
literature. Hence we have increased Kd by two orders (η = 100) of magnitude 
from their reported value. 
Rxn 28. Experimentally determined by fitting initial velocities of AMC release to 
standard Michelis-menton kinetics. 
Rxn 29.XII activation was coarse grained by assuming a first order dependence on XII 
concentration and estimating a rate of production (5×10-4s-1) that would resolve 
the disparity between the Hockin-Mann model prediction and the experimentally 
observed control. 
Rxn 30. Kinetics of XIIa autoactivation (in the presence of negatively charged dextran 
sulfate) was from Tankersley et al. [117]. Griep et al. [118] showed that the 
    
 41
autoactivation (and Kallikrein activation, See 32) of XII is strongly  promoted by 
negatively charged sulfatides.  
Rxn 31. Kinetics of Pre-Kallikrein activation by β-XIIa (in the presence of dextran 
sulfate) was from Tankersley et al. [117]. Pre-Kallikrein activation by XIIa was 
shown to be facilitated by negatively charged phosphoinositides [119]. 
Rxn 32. Kinetics of XII activation by Kallikrein (in the presence of dextran sulfate) was 
from Tankersley et.al [117]. Walsh and Griffin [120] showed that this reaction is 
sped up by the presence of activated platelets. 
Rxn 33. Kinetics of second order Kallikrein autoactivation was from Tans et al. [121]. 
Rxn 34. The pseudo first order rate constant for the inhibition of Kallikrein in plasma (by 
C1 inhibitor, α2-macroglobulin and ATIII) was obtained from Van-Der-Graaf et 
al. [122]. 
Rxn 35. Hojima et al. [93] report a  Ki of 24 nM for the inhibition of XIIa by CTI. 
Rxns 36 and 37. Kinetics of XIIa inhibition by C1inhibitor and ATIII were from Pixley 
et al. [123]. C1 inhibitor is the primary inhibitor of XIIa. ATIII inhibition 
(although minor) was considering for consistency with other inhibitory reactions.  
Rxn 38. Rate constants (in solution) for this reaction are from Gailani et al. [124] .Some 
controversy exists over the physiological surface for this reaction. Oliver et al. 
[125] showed that this reaction happens physiologically on the activated platelet 
surface. However several seminal papers by Baglia-Walsh et al. in the laboratory 
of Peter N. Walsh which originally proposed that this mechanism happens on the 
active platelet have subsequently been retracted. We therefore chose not to 
include a dependence of this reaction on ε. 
Rxn 39. Rate constants (in solution) for this reaction are from Gailani et al. [124]. Walsh 
and Griffin [120], showed that this reaction is sped up by the presence of 
activated platelets. 
Rxn 40. Several authors describe this mechanism of XI auto-activation (See for example 
[124, 136]). However, following the retraction of (Baglia et al. JBC 2000) we are 
not aware of an experimental report of the kinetics of this reaction. Kramoroff et 
al. [126]estimate the second order rate constant of this reaction to be 3.19 μM-1s-1  
by optimizing an ODE model of the intrinsic cascade to experimental 
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measurements of APTT. They consider either XI autoactivation or XI activation 
by thrombin (but not both possibilities) as plausible mechanisms for XI activation 
(in addition to activation by XIIa), thus their estimated value is likely an 
overestimate. We utilized a value 4 fold lower than the value they report for this 
constant, since we consider thrombin activation of XI in addition to 
autoactivation. This was in keeping with the experimental titration of XIa (Figure 
2.4-11 C) where we have noticed strong sensitivity to even minute amounts of 
XIa.  
Rxns 41 - 44. Rate constants are for inhibition of XIa in plasma are from Wuillemein et 
al. [127] 
Rxn 45. Rate constants (in solution) for this reaction are from Walsh et al. [128]. Gailani 
et al. [129] propose a mechanism by which this reaction could happen on the 
platelet surface facilitated by the dimeric form of factor XI. 
Rxn 46. Rawala - Sheikh et al. [111] report a reduction in Km from 45 μM to 390 nM 
from unactivated to thrombin activated platelets. In later publications from the 
same lab, Scandura and Walsh [130] report a Km of 16nM and a kcat of 5.1×10-4 
for the activation of X by IXa alone on SFLLRN activated platelets in a model 
where platelet bound IXa interacts with zymogen X, and Wilkinson et al. [131] 
report a Km of 6.4 nM and a kcat of 7.0×10-4 . 
Rxn 47. Rate constants were obtained from Leipold et al. [132]  using catalytic 
efficiencies reported in Lollar et al. [133]. Activation of VIII by Xa, unlike 
activation by thrombin (reaction 10) was reported to be markedly dependent on 
the presence of either phospholipid or active platelet surface [110]. 
Rxn 48. Rate constants for this reaction were from Komiyama et al. [134]. Unlike the 
activation of X by VIIa alone (see 49) the Km for this reaction was reported to be 
relatively constant over a wide range of added PCPS concentrations, thus unlike 
other unbinding reactions in the model there was no dynamic change in reaction 
rate with platelet activation.  
Rxn 49. Rate constants for this reaction were from Komiyama et al. [134].  The authors 
report a decrease in Km from 1.48 to 0.25 μM with PCPS levels increasing from 
1.4 to 21 μM. 
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Rxns 50-57. Kinetics of fibrin polymerization are taken from Naski et al. [135] 
 
Reactions 1-27 comprise the original Hockin-Mann Model. 
For reactions 1-27, parameter values were from the Hockin-Mann model when a 
reference is not cited.  
Except for reaction 13, ε wherever applicable operates on the off rate usually defined as 
k-1. For reaction 13, ε operates on k1 which is the actual unbinding rate of the VIIIa 
complex. The notation for this reaction is kept consistent with its description in the 
Hockin-Mann Model. 
On-Rates were assumed to be diffusion limited (with a k1 of 1.0 x 108 M-1 s-1) [96], and 
the corresponding off-rate was calculated from Km  using  
on
catoff
m k
kk
K
+= .   
Supporting Information of [102] provides a complete description of the ODEs for all 76 
species in the assembled reaction network, along with the definition of every reaction 
rate.  Essentially all of the model parameters (rate constants and initial conditions) are 
known or estimated from literature (Table 2.4-1).  The use of η clarifies changes from the 
original Hockin-Mann rate constants that are justified by more recent literature 
measurements (See Table 2.4-1 footnotes). Only, the rate of XIIa leakage was estimated 
(i.e. fitted) based on the difference between simulation and experiment at 0 added TF. 
To estimate the sensitivity of our model’s output to the choice of kinetic 
constants, a global sensitivity analysis of the models output thrombin concentration at 0 
and 10 pM TF concentration was studied by the method of weighted averaging of local 
sensitivities (Figure 2.4-15 A and B; Table 2.4-3 and Table 2.4-4). Local sensitivity of 
Ti to 10 fold variations in important parameters (determined from the global sensitivity 
analysis) across the entire range of titrated TF concentrations is shown in Figure 2.4-16. 
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Species 
Hockin-Mann Model Initial 
Concentration (M) 
Platelet-Plasma Model Initial 
Conditions (M) 
TF 0 0 
VII 1.0 x 10-8 1.0 x 10-8 
TF=VII 0 0 
VIIa 1.0 x 10-10 1.0 x 10-10 
TF=VIIa 0 0 
Xa 0 0 
IIa 0 0 
X 1.6 x 10-7 1.6 x 10-7 
TF=VIIa=X 0 0 
TF=VIIa=Xa 0 0 
IX 9.0 x 10-8 9.0 x 10-8 
TF=VIIa=IX 0 0 
IXa 0 0 
II 1.4 x 10-6 1.4 x 10-6 
VIII 7.0 x 10-10 7.0 x 10-10 
VIIIa 0 0 
IXa=VIIIa 0 0 
IXa=VIIIa=X 0 0 
VIIIa1-L 0 0 
VIIIa2 0 0 
V 2.0 x 10-8 2.0 x 10-8 
Va 0 0 
Xa=Va 0 0 
Xa=Va=II 0 0 
mIIa 0 0 
TFPI 2.5 x 10-9 2.5 x 10-9 
Xa=TFPI 0 0 
TF=VIIa=Xa=TFPI 0 0 
ATIII 3.4 x 10-6 3.4 x 10-6 
Xa=ATIII 0 0 
mIIa=ATIII 0 0 
IXa=ATIII 0 0 
IIa=ATIII 0 0 
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TF=VIIa=ATIII 0 0 
Boc-VPR-MCA - 1.0 x 10-5 
Boc-VPR-MCA=IIa - 0 
Boc-VPR - 0 
AMC - 0 
XII - 3.4 x 10-7 
XIIa - 0 
XIIa=XII - 0 
PK - 4.5 x 10-7 
XIIa=PK - 0 
K=XII - 0 
K - 0 
CTI - 4.2 x 10-6 
XIIa=CTI - 0 
C1inh - 2.5 x 10-6 
XIIa=C1inh - 0 
XIIa=ATIII - 0 
XI - 3.1 x 10-8 
XI=IIa - 0 
XIa - 0 
XIIa=XI - 0 
XIa=ATIII - 0 
XIa=C1inh - 0 
α1AT - 4.5 x 10-5 
α2AP - 1.0 x 10-6 
XIa=α1AT - 0 
XIa= α2AP - 0 
XIa=IX - 0 
IXa=X - 0 
Xa=VIII - 0 
VIIa=IX - 0 
VIIa=X - 0 
Fbg - 9.0 x 10-6 
Fbg=IIa - 0 
Fbn1 - 0 
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Fbn1=IIa - 0 
(Fbn1)2 - 0 
(Fbn1)2=IIa - 0 
Fbn2 - 0 
Fbn2=IIa - 0 
(Fbn1)2=IIa=ATIII - 0 
Fbn1=IIa=ATIII - 0 
Fbn2=IIa=ATIII - 0 
 
Table 2.4-2 Initial conditions of species in the Platelet-Plasma model. 
The initial conditions for the first 34 values in Table 2.4-2, were set to the values used in 
the Hockin Mann model [94]. The level of Boc-VPR-MCA was set to 10 μM (this is the 
level of fluorogenic substrate we use in our experiment). The level of CTI was set to 4.2 
μM corresponding to the concentration of 50 μg/ml used in the phlebotomy syringe. XII, 
XI Pre-Kallikrein , C1-Inhibitor, α1AT, α2AP and Fibrinogen are set to their plasma 
concentrations [127, 137, 138]. 
2.4.1 Validation of experimental methods to detect thrombin 
dynamics 
Calibrated Automatic Thrombography (CAT) [90] measures the initiation, 
propagation and destruction phases of the thrombogram. In seeking to trace the complete 
profile, CAT uses a thrombin substrate Z-GGR-MCA that binds weakly (Km = 305 μM) 
and that is consumed slowly (kcat = 1.86 s-1) and requires high concentrations (416 μM) to 
quantify the complete profile. However, fluorogenic substrates can act as competing 
substrates for thrombin, thereby slowing down positive feedback. Z-GGR-MCA can also 
serve as a competitive substrate for Xa. The magnitude and importance of such inhibitory 
mechanisms of Z-GGR-MCA are still debated [91, 139]. Since thrombin has a strict 
requirement for proline in the P2 position [140], we compared Z-GGR-MCA with the 
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highly selective thrombin substrate Boc-VPR-MCA (Km = 61 μM, kcat = 53.8 s-1) used at 
[SIIa] < Km to detect coagulation initiation.  
 Titrations of the fluorogenic substrates Boc-VPR-MCA and Z-GGR-MCA were 
carried out at 0 and 1 pM added TF (Figure 2.4-2 A and Figure 2.4-2 B) to determine 
the initiation time (Ti). Since increasing substrate will take increasing time to be 
consumed, the 5% conversion criterion (see Methods) cannot be used as the metric to 
quantify coagulation initiation. We defined instead, the time when the second derivative 
of fluorescence was maximized as Ti for this experiment.  Without addition of TF 
(Figure 2.4-2 A), the use of Z-GGR-MCA prolonged Ti by 10 to 20 min at all 
concentrations from 1 to 100 μM in comparison to Boc-VPR-MCA.  At 1 pM added TF 
(Figure 2.4-2 B), both fluorogenic substrates were found to be inhibitory to some degree 
as demonstrated by a prolongation in Ti with increasing substrate concentration. 
However, Z-GGR-MCA caused a prolongation of Ti from 13.1 to 33.8 min as substrate 
concentration was increased from 1 to 100 μM, while Boc-VPR-MCA prolonged Ti from 
4.1 to 14.0 min as fluorogenic substrate concentration was increased from 1 to 100 μM.   
Thus, Boc-VPR-MCA used at up to 100 μM provided smaller Ti (less inhibition) when 
compared to Z-GGR-MCA even when used at 1 μM.  
 Thrombin-antithrombin (TAT) formation provided an independent method to 
validate the fluorogenic assays (Figure 2.4-2 C and Figure 2.4-2 D).  Saturation of the 
detector (at maximized gain to detect low substrate concentrations) prevented the testing 
of 416 μM Z-GGR-MCA typical of CAT, thus the use of 100 μM Z-GGR-MCA in this 
comparison.  In the absence of added TF (Figure 2.4-2 C) clotting initiation was 
observed in ~90 min as indicated by a change from baseline levels of TAT. The addition 
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of 10 μM Boc-VPR-MCA or 100 μM Z-GGR-MCA slowed the formation of TAT with 0 
or 1 pM TF addition compared to reactions without fluorogenic substrate (Figure 2.4-2 C 
and Figure 2.4-2 D). In the presence of 1 pM TF (Figure 2.4-2 D), clotting initiated at 
[TAT] ~ 10 nM at a time between 5 to 10 min in the absence of substrate or with 10 μM 
Boc-VPR-MCA present.  However, clotting initated at [TAT] ~ 10 nM at a time between 
10 to 30 min with 100 μM Z-GGR-MCA present.   TAT formation in the propagation 
phase of thrombin production was inhibited by the presence of 100 μM Z-GGR-MCA 
substrate.   Importantly, we have verified that [TAT] at the time of Ti detected by the 
fluorogenic assay with 10 μM Boc-VPR-MCA was 10 to 20 nM which was in excellent 
agreement with the initiation phase of coagulation as defined by the time it takes to 
generate 10 nM thrombin [141].    
The use of a more selective substrate Boc-VPR-MCA at a low concentration of 10 
μM (used for the remainder of this study) allows for accurate detection of only the 
initiation phase and not the entire thrombogram, due to the rapid consumption of the 
substrate much before the complete conversion of prothrombin.  However, the time taken 
for onset of initiation of thrombin generation is one of the most important characteristic 
of a thrombogram, and the use of the substrate at low levels allows for accurate detection 
of this metric without appreciable competitive inhibition of thrombin.   
This was the basis for adding the thrombin detection chemistry (Reaction 28, 
Table 2.4-1) to the Hockin-Mann topology.  In keeping with our experimental 
observation, thrombin formation is slightly inhibited by thrombin occupying the 
fluorogenic substrate and thus unavailable to generate positive feedback upon the 
zymogens V, VII, VIII, XI or activating the platelet.    
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Figure 2.4-2 Validation of experimental protocol. 
 (A) A titration of the fluorogenic substrates Boc-VPR-MCA (blue circle) and Z-GGR-
MCA (green square) with 0 added TF showed a mild  inhibitory influence of Z-GGR-
MCA. *s indicates statistically significant difference (p<0.05) between initiation times 
detected with the two different substrates. (B) A titration of the fluorogenic substrates 
Boc-VPR-MCA and Z-GGR-MCA with 1 pM added TF showed inhibitory influence of 
both substrates where Boc-VPR-MCA was found to be the better substrate to detect 
initiation and exhibited little inhibition at 10 μM concentration.  (C) TAT formation with 
0 added TF, in the absence and presence of fluorogenic substrates showed less inhibitory 
influence of Boc-VPR-MCA on initiation defined by a burst in TAT compared to Z-
GGR-MCA. Absolute [TAT] after initiation is decreased in the presence of either 
substrate. (D) TAT formation with 1 pM added TF, in the absence and presence of 
fluorogenic substrates showed decreased [TAT] during the propagation phase of 
coagulation in the presence of either substrate. Initiation detected by TAT correlated well 
with Ti determined by our fluorogenic assay. In panels C and D, * indicates [TAT] 
significantly greater than baseline levels (p<0.05) and # indicates statistically significant 
differences compared to no substrate (blue). Experiments in panels A, B, C and D were 
carried out with blood from the same phlebotomy. (E) TF titration done in blood 
anticoagulated with CTI alone (green), Citrate + CTI (red) and Citrate alone (blue). 
Dashed lines indicate controls with no added TF. No significant difference was detected 
in titrations done with and without citrate, showing no evidence of inhibition by the 
anticoagulant.  Effects of the contact factor pathway were apparent only below 100 fM 
added TF.  
 
The nonspecific effects of citrate [92] and CTI [142] were also evaluated by performing a 
titration of TF into blood drawn into CTI alone, CTI-citrate, or citrate alone (Figure 
2.4-2 E). Recalcification was done to adjust the concentrations of Ca2+ in each of these 
citrated blood samples to 10 mM. The time difference between recalcification of all the 
samples to the same [Ca2+] and the drawing of uncitrated blood (which was free to 
coagulate in the presence of physiological Ca2+ concentrations) was less than 3 min. It 
has recently been suggested that coagulation studies done with recalcified citrated blood 
are potentially influenced by inhibitory effects of calcium citrate [92].  Similarly, CTI has 
been reported to interfere with factor VIII coagulant activity [142]. We detect no 
significant difference in Ti upon carrying out titrations of TF in blood anticoagulated with 
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CTI alone or CTI-citrate, indicating little inhibitory influence of citrate on the initiation 
of coagulation.  In the absence of added CTI, the effects of contact pathway-induced 
production of XIIa were apparent only below 100 fM added TF as suggested by a 
lowering of Ti in the absence of CTI.  It should be noted that citrated blood is maintained 
for < 5 min prior to recalcification in the current study. 
2.4.2 Coagulation initiation without added TF 
CTI additions beyond 32 μg/ml have been reported to saturate prolongations of 
clot times due to contact activation in otherwise unstimulated blood [77].  We 
reproducibly observe (Figure 2.4-3) that blood drawn into 50 μg/ml CTI will still clot 
between 60 to 120 minutes without addition of TF, for all donors tested. Prior activation 
of platelets with CVX will lower initiation time to ~20 minutes.  
 
Figure 2.4-3 Coagulation initiation in the absence of externally added TF. 
Blood drawn into 50 μg/ml CTI and without added TF, will still reproducibly clot in ~75 
minutes. Prior activation of platelets with CVX will lower initiation time to ~20 minutes. 
Shown are the multiple replicates tested under the same conditions with the same 
phlebotomy. 
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Similar results were obtained with other platelet agonists such as PAR1 peptide 
agonists or ADP (data not shown). Since contact activation is thought to be completely 
inhibited by the use of CTI, it was reasonable to hypothesize that TF from some “blood 
borne” source or other proximal triggers of prothrombinase formation were responsible 
for such initiation.     
2.4.3 Evaluating ‘blood-borne’ TF and other mechanisms that could 
lead to initiation of clotting in blood drawn into CTI without 
exogenous TF addition 
To evaluate the effect of phlebotomy as a source of vessel wall derived TF, 
experiments were conducted with the first 10 ml, 10-20 ml, 20-30 ml and 30-40 ml of 
blood (Figure 2.4-4).  If TF was indeed produced from the phlebotomy, an increase in 
initiation time would be expected with subsequent volumes of blood drawn after the 
initiation of phlebotomy. Clotting initiated in the first 10 ml of resting blood in ~75 min. 
For all subsequent volumes clotting initiated at ~90 min and no further increase in 
initiation times was observed.  Initiation occurred in 25 min in CVX pretreated blood for 
all volumes after the blood draw.  The amount of TF due to phlebotomy appears minor 
and has no role in blood activated with CVX. In subsequent experiments, the first 10 ml 
of blood drawn was discarded.   
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Figure 2.4-4 TF from phlebotomy 
To evaluate the effect of phlebotomy, experiments were conducted ±CVX using the first 
10 mls, 10-20 mls, 20-30 mls and 30-40 mls of blood. No steady increase in Ti was noted 
showing that TF from phlebotomy was not leading to eventual initiation. 
 
P-selectin is expressed on the platelet surface upon activation and induces 
procoagulant PS exposure [143] and TF synthesis in monocytes [144]. TF-containing 
microparticles (MPs) have been reported to be generated by interactions between P-
selectin and PSGL-1. Furthermore the presence of P-selectin on activated platelets helps 
to recruit these MPs to the developing thrombus [145].   However, the addition of a 
function-blocking P-selectin antibody caused no change in the time when a thrombin 
burst was detected, in the absence or presence of CVX (Figure 2.4-5). VIIa can bind 
weakly to activated platelet surfaces and support thrombin generation independently of 
TF [146]. Weeterings et al. have reported recently that GP1bα can bind rFVIIa with a Kd 
of ~20 nM and this interaction enhanced TF-independent thrombin generation [147]. 
However, neither antibodies against VII/VIIa (Figure 2.4-7 B), nor antibodies against 
GP1bα (Figure 2.4-5) had any effect on the initiation of thrombin formation with or 
without CVX stimulation. 
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Figure 2.4-5 Studying the effect of P-Selectin and GP1bα on initiation  
Addition of antibodies against P-selectin or Gp1bα did not prolong initiation either in the 
absence or presence of high dose CVX 
 
 
Protein disulfide isomerase (PDI) has been suggested as a possible trigger for 
tissue factor dependent fibrin generation. PDI originating from adhering platelets [148] 
can activate ‘encrypted or cryptic’ [82] functionally inactive TF by changing the disulfide 
status of the Cys186-Cys209 pair on the TF molecule [149]. Fibrin formation, following 
infusion of TF microparticles were shown to be strongly inhibited by an anti-PDI 
antibody in vivo [150]. However, in our hands an anti-PDI antibody had no significant 
effect in prolonging Ti with or without CVX treatment (Figure 2.4-6), suggesting that TF 
de-encryption via PDI was not a mechanism at play. This is consistent with earlier reports 
that: (1) exogenously added PDI or anti-PDI antibodies had no effect on TF-VIIa 
coagulant activity shown by MDA-MB231 cells stimulated with HgCl2; or (2) PDI 
silencing with PDI shRNA had no effect on procoagulant activity [151].  
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Figure 2.4-6 Studying the effect of PDI and Cathepsin G on initiation 
Addition of antibodies against PDI or cathepsin G did not prolong initiation either in the 
absence or presence of high dose CVX. 
 
 
The integrin Mac-1 (CD11b/CD18) on neutrophils or monocytes can bind FX 
which can be converted to Xa by cathepsin G. Inflammatory stimuli or Mac-1 
engagement of its ligands (including fibrinogen and FX) stimulates degranulation and 
release of cathepsin-G [152]. Such a mechanism of X activation could lead to initiation in 
the absence of TF. However, the addition of a anti-cathepsin G antibody had no effect in 
prolonging the time at which a burst in thrombin production occurred with or without 
CVX treatment (Figure 2.4-6).   
We note that in all experiments utilizing antibodies and without prior platelet 
activation there was slight reduction (relative to the control where no antibody was 
added) in the time taken for initiation to occur. For instance, sheep IgG by itself reduces 
Ti (Figure 2.4-5) from 91.82±13.35 (control) to 70.08±10.57 min. Such effects were 
possibly mediated by non specific Fcγ-R mediated platelet activation [153] and were not 
apparent when the platelets were already fully activated with CVX. 
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Figure 2.4-7 Effect of TF translation and activity 
(A) The ribosome inhibitor puromycin; the Clk1 kinase inhibitor Tg003; (B) antibodies against 
TF, VII/VIIa; or (C) VIIai did not prolong initiation either in the absence or presence of high dose 
CVX. This shows that initiation is unaffected by either ‘bloodborne’ or platelet synthesized TF on 
the time scales of our experiments. 
 
Platelets may have the capacity to rapidly splice TF pre-mRNA to a mature 
transcript and rapidly translate TF protein intracellularly [154].  We added Tg003 and 
puromycin to inhibit Cdc2-like kinase (Clk)1 and ribosomal function, respectively, two 
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platelet functions reported to be responsible for splicing TF pre-mRNA and rapid TF 
mRNA translation [154]. A level of 10 μM Tg003 and 5 μM puromycin had no effect on 
the initiation (Figure 2.4-7 A), either in the absence or presence of CVX. This suggests 
that the capacity of platelets to splice TF pre-mRNA and rapidly express TF protein does 
not contribute to clotting initiation at least on the time scales of the experiment. Also, the 
addition of 20 μg/ml anti-TF, 20 μg/ml anti-VII/VIIa (Figure 2.4-7 B) or 1 μM active site 
inhibited factor VIIa, VIIai (Figure 2.4-7 C) caused no increase in Ti with or without 
CVX activation of the platelets. This further suggests that in whole blood endogenous TF 
mediated mechanisms are not responsible for clotting initiation.      
2.4.4 Evaluating the role of CTI 
In the absence of evidence for kinetically-significant blood borne TF, we 
evaluated the efficacy of CTI (Figure 2.4-8). Without inclusion of CTI in the syringe or 
in the well plate, clotting initiated in 57.3 ± 9.9 min.  When 10 μg/ml CTI (final 
concentration) was included in the well plate, initiation occurred in 77.4 ± 7.0 min due to 
inhibition of XIIa production. When the same final concentration was achieved (after a 
5x final dilution of blood in the well plate) by including 50 μg/ml CTI in the phlebotomy 
syringe, initiation time was markedly prolonged to 110.0 ± 17.0 min.  Liquid handling of 
citrated blood after phlebotomy takes ~3 minutes before recalcification and this result 
points to the significant production of XIIa during this initial period. When very high 
concentrations (100 μg/ml) of CTI were achieved by including CTI in the syringe (50 
μg/ml, diluted 5x in the well plate) and 90 μg/ml preexisting CTI in the well plate, 
initiation occurred in 96.6 ± 15.1 min and was not prolonged further.  Thus, the inhibitory 
effect of CTI saturates, pointing to the possibility of a XIIa leak past CTI.   
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Figure 2.4-8  Saturation of the effects of CTI  
To evaluate the possibility of leakage past CTI, experiments were conducted with no 
CTI, CTI addition in well plate, CTI addition during phlebotomy and large quantities of 
CTI during phlebotomy as well as in well plate. The inclusion of 50 μg CTI/ml whole 
blood (before a 5x dilution in the well plate) produced saturating effects. 
 
2.4.5 Anti-XI and XII used simultaneously prevent initiation in resting 
blood 
Combined addition of 50 μg/ml of anti-XI and anti-XII to diluted whole blood 
(with CTI) completely abolished initiation (Figure 2.4-9) demonstrating that for 
conditions lacking platelet activation a steady leak of XIIa activity past CTI was the most 
proximal trigger of platelet activation and subsequent clotting of minimally perturbed 
blood in vitro.  Interestingly, anti-XII when used alone did not prevent initiation (not 
shown), suggesting that inspite of our best attempts at preventing XII activation in diluted 
whole blood (CTI and anti-XII used together), some XIIa is still formed on the time scale 
of our experiments, necessitating the inhibition of XI activity as well. Also, anti-XI by 
itself did not prevent initiation in whole blood (not shown), suggesting strong 
autocatalytic amplification by very minute amounts of XIa formed inspite of the use of 
the inhibitory XI antibody.  Despite the efficacy of high dose CTI in conjunction with 
anti-XI and anti-XII in preventing activation in resting blood, there was no effect of these 
antibodies on Ti when blood had been treated with CVX. The levels of thrombin 
produced during the initial moments of the propagation phase of thrombin production 
(after Ti) were however diminished as demonstrated by lowered rates of fluorescence 
increase. This was possibly a consequence of the inhibition of thrombin- mediated 
feedback on FXI after initiation [155]. 
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Figure 2.4-9 Effect of anti-XI and anti-XII. 
Addition of 50 μg/ml of anti-XI and anti-XII will completely prevent initiation of clotting 
in resting blood showing that initiation is a result of leak past saturated effects of CTI. 
However, on CVX activated platelets initiation is still unaffected by the presence of both 
CTI and these antibodies. Initial thrombin production during the propagation phase is 
however diminished due to abolition of thrombin feedback on FXI. Insert shows initial 
rates of thrombin formation in the presence of these antibodies. 
 
2.4.6 Preventing initiation in CVX treated blood  
 Unlike the case of resting blood, initiation could not be prevented in blood 
pretreated with CVX by the use of antibodies against XI and XII. To probe further the 
mechanism responsible for such initiation, we supplemented CTI-treated regular plasma 
and CTI-treated plasmas deficient in factors VII, XI and XII with washed platelets.  
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Thrombin generation in these samples as well as samples of plasma that had been treated 
with antibodies against TF, VII, XI, XII, or XI/XII/VII was studied following CVX 
activation (Figure 2.4-10). Antibodies against TF had no detectable effect. Thrombin 
formation was not completely inhibited by blocking any single factor individually, but 
was inhibited in samples where the activities of XI, XII and VII were simultaneously 
inhibited (Figure 2.4-10, last row of subplots). In particular clotting was completely 
inhibited in 6 out of 8 wells in XI-deficient plasma treated with antibodies against XI, XII 
and VII. Inhibition of VIIa activity alone is insufficient (initiation times are almost 
unchanged in VII-deficient plasma treated with a VII antibody) because XIa formation 
beyond the XIIa leak past CTI, is still sufficient to trigger thrombin formation. Inhibition 
of XI activity (XI-deficient plasma with an XI antibody) has pronounced inhibitory 
effect, but was still insufficient with VIIa being functionally active on the active platelet. 
Thus upon activated platelets, in addition to blocking factors XI and XII, VIIa activity too 
must be inhibited to prevent thrombin generation. 
It should be noted that immunodepleted plasmas deficient in coagulation factors 
have <1% normal activity of the particular factor, but are still not completely devoid of 
the depleted protein. This explains why initiation is prolonged further by antibodies 
against a protein that had already been immunodepleted in plasma. For instance thrombin 
generation in anti-XI treated, XI- deficient plasma is inhibited compared to that observed 
in XI-deficient plasma alone. The use of deficient plasmas offers a “cleaner inhibition” 
because the protein being targeted for inhibition is largely absent from the onset, as 
opposed to reliance on the inhibitory antibody to exert its effect before the protein is 
functionally active.   
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Figure 2.4-10 Prevention of initiation on CVX activated platelets. 
CTI-treated regular plasma or plasma deficient in factors VII, XI or XII were 
supplemented with washed (plasma free) platelets. These samples were left untreated or 
were treated with antibodies against TF; VII; XI; XII or XI, XII and VII simultaneously; 
and tested for thrombin generation without exogenous TF addition after activating 
platelets with 25 nM CVX.  Simultaneous inhibition of XI, XII and VII activity was 
required to completely abolish thrombin generation. 
 
Thrombin formation, once clotting is initiated by a single activator for instance by 
the addition of TF or Xa (See Figure 2.4-11) yields relatively small variations in 
initiation time when tested in multiple replicates. However, given the strongly 
autocatalytic nature of the cascade, complete abolition of a triggering mechanism is much 
more challenging. Even small localized diffusional or binding limitations of the 
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inhibitory antibody will allow individual molecules that bypass the inhibitors to trigger 
the cascade. This accounts for the relatively large variations we observe in trying to 
inhibit initiation upon activated platelets, where thrombin formation occurs stochastically 
past inhibitory antibodies against targeted coagulation proteins. 
2.4.7 Titrations of TF and active proteases into blood  
Addition of exogenous lipidated TF was used to initiate coagulation via the 
extrinsic pathway.  Concentrations from 0.5 fM to 5 pM were added to whole blood 
(Figure 2.4-11 A).   Added TF resulted in a continual, statistically significant reduction 
of initiation time over a wide dynamic range of 3 orders of magnitude of concentration 
from 20 fM to 20 pM.  Distinct from flow experiments where a concentration threshold 
exists between 2 and 20 molecule-TF/μm2 [156], no switch-like regime was detected 
under static conditions. This suggests that the barrier to be overcome in the flow system 
to exceed the threshold is not a chemical inhibition barrier since such a barrier would be 
present under stasis as well. The observation is consistent with Fogelson and Tania [157] 
who note the barrier responsible for the threshold under flow is a physical one dependent 
on competition between flow-mediated removal and rate of production of procoagulants. 
Next, we investigated the individual components of prothrombinase (XaVa 
complex) on coagulation initiation (Figure 2.4-11 B). Addition of Va showed negligible 
effects with minimally decreased initiation time from 0.3 nM to 4 nM added Va (>10% of 
the plasma concentration of V).  This relative insensitivity indicated that Va was not a 
limiting during coagulation initiation, in agreement with previous studies that show that 
Va may be present in platelets or be rapidly displayed or produced during activation 
[158]. In contrast, Xa additions produced a marked switch-like action by moving from a 
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negligible change in Ti at 10 pM to nearly saturating effect at 100 pM, a concentration 
that is <0.1% of the plasma concentration of X.  This switch-like behavior was consistent 
with the well understood rate limiting role of Xa [94].   
Further, we explored reactions proximal to thrombin production by addition of 
increasing amounts of Factors VIIa, IXa and XIa to blood (Figure 2.4-11 C).  The 
nominal concentrations of endogenous VIIa (1 % of VII) prior to exogenous addition in 
5x blood is 20 pM [159].  Using 5x final blood dilution, we extended these 
concentrations to reach an effective concentration of VIIa above 1 nM. VIIa has no 
significant effect until above 1 nM, approximately 10% of the circulating amount of VII.  
For comparison, high dose rVIIa therapies use up to ~17 nM final concentrations [160].  
The dynamic range for added IXa extended from below 5 pM to above 500 pM and that 
for XIa extended from below 2 pM to above 200 pM.  The upper end of these ranges are 
less than 1% of the circulating IX and XI concentration respectively [161]. Similar to 
results for TF, the addition of IXa or XIa in this assay did not display a switch-like 
regulatory function, i.e. changing from no effect to full effect over some narrow 
concentration range, but rather displayed a broad dynamic response over a wide range of 
concentrations. 
Baseline low level protease activity can exist even in healthy individuals (the 
“engine idling” theory). Knowledge of the upper bounds of these proteases defines the 
levels of these enzymes that allow blood to remain in a stable state (flowing normally) in 
spite of their presence.  Experimentally measured values of active proteases for a patient 
that are significantly different from these values might indicate underlying coagulation 
disorders or heightened sensitivity to weak triggers of clotting.   
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Figure 2.4-11 Titration of TF and active proteases into blood.   
(A) Effect of exogenous TF on initiation time.  TF was titrated from 0.5 fM to 5 pM in 
5x  diluted blood. The black solid line is the simulated initiation time for the Hockin-
Mann model (with SIIa) and the blue dashed line is the prediction of the Platelet-Plasma 
model. The light green solid line is the experimental control with no added TF. (B) 
Addition of prothrombinase components.  Xa (red) and Va (green) was added to 5x  
diluted blood. The black solid line is the simulated initiation time for the Hockin-Mann 
model (with SIIa). The red and green dashed lines are the prediction of the Platelet-Plasma 
model for Xa and Va, respectively. The light green solid line is the experimental control 
with no added proteins. (C) Addition of VIIa, IXa and XIa. Various concentrations of 
VIIa (green), IXa (red) and XIa (blue) were added to blood at 5x dilution. The dashed 
lines of the corresponding color are simulations done with the Platelet-Plasma model.   
The light green solid line is the experimental control. (Experiments courtesy Bill Denney) 
 
2.4.8 Platelet-Plasma model of thrombin production in human blood 
The Hockin-Mann model was used to simulate these tirations and was found to be 
quite accurate for TF concentrations above 1 pM, but diverged dramatically at 
concentrations below 1 pM (Figure 2.4-11 A, black solid line) of added TF. We have 
shown experimentally, that a leak of XIIa past saturating levels of CTI is responsible for 
eventual intiation. This prompted us to include the contact factor pathway to Hockin-
Mann topology.  
Upon contact with anionic surfaces a conformational change occurs in the 
zymogen  FXII, resulting in the formation of active FXIIa. The exact mechanism for XII 
surface adsorption, conformation change and activation remain ambiguous and cannot be 
modeled easily.  We therefore coarse grained surface mediated XII activation by 
assuming a first order dependence on XII concentration (Reaction 29, Table 2.4-1) and 
estimating a rate of production (5×10-4s-1) that would resolve the disparity between the 
Hockin-Mann model prediction and the experimentally observed control (green) at 0 TF 
(without disrupting its predictive ability at high TF).  It should be noted that this 
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estimated rate of XIIa production was based solely on observations in our experimental 
surfaces (Corning 384-well plates) and may well be different on other surfaces. The small 
amount of XIIa that is initially formed auto-activates upon negative surfaces in vitro 
(Reaction 30, Table 2.4-1). Formed XIIa further activates Pre-Kallikrein to active 
Kallikrein (Reaction 31, Table 2.4-1), which in turn reciprocally activates XII (Reaction 
32, Table 2.4-1) and Pre-Kallikrein (Reaction 33, Table 2.4-1). Both Kallikrein and 
XIIa are inhibited by plasma protease inhibitors (Reaction 34, 36-37; Table 2.4-1). 
Further, XIIa is inactivated by CTI included at high concentrations specifically to inhibit 
contact activation (Reaction 35, Table 2.4-1). Despite the efficacy of CTI, it is a 
reversible inhibitor of XIIa; and thus there is always some active XIIa beyond CTI 
resulting from the unbinding of the XIIa=CTI complex. Such XIIa that has “leaked past” 
CTI can in turn activate XI (Reaction 39, Table 2.4-1). Thrombin feedback on XI has 
also been considered (Reaction 38, Table 2.4-1) as a mechanism for XI activation.  
We have experimentally observed (Figure 2.4-11 C) strong sensitivity of blood to 
very minute doses of XIa (even 2 pM of added XI reduced Ti significantly from that of 
the control). Also complete abolition of clotting without exogenous TF, required 
inhibition of XI activity in addition to XII (Figure 2.4-9 and Figure 2.4-10) suggesting 
that the very little XIa that is formed downstream of XIIa is able to strongly self amplify 
(especially if the pro-coagulant surface of the activated platelet is readily available). With 
inhibition by ATIII, C1-inhibitor, α1-antitrypsin and α2-antiplasmin (Reaction 41-44; 
Table 2.4-1), such sensitivity could not be adequately explained by just XIIa mediated 
activation and thrombin feedback on XI. Therefore we also included the mechanism of 
XI auto-activation [136] on negatively charged surfaces to the topology of the network 
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(Reaction 40, Table 2.4-1). Following the retraction of Baglia and Walsh, JBC 2000 we 
are not aware of experimental reports on the kinetics of this reaction. However, 
Kramoroff et.al [126] estimate the second order rate constant of this reaction to be 3.19 
μM-1s-1  by optimizing an ODE model of the intrinsic cascade to experimental 
measurements of APTT. They consider either XI autoactivation or XI activation by 
thrombin (but not both possibilities) as plausible mechanisms for XI activation (in 
addition to activation by XIIa), thus their estimated value is likely an overestimate. We 
utilized a value 4-fold lower than the value they report for this constant, since we 
consider both mechanisms. 
The XIa that is formed activates IX (Reaction 45, Table 2.4-1). Unlike the 
original Hockin-Mann topology, IXa in the absence of its cofactor is now able to activate 
some factor X (Reaction 46, Table 2.4-1) albeit very inefficiently. This minute amount 
of Xa contributes to the activation of VIII (Reaction 47, Table 2.4-1), in addition to the 
VIII activation by thrombin in the Hockin-Mann structure (Reaction 10, Table 2.4-1).  
VIIIa once formed dramatically raises the efficacy of IXa and hence subsequent thrombin 
formation.  Thus such participation of Xa in VIII activation (in addition to its ability to 
directly convert prothrombin) helps it to function in simulation as the dramatic switch 
like controller of the cascade we observed experimentally (Figure 2.4-11 B).  
VIIa above 1 nM concentrations is able to produce significant lowering of Ti 
independently of TF (Figure 1.1-1 C). Furthermore, with platelet activation, inhibition of 
VII activity was required (in addition to the inhibition of XI and XII activity) to 
completely block thrombin generation (Figure 2.4-10). This suggests that VIIa activity 
independent of TF, is effective at high concentrations and on the activated platelet. This 
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prompted us to include VIIa’s ability to convert IX and X (independent of TF) in the 
structure of the model (Reactions 48-49; Table 2.4-1). 
Fibrinogen can act as an efficient sink for thrombin in experiments conducted in 
whole blood, and thus limit its ability to generate positive feedback by converting other 
zymogens or activating platelets. The thrombin catalyzed formation of fibrin I and fibrin 
II, release of fibrinopeptides A and B and the irreversible entrapment of thrombin in 
complexes with fibrin and antithrombin  are described in (Reactions 50-57; Table 2.4-1) 
using published kinetics [135]. 
With these additions to the structure of the Hockin-Mann topology, we could now 
obtain quantitative agreement between experimental and simulated titrations of the 
procoagulant proteins TF, Va, VIIa, IXa, Xa and XIa into 5x diluted blood. The original 
Hockin-Mann topology could predict finite Ti for only high dose TF/ Xa (Solid lines in 
Figure 2.4-11 A and B). 
Although there is evidence to suggest that TF dependent reactions (Table 2.4-1, 
Reactions 1, 2, 6-8 and 21) are sped up on acidic phospholipids (See Comments in 
footnotes to these reactions in Table 2.4-1), no ε dependence was used for these reactions 
in our simulations of the TF titration in Figure 2.4-11 A. This is because TF was already 
added in lipidated form in these experiments, and thus the TF-VIIa assembly or activity 
will not be affected by changing lipid composition upon the platelet surface. 
The Kuharsky-Fogelson model [96] for thrombin formation under flow in the 
presence of collagen activated platelets shows [Xa] remaining at levels of about 10 pM 
throughout the duration of simulation.  In the Hockin-Mann model with a TF stimulus of 
5 pM, Xa concentrations are 10-100 pM during the times that substantial thrombin 
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formation first occurs and subsequently this rises by about 10-fold. Our results, along 
with the modeling predictions in these papers suggest why it is necessary that clotting be 
sensitive to low levels of Xa in vivo. Namely, if levels produced under flow (where Xa 
can be rapidly convected downstream) are to be efficacious at all, they must produce 
substantial effects at very low levels (~10 pM), despite the presence of much higher 
concentrations of X, or the system’s ability to produce much larger concentrations of Xa 
under conditions of stasis. 
 
Figure 2.4-12 Simulated transients of selected species during coagulation with TF. 
Shown above are the time courses of thrombin, Xa, Xa:Va, Va and the platelet’s 
activation state (ε) for coagulation triggered with 5pM TF in whole blood.  Before 
initiation sufficient catalyst quantities are built up by the minute (subnanomolar levels) of 
thrombin being formed. Concentrations of all species increase steeply beyond initiation 
(and full platelet activation) during the propagation phase of the thrombogram.  Note, the 
shift in equilibrium of Va towards Xa:Va following platelet activation. Thrombin 
concentrations eventually start decreasing because of destruction of the free enzyme by 
ATIII and consumption of limited reserves of prothrombin inspite of the presence of 
sufficient prothrombinase catalyst. 
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Similar to Kuharsky-Fogelson (Figure 7 of reference [96]), we show in Figure 
2.4-12 simulations for the concentrations of thrombin, Xa, Xa:Va, and Va for a stimulus 
of 5 pM TF (Also, compare to Hockin-Mann, Figure 8B of reference [94]). We found 
free Xa concentrations growing to about 20 pM during the initial instants followed by a 
much more substantial burst (that increases Xa levels by ~3 orders) following platelet 
activation.  The Va concentrations grow steadily, but beyond full platelet activation (~10 
nM thrombin), there is a dramatic shift in the equilibrium towards Xa:Va and thus the 
amount of free Va drops rapidly, as prothrombinase levels rise steeply. 
2.4.9 Simulations of clotting times in whole blood 
 Our high throughput experimental system allows us to efficiently study 
coagulation reactions under various perturbations with multiple replicates. However, 
reaction volumes in our 384-well plate systems are only 50 μl, preventing us from 
studying undiluted whole blood. Automated liquid handling can dispense with high 
precision volumes of 5 μl, but for lower volumes experimental variability is high. Since 
each individual well must contain several reagents (calcium, fluorogenic substrate, 
platelet agonists, antibodies and coagulation proteases) other than human blood, there is a 
limitation to the volume of blood that can be used in each well.  
De Smedt et al. [162] have recently reported that anticoagulant pathways 
(particularly the TFPI and APC mediated) are more affected by dilution than the 
procoagulant pathways. However, they did not observe any significant effect of dilution 
on the duration of the initiation phase, both for TF and Kaolin stimulated coagulation 
reactions in PPP upto dilutions of 12x (detectable effects on endogenous thrombin 
potential and peak height of the thrombograms were however reported).  Blood at 5x 
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final dilution is below this limit of 12x dilution beyond which linear scaling of initial 
conditions with the dilution factor might not be sufficient to account for the kinetics of 
thrombin generation initiation, and provides a tractable system for extensive high 
throughput experimentation. In simulating such experiments, the initial conditions of all 
species were divided by 5 to account for the dilution in each well. 
 
Figure 2.4-13 Simulating clotting times in whole blood. 
The very small reaction volumes in a 384 well plate prevent us from studying coagulation 
reactions in whole blood (See text). To simulate the kinetics of initiation in whole blood 
we simulated clotting times for  additions  of TF, thrombin (IIa), IXa , Xa or 
combinations of all 3 proteases at low and high doses reported by Butenas et al. [163] in 
the Mann laboratory. We found good qualitative agreement between experimental 
clotting times (blue) and initiation times predicted by the Platelet-Plasma model (green). 
The Hockin-Mann (with fluorogenic thrombin substrate, SIIa) model (red) predicts finite 
initiation times only in the presence of high dose TF or Xa. 
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To test the ability of the model to predict perturbations in whole blood, we 
simulated clotting times (a good measure of the time to generate a burst in thrombin) for 
additions of either  TF; IXa, Xa, thrombin; or all 3 proteases together reported by Butenas 
et al. [163]. We found good agreement between experimentally reported values of 
clotting time and predicted initiation times across all conditions (Figure 2.4-13). The 
original Hockin-Mann model could predict finite Ti in the presence of high dose TF/ Xa, 
or when low dose thrombin, IXa  and Xa were present simultaneously. 
2.4.10 Simulating platelet activation 
The Hockin–Mann model assumes a fully activated platelet at t=0.  In the 
Kuharsky-Fogelson model [96] or the Cellular Potts model [164], platelets can exist 
either in discrete “unactivated” or “activated” states. We do not consider platelets 
explicitly, but all reaction rates reported in literature to be dependent on platelet 
activation are altered by a single function (ε) of thrombin concentration (See Methods). 
As the platelets are activated by thrombin, they expose anionic phospholipids like PS on 
their surface, and the “platelet activation status” ε increases from a basal state of 0.01 to 
1.00.  The unbinding rates of all enzyme-substrate complexes are set to their literature 
values at saturating PS levels, but are all divided by ε. Thus, as the platelet activates the 
unbinding rates dynamically decrease by two orders of magnitude, consistent with the 
notion that the platelet surface becomes more procoagulant. In the Kuharsky-Fogelson 
model of intravascular thrombosis under flow, reaction rates depend on the availability of 
fully activated platelets (contributing maximal platelet binding sites for the coagulation 
factors).  Since binding sites change with the concentration of activated platelets, the 
local effective reaction rates change as well.  For modeling isotropic coagulation in a well 
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plate, we account for a continuum of platelet activation states by thrombin and assume an 
excess of PS once platelets fully activate (as opposed to discrete saturable binding sites in 
the Kuharsky-Fogelson model). 
Reactions that have been reported in literature (See Table 2.4-1 footnotes) to be 
accelerated by acidic phospholipids are upregulated in the model when platelets are 
activated by thrombin as ε increases (and dissociation rates decrease). Platelets provide 
the negative surfaces for coagulation factor assembly in vivo, yet most current 
enzymology studies of coagulation enzyme kinetics in vitro use artificial phospholipid 
surfaces since standardizing platelet surfaces for kinetic assays is difficult. 
In reality, surface adsorption of procoagulant molecules might also alter the 
catalytic efficiency (kcat), but for the sake of simplicity all kcat values are set to their 
reported values at saturating PS levels (with the assumption that loose enzyme substrate 
complexes will hardly be formed in the first place and thus rarely get converted). The 
assumption that all unbinding rates change by two orders of magnitude is also made for 
simplicity. (In reality some enzyme substrate complexes are dramatically strengthened on 
exposed PS surfaces, while others show only weak dependence. See Table 2.4-1 
footnotes.) 
We make the assumption that the amount of active surface available upon 
activation of platelets at normal platelet counts (3×106 platelets per 50 μl reaction well for 
5×diluted blood with a platelet count 3×108 platelets/ml) is sufficient for coagulation 
reactions to proceed at their most optimal rates. Thus, like the Hockin-Mann model we 
assume an excess of phospholipid surfaces once the platelets are activated. Yet, our 
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approach accounts for the fact that surface reactions occur at a rate dependent on the 
extent of platelet activation rather than being fixed at the highest level at t = 0. 
As a pseudohomogeneous and single phase model of coagulation, we do not treat 
platelets as separate entities (or account for free and plate bound species).  Thus, the fact 
that each platelet may have a limited number of specific binding sites is not considered. 
Our approach assumes that sufficient binding sites are available in 5×diluted blood, an 
assumption that may not be valid at greater dilutions. Also, we assume that coagulation in 
a well plate is well mixed, lacks spatial gradients, and is not transport-controlled.  In 
contrast, intravascular thrombosis occurs under conditions with (1) substantial gradients 
of reactive species and platelet binding sites, (2) significant effects of convective 
transport on soluble species, and (3) intrathrombic diffusion limitations. 
Setting the initial activation state
0max
ε , allows us to control in simulation the basal 
level of activation of the platelet (Figure 2.4-14 B). For 01.0
0max
=ε  (akin to assuming 
1% PS exposure on the surface of unactivated platelets), we obtain a burst in thrombin 
production (and hence fluorogenic substrate cleavage) at ~75 min in the Platelet-Plasma 
model. To simulate experiments where coagulation reactions occur upon pre-activated 
platelets, 
0max
ε is set to a value of 1.0 (with the assumption that the fully activated 
platelets have exposed all of their PS) giving Ti ~15 min. These values are in good 
agreement (Figure 2.4-14 A) with the mean initiation times obtained upon unactivated 
platelets (solid lines) and activated platelets (dashed lines) for the 4 donors shown in 
Figure 2.4-3.  
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Figure 2.4-14 Simulating platelet activation. 
(A) Mean substrate conversion across all replicates for the donors shown in Figure 2.4-3. 
Substrate conversion traces without platelet activation are shown in solid lines and 
conversion traces upon activated platelets are shown in dashed lines. (B) Setting the 
initial activation state ( )
0max
ε   allows us to simulate platelet activation and its dynamic 
effect on all platelet dependent unbinding rates (see methods). The red line indicates 
simulations of substrate conversion without prior platelet activation ( )01.0
0max
=ε . The 
blue dashed line indicate simulations of substrate conversion upon instantaneously fully 
activated platelets at t = 0. ( )0.1
0max
=ε  
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We note that the rate of thrombin production (substrate conversion) in simulation 
beyond Ti increases more sharply than actually observed in experiment.  Thrombin 
concentrations at Ti are ~10 nM, corresponding to a fully activated platelet (Figure 2.3-2) 
beyond Ti. This suggests that a method of prothrombinase inhibition (that has not been 
considered in our reaction topology) may exist once platelets are activated. Inhibition of 
XaVa in vitro in the absence of endothelial thrombomodulin is poorly understood. 
Further experiments will be required to pinpoint this inhibitory mechanism, but for the 
present the Platelet-Plasma model is a reliable indicator of the time taken to generate a 
burst in thrombin in vitro.  
2.4.11 Sensitivity analysis of the Platelet-Plasma model 
We estimated global parameter sensitivities for the Platelet-Plasma Model’s 
output for 10 pM added TF (Figure 2.4-15 A and Table 2.4-3) and 0 added TF (Figure 
2.4-15 B and Table 2.4-4) input stimuli by the method by the method of weighted 
averaging of local sensitivities [165]. In this method local parameter sensitivities in 
output ‘y’, for a parameter ‘j’ (j = 1, …, 105)  at a point ‘i’ in parameter space is first  
calculated by introducing a 2% increment in the parameter pj : 
              
jj
ij pp
yys
/
/
∂
∂=       (2.4.1)  
We define ‘y’ to be the thrombin concentration at the initiation time (Ti) of the 
nominal parameter set. Note Ti  cannot be used as the output during sensitivity analysis 
because 5% conversion of the fluorogenic substrate is not achieved in some perturbed 
parameter sets. Local sensitivities were calculated at multiple random points ‘i’ in a very 
large parameter space where each of the 105 parameters has a spread of half an order of 
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magnitude around their nominal value. In total 10,000 points were explored (10,000 ×105 
simulations) and global sensitivity indices were determined by calculating a weighted 
average of local sensitivities. Similar to Bentele et al. [165] we use the Boltzmann- 
Distribution exp (-E / kbT) for weighting, in which E is the difference in thrombin 
concentration between the nominal and perturbed states and kbT is a scaling factor (we 
use minimum E for scaling). Based on the assumption that parameter sets resulting in 
output values close to the experimental observation are the most probable, this approach 
statistically amplifies the sensitivities of parameter sets that result in outputs close to the 
nominal solution.  For ease of visualization sensitivity indices were normalized between 
0 and 1 and the values for ranked according to decreasing sensitivity. 
Other methods of global sensitivity analysis like ‘Sobol’s method’ [166] or the 
‘Extended FAST method’ [167] provide non-biased sampling over the entire parameter 
space . Such methods were attempted (not shown) and provide similar rank orderings of 
sensitivities. However convergence was not achieved in a feasible amount of time.  
For 10 pM added TF (Figure 2.4-15 A and Table 2.4-3), the rate of binding of 
TF to VIIa was found to be the most sensitive, followed by the rate of binding of X to 
TF:VIIa. Interestingly, thrombin production was also found to be strongly sensitive to TF 
independent VIIa binding to IX, as well as VIIa ‘s ability to convert X by itself. 
Reactions regulating prothrombinase formation (Ranks 7 and 8) were also found to be 
sensitive. Contact activation (XIIa) mediated reaction rates were generally too slow too 
have any appreciable effect, although thrombin feedback on XI was found to be 
moderately sensitive (Ranks 17 and 18). 
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Figure 2.4-15 Global sensitivity analysis of the Platelet-Plasma model 
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Rank Parameter  Rank Parameter 
1 'k_on_TF_VIIa' 54 'k_on_Fbn1_binding_IIa' 
2 'k_on_X_TF_VIIa' 55 'k_off_X_VIIa' 
3 'k_off_IX_VIIa' 56 'k_off_IXa_X' 
4 'k_on_IX_VIIa' 57 'k_on_IXa_X' 
5 'k_cat_VII_Xa' 58 'k_off_Xa_VIII' 
6 'k_cat_V_IIa' 59 'k_off_Fbn1_2_unbinding_Fbn1_IIa' 
7 'k_on_Xa_Va' 60 'k_cat_Xa_VIII' 
8 'k_off_Xa_Va' 61 'k_on_TF_VIIa_Xa_TFPI' 
9 'k_cat_II_Xa' 62 'k_cat_VII_IIa' 
10 'k_cat_mIIa_Xa_Va' 63 'k_on_IXa_ATIII' 
11 'k_on_II_Xa_Va' 64 'k_off_XIIa_XI' 
12 'k_off_Xa_TF_VIIa' 65 'k_off_VIII_HC_LC_IXa' 
13 'k_cat_X_TF_VIIa' 66 'k_cat_XIIa_producing_Kallikrein' 
14 'k_on_TF_VII' 67 'k_on_bXIIa_binding_PreKallikrein' 
15 'k_on_TFPI_TF_VIIa_Xa' 68 'k_on_wall_XIIa_production' 
16 'k_off_TF_VII' 69 'k_off_XII_unbinding_Kallikrein_XII' 
17 'k_off_XI_IIa' 70 'k_off_XII_XIIa' 
18 'k_on_XI_IIa' 71 'k_on_Xa_VIII' 
19 'k_cat_off_mIIa_Xa_Va' 72 'k_on_CTI_XIIa' 
20 'k_off_TFPI_TF_VIIa_Xa' 73 'k_cat_XI_IIa' 
21 'k_off_II_Xa_Va' 74 'k_off_X_IXa_VIIIa' 
22 'k_on_IIa_ATIII' 75 'k_on_Fbn1_2_destruction_by_ATIII' 
23 'k_on_Xa_ATIII' 76 'k_cat_XIIa_XI' 
24 'k_on_Fbg_binding_IIa' 77 'k_off_CTI_XIIa' 
25 'k_off_Fbg_unbinding_Fbg_IIa' 78 'k_on_XI_autoactivation' 
26 'k_plt_delay' 79 'k_off_VIII_HC_LC_IXa_X' 
27 'k_off_Boc_VPR_AMC_IIa' 80 'k_off_VIII_HC_LC' 
28 'k_on_Boc_VPR_AMC_IIa' 81 'k_off_Fbn2_IIa_dissociation' 
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29 'k_on_IX_TF_VIIa' 82 'k_on_Fbn2_IIa_association' 
30 'k_off_IX_TF_VIIa' 83 'k_on_XII_binding_Kallikrein' 
31 'k_on_mIIa_ATIII' 84 'k_on_C1inh_inhibition_of_XIIa' 
32 'k_cat_IIa_producing_Fbn1' 85 'k_on_Fbn2_IIa_destruction_by_ATIII' 
33 'k_cat_IX_TF_VIIa' 86 'k_on_XIa_IX' 
34 'k_on_TF_VIIa_ATIII' 87 'k_on_ATIII_inhibition_of_XIIa' 
35 'k_off_Xa_TFPI' 88 'k_on_XIa_inhibition_by_alpha1AT' 
36 'k_on_Xa_TFPI' 89 'k_on_Kallikrein_autoactivation' 
37 'k_on_IXa_VIIIa' 90 'k_on_C1inh_inhibition_of_XIa' 
38 'k_cat_VIII_IIa' 91 'k_cat_IIa_producing_Fbn2' 
39 'k_on_X_IXa_VIIIa' 92 'k_on_XIa_inhibition_by_alpha2AP' 
40 'k_cat_Boc_VPR_AMC_IIa' 93 'k_on_VIII_HC_LC' 
41 'k_off_Fbn1_unbinding_Fbn1_IIa' 94 'k_cat_X_VIIa' 
42 'k_off_TF_VIIa' 95 'k_on_XIIa_XI' 
43 'k_off_X_TF_VIIa' 96 'k_on_XII_XIIa' 
44 'k_on_Fbn1_2_dimer_association' 97 'k_cat_XIa_IX' 
45 'k_on_Xa_TF_VIIa' 98 'k_cat_Kallikrein_producing_XIIa' 
46 'k_off_IXa_VIIIa' 99 'k_cat_IIa_producing_Fbn2_2' 
47 'k_cat_IXa_X' 100 'k_on_Kallikrein_inhibition' 
48 'k_cat_X_IXa_VIIIa' 101 'k_cat_XIIa_production' 
49 'k_on_Fbn1_IIa_destruction_by_ATIII' 102 'k_off_XIa_IX' 
50 'k_on_X_VIIa' 103 'k_off_bXIIa_unbinding_PreKallikrein_XIIa' 
51 'k_cat_IX_VIIa' 104 'k_on_ATIII_inhibition_of_XIa' 
52 'k_on_Fbn1_2_binding_IIa' 105 'k_off_Fbn1_2_dimer_dissociation' 
53 'k_cat_VII_TF_VIIa'     
 
Table 2.4-3 Rank order of sensitivities at 10 pM added TF 
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Rank Parameter  Rank Parameter 
1 'k_on_XI_autoactivation' 54 'k_off_VIII_HC_LC_IXa' 
2 'k_on_IIa_ATIII' 55 'k_off_Xa_TFPI' 
3 'k_on_C1inh_inhibition_of_XIa' 56 'k_on_XII_binding_Kallikrein' 
4 'k_on_XIa_inhibition_by_alpha1AT' 57 'k_cat_Kallikrein_producing_XIIa' 
5 'k_on_ATIII_inhibition_of_XIa' 58 'k_cat_XIIa_producing_Kallikrein' 
6 'k_cat_II_Xa' 59 'k_on_bXIIa_binding_PreKallikrein' 
7 'k_off_XIa_IX' 60 'k_off_XII_unbinding_Kallikrein_XII' 
8 'k_on_XIa_IX' 61 'k_on_C1inh_inhibition_of_XIIa' 
9 'k_cat_XIa_IX' 62 'k_off_bXIIa_unbinding_PreKallikrein_XIIa' 
10 'k_off_XIIa_XI' 63 'k_on_Kallikrein_inhibition' 
11 'k_cat_VIII_IIa' 64 'k_on_mIIa_ATIII' 
12 'k_on_Fbg_binding_IIa' 65 'k_cat_XI_IIa' 
13 'k_on_CTI_XIIa' 66 'k_on_Xa_VIII' 
14 'k_on_Fbn2_IIa_destruction_by_ATIII' 67 'k_cat_Xa_VIII' 
15 'k_cat_XIIa_XI' 68 'k_off_Xa_VIII' 
16 'k_on_XIIa_XI' 69 'k_on_IXa_ATIII' 
17 'k_off_CTI_XIIa' 70 'k_off_Fbn1_2_unbinding_Fbn1_IIa' 
18 'k_off_Fbn2_IIa_dissociation' 71 'k_on_Fbn1_2_binding_IIa' 
19 'k_on_wall_XIIa_production' 72 'k_on_ATIII_inhibition_of_XIIa' 
20 'k_off_Fbg_unbinding_Fbg_IIa' 73 'k_off_VIII_HC_LC_IXa_X' 
21 'k_on_Fbn2_IIa_association' 74 'k_on_Kallikrein_autoactivation' 
22 'k_on_Fbn1_2_dimer_association' 75 'k_cat_IIa_producing_Fbn2_2' 
23 'k_off_Fbn1_unbinding_Fbn1_IIa' 76 'k_on_Fbn1_2_destruction_by_ATIII' 
24 'k_cat_IIa_producing_Fbn1' 77 'k_off_Fbn1_2_dimer_dissociation' 
25 'k_on_X_IXa_VIIIa' 78 'k_cat_VII_Xa' 
26 'k_on_IXa_VIIIa' 79 'k_on_VIII_HC_LC' 
27 'k_cat_IXa_X' 80 'k_cat_X_VIIa' 
28 'k_off_IXa_X' 81 'k_off_XII_XIIa' 
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29 'k_on_Fbn1_binding_IIa' 82 'k_cat_VII_IIa' 
30 'k_cat_IIa_producing_Fbn2' 83 'k_on_X_VIIa' 
31 'k_on_IXa_X' 84 'k_cat_XIIa_production' 
32 'k_cat_V_IIa' 85 'k_on_XII_XIIa' 
33 'k_cat_X_IXa_VIIIa' 86 'k_off_X_VIIa' 
34 'k_on_XIa_inhibition_by_alpha2AP' 87 'k_off_IX_TF_VIIa' 
35 'k_on_Boc_VPR_AMC_IIa' 88 'k_on_TF_VII' 
36 'k_on_Xa_ATIII' 89 'k_off_TF_VII' 
37 'k_off_Xa_Va' 90 'k_on_TFPI_TF_VIIa_Xa' 
38 'k_off_II_Xa_Va' 91 'k_on_TF_VIIa_Xa_TFPI' 
39 'k_on_II_Xa_Va' 92 'k_on_Xa_TF_VIIa' 
40 'k_off_VIII_HC_LC' 93 'k_off_TF_VIIa' 
41 'k_on_Xa_Va' 94 'k_cat_IX_TF_VIIa' 
42 'k_on_XI_IIa' 95 'k_off_Xa_TF_VIIa' 
43 'k_cat_mIIa_Xa_Va' 96 'k_on_TF_VIIa_ATIII' 
44 'k_cat_off_mIIa_Xa_Va' 97 'k_off_TFPI_TF_VIIa_Xa' 
45 'k_off_IXa_VIIIa' 98 'k_on_IX_TF_VIIa' 
46 'k_cat_IX_VIIa' 99 'k_on_TF_VIIa' 
47 'k_off_Boc_VPR_AMC_IIa' 100 'k_off_X_IXa_VIIIa' 
48 'k_plt_delay' 101 'k_on_Fbn1_IIa_destruction_by_ATIII' 
49 'k_off_XI_IIa' 102 'k_off_X_TF_VIIa' 
50 'k_cat_Boc_VPR_AMC_IIa' 103 'k_cat_X_TF_VIIa' 
51 'k_off_IX_VIIa' 104 'k_on_X_TF_VIIa' 
52 'k_on_IX_VIIa' 105 'k_cat_VII_TF_VIIa' 
53 'k_on_Xa_TFPI'     
 
Table 2.4-4 Rank order of sensitivities at 0 added TF 
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Figure 2.4-16 Effect of variation of important parameters across a TF titration. 
The experimental values of Ti for a titration of TF are shown in blue. The experimental 
value of the control is shown in green. Simulated values of Ti are shown by the blue 
dashed line. Important individual parameters were locally perturbed by either 10× (red 
dashed lined) or 0.10× (black dashed line) and the resulting simulated titrations are 
shown above. This local sensitivity analysis was performed for the 3 most globally 
sensitive parameters (subplots 1-3) in the absence of added TF (Figure 2.4-15 B and 
Table 2.4-4), the estimated rate of XIIa produced from the wall (subplot 4), as well as for 
the 4 most globally sensitive parameters (subplots 5-8) in the presence of 10pM added TF 
(Figure 2.4-15 A and Table 2.4-3). 
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In the absence of external TF (Figure 2.4-15 B and Table 2.4-4), regulation of XIa 
activity resulting from its production by autoactivation or inhibition by C1-inhibitor, 
alpha1- antitrypsin or ATIII was found to be the most sensitive. The estimated XIIa 
production rate was moderately sensitive (Rank 19) but not the most crucial determinant 
of contact activation in the presence of CTI.  This is in accordance with our observation 
that very minute amounts of XIIa, leakage past CTI can strongly self amplify via XIa. On 
the slow timescales of activation in these simulations, inhibition of thrombin activity by 
ATIII or by its binding to fibrinogen was also found to be important. On expected lines, 
no sensitivity to TF mediated reactions was observed. 
2.5 Discussion 
Human blood is the only living tissue that is routinely and easily obtained for in 
vitro research and clinical diagnostics.  Blood is fully amenable to high throughput 
functional phenotyping and strong genotype-phenotype linkages are the basis of 
significant human disease.   The platelet and the plasma form the basis for hemostasis and 
have been modeled from a bottom-up systems biology approach [94, 96, 97, 168] with 
the distinct advantage of relatively well defined reaction topology and freedom from 
genome-wide transcriptional complexity.   
We have developed a high throughput assay that allowed us to study thrombin 
generation in diluted blood, across several conditions simultaneously with multiple 
replicates at each condition. The use of diluted blood in this assay is a limitation of the 
small reaction volumes in a 384-well plate and scales the initial concentrations of all 
species by the final dilution factor. The presence of an externally added fluorogenic 
substrate for the purpose of detection represents a subtle alteration of thrombin-mediated 
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feedback of its own generation by competitively occupying thrombin’s active site.  We 
evaluated the commonly used thrombin substrates Z-GGR-MCA and Boc-VPR-MCA 
(Figure 2.4-2 A, B, C and D). The latter substrate was found to have acceptably small 
inhibitory effects on Ti at a concentration of 10 μM. In contrast, Z-GGR-MCA at a 
concentration of 100 μM was found to markedly hinder Ti for 1 pM TF triggered 
coagulation. The use of 416 μM of this substrate in the ‘Calibrated Automatic 
Thrombography’ assay may be necessitated by the objective of tracing the ‘complete’ 
thrombogram. The use of 10 μM Boc-VPR-MCA suffices for the purpose of detecting 
coagulation ‘initiation’ and reduces assay interference. Also, the use of citrate as an 
anticoagulant was not found to have any significant influence on clot initiation times and 
permitted us to have a well defined activation time (t=0) for the coagulation reaction 
space defined as the time of recalcification of all the wells.  Effects of the contact factor 
pathway were significant at concentrations less than 100 fM TF and were subsequently 
prevented by the use of CTI (Figure 2.4-2 E). 
We and others have consistently observed that CTI-treated human blood clots in 
the absence of added TF in vitro.  In keeping with the notion of “blood borne TF” it is 
tempting to attribute such clotting initiation to platelet-dependent sources [81, 154]. We 
explored several possible mechanisms with neutralizing antibodies against TF, VII/VIIa, 
PDI, P-selectin, GPIb, and cathepsin G but none had affect on thrombin generation. 
Similar to the experiments of Butenas et al. [169], we have not found any evidence for 
functional TF in static whole blood (a closed system). 
CTI inhibits β XIIa  [170] and has relative specificity for this form of XIIa [171]. 
The β form of XIIa does not bind to surfaces and has little ability to activate XI, although 
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it does activate Pre-Kallikrein (which in turn amplifies XIIa production). The 
effectiveness of CTI in prolonging APTT is probably a result of prevention of XIIa 
amplification by Kallikrein produced by β XIIa.  The surface bound α form of XIIa is the 
main activator of FXI and the intrinsic coagulation system [172]. Such XIa produced by α 
XIIa on negative surfaces could get past CTI and lead to contact activation.    We have 
demonstrated that in resting whole blood XIIa can leak past even very high 
concentrations of CTI, eventually leading to a significant burst in thrombin production 
(Figure 2.4-8).  Without CVX activation, the combined use of CTI, anti-XII and anti-XI 
block all proximal triggers of clotting in the 4 hr assay (Figure 2.4-9). With CVX 
activation, VIIa activity on the active platelet alone (independent of TF) is kinetically 
significant, but the local activity of single molecules of XIa (formed downstream of a 
XIIa leak past CTI) in the proximity of the active platelet surface, can lead to efficient 
thrombin production (Figure 2.4-10).  
We highlight a recent report by Back-Nilsson et al. [173] where the authors 
showed that the levels of XIIa-AT, XIa-AT and Kallikrein-AT complexes were not 
affected by CTI treatment if contact activation of XII is allowed to occur on activated 
platelet surfaces. In contrast, if contact activation is allowed to occur on artificial 
negative surfaces like glass or kaolin, the formation of XIIa inactivation complexes is 
completely abolished by CTI (Back et al. Figures 1-3). Thus, there exists strong evidence 
that CTI is ineffective against XIIa formed on active platelet surfaces. Several reports 
attribute in vitro thrombin generation following platelet activation to endogenous TF. 
Caution must be exercised in interpreting such results because contact activation still 
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occurs upon active platelet surfaces even in the presence of CTI (and antibodies against 
XII and XI). 
Initiation times obtained by titrations of active proteases provide estimates of 
upper limits for endogenous active proteases.  Activation peptides of several proteases 
have indeed been detected in blood indicating that these proteases do exist in active form 
albeit in concentrations low enough to have little effect on physiologic time scales [84-
87].  Our experimental titrations (Figure 2.4-11) bounded the initial conditions of active 
proteases (or TF) in blood to: <~500pM Va, <1 nM VIIa, <1 pM IXa, <10 pM Xa, <1 pM 
XIa and <~40 fM of pre-synthesized TF. Titrations of added thrombin are difficult to 
deconvolute using fluorogenic thrombin substrates. Circulating thrombin levels must be 
<100 pM to maintain platelets in an unactivated state (Figure 2.3-2). With respect to 
initial conditions of active proteases at t=0, we attempted to search the initial condition 
space of blood using Simulated-Annealing and Particle-Swarm optimization algorithms 
to find the best fit of initial conditions, subject to the above upper bounds for non-zero 
initial levels of Va, VIIa, IXa, Xa, XIa and bloodborne TF. Despite more than 100,000 
simulations, no acceptable fit was obtained by optimization of initial conditions alone. 
Importantly, adjustment of XIa (t=0) was insufficient to maintain an “engine idling” 
model of blood consistent with the results in Figure 2.4-11, Figure 2.4-13 and Figure 
2.4-14.  It was necessary to include a source term that generated XIIa at a rate slow 
enough to have little effect on short time scales in the presence of high concentrations of 
active proteases, but fast enough to limit Ti to that of the control. TF independent VIIa 
activity was found to be appreciable at high concentrations and upon active platelet 
surfaces and was therefore also considered as a proximal trigger of coagulation initiation.  
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The estimation of a rate of XIIa production (Reaction 29, Table 2.4-1) allows us 
to extend the predictive capacity of the Hockin-Mann model to low concentrations of TF. 
Further we were also able to simulate titrations of Va, VIIa, IXa, Xa and XIa in 5x 
diluted blood (Figure 2.4-11); clotting times observed with additions of TF, IXa, Xa and 
thrombin in whole blood (Figure 2.4-13); and the observed consequences of platelet 
activation (Figure 2.4-14). However, the Platelet-Plasma model remains a coarse grained 
platelet and pseudo-homogeneous model. No distinction is made explicitly between bulk 
and surface phases and binding of reactants onto the platelet surface is not considered 
separately. Net conversion rates were sped up as the platelet activates by decreasing the 
unbinding of the enzyme-substrate complex (representing the role of anionic lipid 
exposure), but no explicit attempt was made to model the change in exposed surface area 
and chemistry, and its effect on reaction rates. For the sake of simplicity, a single 
functional form (ε) was assumed for the changes in rates as the platelet activates, 
resulting in a two order change in rate of all desorption reactions on the platelet surface. 
We have shown recently that it is possible to construct donor specific models of platelet 
calcium mobilization as a function of combinatorial agonist concentrations at the site of 
the thrombus [101]. To incorporate donor specific descriptions of platelet function in 
models of coagulation, the correlation between intracellular calcium and PS exposure 
must be defined.  
The present study indicates the future feasibility of a full description of blood 
accounting for intracellular platelet metabolism and heterogeneous reactions on the 
dynamic platelet surface. In keeping with the static environment in a well plate and the 
absence of endothelium, no consideration was made of fluid flow, mass transfer from the 
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bulk onto the platelet surface or thrombomodulin/APC mediated pathways. Our model 
extends the topology of the Hockin-Mann structure to better simulate in vitro clotting 
initiation of whole blood under diverse initial conditions, however the assumption of a 
well mixed static system is not appropriate for simulations of thrombosis under flow in 
vivo.  
Our high throughput measurement system allows us to rapidly and reproducibly 
quantify the duration of the initiation phase across numerous conditions from a single 
blood draw. This has the potential to efficiently identify coagulation pathologies. For 
instance, an extended duration of this metric for a donor would indicate propensity to 
bleeding diseases like hemophilia while a shortened metric would indicate predisposition 
to thrombosis. Titration experiments with added proteases provide a higher dimensional 
examination of blood function than simply measuring the clotting time after addition of 
high doses of TF. 
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Chapter 3  
Pairwise agonist scanning of human platelets reveals 
the high dimensional response to combinatorial 
mediators of thrombosis 
3.1 Abstract 
Prediction of cellular response to multiple stimuli is central to evaluating patient-
specific clinical status and to basic understanding of cell biology. Cross-talk between 
signaling pathways cannot be predicted by studying them in isolation and the 
combinatorial complexity of multiple agonists acting together prohibits an exhaustive 
exploration of the complete experimental space. Here we describe pairwise agonist 
scanning (PAS), a strategy that trains a neural network model based on measurements of 
cellular responses to individual and all pairwise combinations of input signals. We apply 
PAS to predict calcium signaling responses of human platelets in EDTA-treated plasma 
to six different agonists (ADP, convulxin, U46619, SFLLRN, AYPGKF and PGE2) at 
three concentrations (0.1, 1 and 10 × EC50). The model predicted responses to 
sequentially added agonists, to ternary combinations of agonists and to 45 different 
combinations of four to six agonists (R = 0.88). PAS could distinguish between the 
phenotypic responses of platelets from ten healthy male donors and even showed promise 
in stratifying donors based on ethnicity and gender. Further, PAS was performed in the 
presence of external calcium for the 3 agonists ADP, CVX and U46619, both without 
pharmacological intervention and with inhibitors against targeted pathways. This was 
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used to train patient specific neural network models of regular response, as well as 
response to therapy, and forms the basis of the platelet activation module in a multiscale 
Lattice Kinetic Monte Carlo model of thrombosis. Training neural networks with pairs of 
stimuli across the dose-response regime represents an efficient approach for predicting 
complex signal integration in a patient-specific disease milieu. Finally this approach can 
be extended to study not just human platelets, but also murine platelet phenotypes (both 
regular and genetically modified) across a broad range of conditions using very small 
volumes of blood. 
3.2 Introduction 
Since cells can respond to numerous signals and integrate their response to dose-
dependent combinations of these inputs, efficient methods are needed to survey such high 
dimensional systems. The evaluation of response to pairs of stimuli offers a direct and 
rapid sampling of a response space that can be built-up into a higher level predictive tool 
through the use of neural networks. Central to cardiovascular disease, platelets are cells 
that respond in a donor specific manner to multiple signals in vivo and their activation in 
response to thrombotic signals is central to the thrombotic risks and events surrounding 
1.74 million heart attacks and strokes, 1.115 million angiograms and 0.652 million stent 
placements in the United States each year [174].  
During a clotting event, platelets experience diverse signaling cues 
simultaneously. After capture of the flowing platelet via glycoprotein GPIb-IX-V binding 
to von-willebrand factor, exposed collagen activates glycoprotein VI (GPVI)-dependent 
tyrosine kinase signaling leading to phospholipase Cγ2 activation, which in turn triggers 
calcium mobilization and α2β1 and α2bβ3 integrin activation.  ADP is released from dense 
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granules to activate the G-protein coupled receptors (GPCR) P2Y1 and P2Y12, while 
thromboxane A2 (TxA2) is synthesized by platelet cyclooxygenase 1 (COX1) and binds 
platelet TP receptors.  Tissue factor at the site of the damaged vascular wall leads to the 
production of thrombin which cleaves the platelet GPCR protease activated receptors 
PAR1 and PAR4 on the platelet surface.  These activating signals occur in the context of 
inhibitory signals from endothelial nitric oxide and prostacyclin.   
While these diverse signaling events occur simultaneously in vivo during 
thrombosis, most in vitro studies examine single agonists in isolation. ADP[175], 
thrombin[176], collagen[177] have been investigated in detail, yet these studies do not 
capture the highly heterogeneous and dynamic thrombotic environment. Platelet signaling 
varies spatially and temporally in growing thrombi[178]. Few experimental or 
computational tools are available for building a global understanding of how a cell 
integrates multiple stimuli present at varying levels.    
We have developed a high-throughput experimental platform that measures the 
human platelet response to all pairwise combinations of six major agonists. Agonists 
tested in this study were: convulxin (CVX; GPVI activator), ADP, the thromboxane 
analog U46619, PAR1 agonist peptide (SFLLRN), PAR4 agonist peptide (AYPGKF), 
and PGE2 (activator of IP receptor).  The method yields high-resolution time-series 
measurements of intracellular calcium which is the convergent node of these platelet 
signaling pathways (Figure 3.2-1) and is critical to granule release, exposure of 
phosphatidylserine, actin polymerization, shape change, and integrin activation[179].  We 
first tested the platelet response to all pair-wise combinations of 6 agonists at 3 separate 
doses (0.1, 1, 10×EC50). These 135 calcium traces trained a 2-layer neural network (NN) 
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to successfully represent an individual’s platelet phenotype.  The Pairwise Agonist 
Scanning (PAS) method demonstrates that sampling all dual orthogonal "axes" (every 
agonist pair) can successfully predict the dynamic responses and cross-talks of a higher 
dimensional system (6 agonists in this case). 
 
 
 
 
 
 
 
 
 
Figure 3.2-1 Signaling pathways in human platelets converge on calcium  
Platelets integrate signals from numerous simultaneous thrombotic inputs. The signals 
considered in this study include Collagen (CVX), thromboxane (U46619), thrombin 
(AYPGKF and SFLLRN), ADP and PGE2. All of these signals regulate the levels of 
cytosolic calcium and an elevation of calcium concentration precedes several responses 
including integrin activation, granule release and shape change. (Also see Section 1.2 and 
Figure 1.2-1). 
 
3.3 Materials and methods 
3.3.1 Materials 
The protease activated receptor-1 (PAR-1) agonist peptide SFLLRN (thrombin 
receptor agonist peptide, TRAP) and the PAR-4 agonist peptide AYPGKF were obtained 
from Bachem (King of Prussia, PA). Convulxin (CVX), was obtained from Centerchem, 
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(Norwalk, CT). Thrombin and GGACK were obtained from Haematologic Technologies 
(Essex Junction,VT). Clear, flat bottom black 384-well plates were obtained from 
Corning (Corning, NY).  ADP, U46619, PGE2, EDTA, HEPES, the fibrin polymerization 
inhibitor Gly-Pro-Arg-Pro (GPRP), NaCl, NaOH, apyrase, indomethacin and sodium 
citrate were all from Sigma (St. Louis, MO). Fluo-4 NW Calcium assay kits were 
obtained from Invitrogen (Carlsbad, CA). The buffer used for all dilutions was HEPES 
buffered saline (HBS, sterile filtered 20 mM HEPES and 140 mM NaCl in deionized 
water adjusted to pH 7.4 with NaOH). 
3.3.2 Platelet preparation 
Whole blood was drawn from healthy male volunteers according to the University 
of Pennsylvania Institutional Review Board guidelines, into citrate anticoagulant (1 part 
sodium citrate to 9 parts blood). All donors affirmed to not taking any medications for the 
past 10 days and not consuming alcohol for the past 3 days before phlebotomy. After 
centrifugation at 120g for 12 min to obtain platelet-rich plasma, 2 ml of platelet-rich 
plasma was incubated with each vial of Fluo4-NW dye mixture reconstituted into 8 ml of 
buffer for 30 min. 
3.3.3 High throughput experimentation 
An ‘agonist plate’ containing varying combinatorial concentrations of platelet 
agonists was prepared on a PerkinElmer Janus (PerkinElmer Life and Analytical 
Sciences) using 10× stock solutions of ADP, CVX, SFLLRN, AYPGKF and U46619. A 
separate ‘platelet plate’ containing dye-loaded platelets was prepared on a PerkinElmer 
Evolution.  
    
 96
 
Figure 3.3-1 High throughput experimental procedure 
An agonist plate containing combinatorial agonist combinations and a platelet plate 
containing dye-loaded platelets were separately assembled. Agonists were dispensed onto 
platelet suspensions and fluorescence changes were measured to quantify platelet calcium 
concentrations [Ca2+]i. [Ca2+]i transients can be represented as overlapping plots (lower 
right) or parallel heat maps (lower left). RFU, relative fluorescence units.   
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Final platelet rich plasma (PRP) concentrations were 12% by volume (6 μl/well) 
after agonist addition, and 5 mM EDTA was included in every well. Agonists (10 
μl/well) were dispensed after a 20-s baseline read from columns of the ‘agonist plate’ 
onto the corresponding columns of the ‘platelet plate’ on a Molecular Devices 
FlexStation III. Fluo4 fluorescence was measured at excitation 485 nm and emission 535 
nm for 4 min in every column of the plate. The fluorescence F(t) was scaled to the mean 
baseline value for each well F0(t) and relative calcium concentrations were quantified as 
F(t)/F0(t). An entire 384-well plate was read in ~90 min. 
3.3.4 Agonist selection 
The number of agonists tested in a PAS experiment is limited to 6 by the need of 
testing all the 154 conditions in duplicate in a single 384-well plate. Agonists were 
chosen to be representative of physiological signaling cascades. Convulxin is a selective 
GPVI activator [180] and under static conditions this receptor is the predominant 
determinant of collagen induced signal strength [181] . In contrast, the soluble 
monomeric form of collagen interacts only with α2β1, which regulates platelet adhesion 
but has little direct effect in mediating signaling [182, 183]. “Horm” collagen 
preparations are insoluble making them poorly suited for automated liquid handling. 
Although ADP stimulates both P2Y1 and P2Y12, the latter receptor has minor effect on 
calcium mobilization [184], allowing us to use the physiological agonist ADP instead of 
specific P2Y1 ligands.  Thrombin signals through two separate Gq coupled receptors 
PAR1 and PAR4 both of which produce temporally separate calcium signals [185, 186]. 
This prompted us to use selective PAR agonist peptides (SFLLRN and AYPGKF) to 
distinguish the separate signal contribution of both these receptor pathways. Moreover 
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thrombin stimulation of unwashed PRP requires inhibition of fibrin and FXa formation 
(See Figure 3.4-21). Washing or gel filtering platelets is a processing step that decreases 
throughput in a large scale experiment and often causes residual platelet activation in the 
absence of PGE2 or other PGI2 analogs. The use of a short lived prostaglandins like PGI 2 
[187] is unsuitable for assembly of agonist plates (requiring ~120 min) and plate reading 
(requiring ~90 min). In contrast, prostaglandins of the E series are chemically stable 
prompting us to use PGE2 as an agonist causing elevation in intracellular cAMP. 
Similarly, for reasons of stability during the course of the experiment the thromboxane 
analogue U46619 was used instead of its physiological equivalent TxA2 [188].  
3.3.5 Choice of synergy score 
To quantify cross talks between agonist combinations, the ‘Synergy score’ was 
defined as the difference between the observed and the predicted additive response. For 
ease of visualization this difference was scaled to the maximum synergy score observed 
in an experiment (or simulation) giving a metric that ranges from -1 (antagonism) to +1 
(positive synergy). A similar synergy metric was previously defined as the ratio of the 
observed and the predicted additive response to demonstrate synergistic calcium 
signaling between C5a and UDP in RAW264.7 cells and bone marrow derived 
macrophages[189].  The use of a ratio rather than a difference is prone to numerical 
errors for small values of the predicted additive response.   
3.3.6 Neural network model construction, training and simulation 
Neural network modeling and analysis was performed using the Neural Network 
Toolbox for MATLAB (The MathWorks). Training data consisted of (i) the dynamic 
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inputs, which represent the combination of agonist concentrations present at each time 
point for a particular experiment. Because the concentration of agonists remains 
essentially constant throughout each experiment, these values were generally a constant 
vector of concentration values repeated at 1-s intervals. (ii) The dynamic outputs, which 
represent the experimentally measured calcium concentrations, also interpolated at 1-s 
intervals. To normalize the input data, agonist concentrations of 0, 0.1, 1 and 10 × EC50 
were mapped to the values (–1, –0.333, +0.333, +1) before introducing them to the 
network, so as to fall within the working range of the hyperbolic tangent sigmoid transfer 
function, which was used for all processing nodes. Output values (fluorescence 
measurements) were normalized between –1 and +1, so that the basal concentration of 
calcium at t = 0 was defined to be 0. After training all 420 possible one- and two-layer 
neural networks with between 1 and 20 nodes in each processing, or ‘hidden’, layer and 
testing each network for accuracy, a final neural network topology with a six-node input 
layer (representing the six agonists), two processing layers (eight nodes/four nodes) and a 
single-node output layer (representing the intracellular calcium concentration) [190] was 
most optimal (best predicted the ‘net’ output response [Ca2+]I for a given multivariate 
input using the fewest neurons) and thus selected to predict successive time points from 
all 154 Ca2+ release curves gathered experimentally (Figure 3.4-3). For the sake of 
simplicity and because we already obtain reasonably accurate time series predictions of 
[Ca2+]i, more processing layers or >20 neurons in each layer were not tested.  
The work training, testing and utilizing the predictions of the Neural Network 
model in Section 3.4 was done in collaboration with Jeremy Purvis. 
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Figure 3.3-2 Dynamic neural network used to train platelet response  
A constant sequence of input signals (agonist concentrations) is introduced to the two-
layer, 12-node network at each time point. Processing layers integrate input values with 
feedback signals to predict [Ca2+]i at the next time point 
 
From a purely biological perspective, the model architecture is arbitrary and no 
particular meaning should be inferred from the narrowing of eight nodes in the first layer 
to four nodes in the second processing layer. Moreover, this neural network model 
(Figure 3.3-2) does not correspond to an actual signaling network (Figure 3.2-1) but 
does provide a highly efficient framework for use as an independent signaling module in 
multiscale models of thrombosis under flow. From a mathematical perspective this 
architecture represents a multivariate regression to obtain optimal good fits of high-
dimensional data and allow extrapolation onto experimentally unexplored spaces. 
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NARX (nonlinear autoregressive network with exogenous inputs) models are 
recurrent dynamic networks with feedback connections enclosing multiple layers of the 
network, and are well-suited for predicting time series data [191] because they process 
inputs sequentially, that is, at successive time points. Calcium outputs before the current 
instant were fed back to hidden layers using a delay line spanning 128 s. Initial states of 
the delay line were set to 0, corresponding to the steady state of the platelet before 
agonist stimulation. Such a structure allows the network output to progress over time, 
using the ‘memory’ of the previous 128 s in calculating the current output. Training was 
performed using Levenberg-Marquardt back-propagation until the performance of the 
model (mean squared error between the simulated and experimentally measured PAS 
responses.) did not improve >1 × 10−5. During training, the pairwise agonist data (154 
time-course traces) was divided into training, validation and testing vectors. Validation 
and testing vectors were each generated by randomly selecting 23 (15%) of the 154 
pairwise time-course traces. The training vectors were used to directly optimize network 
edge weights and bias values to match the target output. The validation set was used to 
ensure that there is no overfitting in the final result. The test vectors provide an 
independent measure of how well the network can be expected to perform on data not 
used to train it 
Mathematically, the output y at an instant t, for an input vector I of the 
concentrations of the six inputs species can be compactly described by 
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where IW is the matrix of input weights, 2L and 3L  are the weight matrices that operate 
on the ‘inputs’ coming from the first and second processing layers respectively. 1H and 
2H  are matrices that contain history coefficients that weigh the history vector 
hy (containing the output of the system 1, 2, 4, 8, 16, 32, 64 and 128 s prior to the current 
instant).  1b , 2b and 3b are bias vectors that add constant biases to each weighted input  
and weighted histories to produce the ‘net input’ to each transfer function. f is the 
hyperbolic tangent function that operates on a vector of ‘net inputs’ to yield the 
corresponding transformed output. Numbers in parentheses show the sizes of relevant 
matrices or vectors. The NARX model presented here, represents a nonlinear regression 
model with input stimuli and system history. The use of simple 1st and 2nd order 
polynomial terms (with lower number of optimizable parameters) did not produce 
acceptable fits (not shown), necessitating the use of the NARX architecture.  A 3rd order 
polynomial was not attempted since it requires 316 fitting parameters, far exceeding the 
number of parameters in the neural network model. 
It should be noted that each trained neural network model produces a 
deterministic prediction of platelet activation. Experimental variations are inherent in 
replicates of donor-specific training data (Figure 3.4-17), and the tightness of the 
measured mean will determine the predictive quality of such a donor-specific neural 
network model. 
Busch et al.[192] used a continuous time recurrent neural network (CTRNN), to 
describe the fold expression kinetics of 9 “top ranked” genes involved in the sustained 
migration of keratinocytes after hepatocyte growth factor (HGF) treatment. Utilizing the 
NN weights for a signaling network, they define the modulation and control elements of 
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the response [192]. Also, previous studies have used Partial Least Squares Regression 
Analysis (PLSR) to understand the interplay of molecular mechanisms during signaling 
[193, 194].  PLSR measures multiple intermediate signaling molecules at various time 
points for a relatively small number of inputs, and identifies principal components that 
capture the phenotype of the system.  In comparison, the PAS approach offers less 
mechanistic dissection, but provides rapid (a 2-hr experiment) and efficient prediction of 
dynamic input-output relationships at numerous (~102) physiologically relevant 
conditions. Geva Zatorsky et al. [195] have recently reported similar utility of sampling 
the effects of drug pairs in predicting the dynamics of response to three or four drug 
combinations in lung cancer cells. 
3.4 Results 
3.4.1 Defining the dynamic range of individual agonists 
To determine appropriate dynamic ranges for the 6 agonists (Figure 3.2-1), each 
compound was first tested individually. Dose response curves were constructed in terms 
of the peak fluorecense signal at each agonist dose (Similar dose responses were obtained 
for the integrated signal). This allows us to define the complete dynamic range for each 
agonist and to determine their half maximum response (EC50) values (Figure 3.4-1). The 
inhibitory response of PGE2 was studied by concomitantly stimulating the platelet with 
60 μM SFLLRN. These dose responses were determined both in the absence and 
presence of external calcium.  The removal of external calcium does not affect the ability 
of the studied receptors to signal, as no appreciable difference in EC50s were noted with 
or without external calcium (Figure 3.4-1 a and b). 
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Figure 3.4-1 Single agonist dose response curves 
Single agonist dose response curves were constructed for platelet responses to the 
agonists ADP, CVX, U46619, SFLLRN, AYPGKF and the antagonist PGE2. All 
conditions are for a single donor with 8 replicates per agonist dose. EC50 levels were 
determined by fitting a 4 parameter curve (dashed lines) to the peak calcium signal. EC50 
levels were almost unchanged in (a) 1.5 mM extracellular Calcium (with 15 μM 
Indomethacin  to prevent autocrinic amplification via TXA2) or (b) 5 mM EDTA. Values 
shown are mean ± standard deviation. 
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3.4.2 Supression of autocatalytic signal amplification 
To eliminate the sensitivity of cells to confounding autocrine effects of soluble 
mediators that are dependent on platelet concentrations and transport processes, we 
conducted all experiments in 5 mM EDTA, which chelates extracellular calcium. Inspite 
of the absence of external calcium the ability of the receptors studied to signal is not 
affected (Figure 3.4-1 a and b). Although such an experimental  design does not capture 
the contribution of store operated calcium entry, it offers several operational advantages 
by (i) lowering background fluorescence without extensive platelet washing, (ii) 
preventing thrombin production,  (iii) inhibiting granule release [196, 197] as well as 
TxA2 formation [198], and (iv) inhibiting integrin mediated signaling downstream of Ca2+ 
release [199]. Thus, the resulting traces of Ca2+ are directly dependent only on receptor 
mediated release from intracellular stores. The operational advantages of using EDTA, 
however, prevent prediction of important physiologic phenomena like granule release, 
integrin activation and outside-in signaling 
To test whether the intracellular Ca2+ signal detected was being influenced by 
endogenously released agonists, we studied  the effects of  2 units/ml apyrase (which 
hydrolyzes released ADP) or 15 μM indomethacin (which inhibits production of TxA2 ) . 
Both these inhibitors had no effect on individual responses (Figure 3.4-2, and Table 
3.4-1 and Table 3.4-2), suggesting that endogenous agonists have no effect on the Ca2+ 
signal. This confirms that the resulting traces of Ca2+ are directly dependent only on 
receptor-mediated release from intracellular stores. 
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Figure 3.4-2 Addition of Apyrase and Indomethacin. 
Possible secondary autocrinic amplifications by secreted ADP or synthesized 
thromboxane were evaluated by adding the ADP hydrolyzing enzyme apyrase or the 
COX inhibitor indomethacin. No statistically significant reduction in (a) the peak calcium 
signal or (b) the integrated calcium signal was noted upon stimulation with either 0.1, 1, 
or 10x EC50 levels of CVX, U46619, SFLLRN, AYPGKF or PGE2. *s represent 
conditions where the use of the inhibitor produced a significant reduction (P Value 
<0.05). The PValues for all the comparisons carried out are listed in Table 3.4-1 and 
Table 3.4-2. Values shown are mean ± standard deviations. 
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Agonist 
Dose 
(×EC50) 
15μM  
Indomethacin 
2 Units/ml 
Apyrase 
Both Inhibitors 
added 
CVX 0.1 0.6039 0.6504 0.6504 
 1 0.3312 0.4686 0.4091 
 10 0.3961 0.5314 0.3496 
U46619 0.1 0.7857 0.0325* 0.4091 
 1 0.6039 0.9794 0.9794 
 10 0.3961 0.9535 0.9535 
SFLLRN 0.1 0.3961 0.6504 0.5314 
 1 0.8355 0.9924 0.9957 
 10 0.5346 0.5314 0.7576 
AYPGKF 0.1 0.0087* 0.0898 0.2944 
 1 0.2684 0.5909 0.2944 
 10 0.6039 0.9102 0.8799 
PGE2+60μM SFLLRN 0.1 0.6039 0.9102 0.8452 
 1 0.6039 0.803 0.3496 
 10 0.3312 0.7056 0.5909 
 
Table 3.4-1 Comparison of peak signals in the presence and absence of inhibitors 
against autocatalytic signal amplification pathways 
P Values comparing the peak calcium signal in the presence of various inhibitors 
(columns 3, 4 and 5) with no added inhibitor at various agonist doses (column 2). *s 
indicate significant reductions in peak signal and were noted in 2 out of 45 conditions 
tested. 
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Agonist 
Dose 
(×EC50) 
15μM  
Indomethacin 
2 Units/ml 
Apyrase 
Both Inhibitors 
added 
CVX 0.1 0.5346 0.6504 0.7056 
 1 0.2684 0.5314 0.4091 
 10 0.3961 0.5314 0.4091 
U46619 0.1 0.1234 0.0325* 0.5314 
 1 0.2684 0.8799 0.934 
 10 0.1234 0.987 0.987 
SFLLRN 0.1 0.1645 0.5314 0.4686 
 1 0.8355 0.9957 0.9957 
 10 0.1645 0.6504 0.5314 
AYPGKF 0.1 0.0152* 0.0076* 0.0898 
 1 0.4654 0.8452 0.2424 
 10 0.7316 0.9102 0.8799 
PGE2+60μM SFLLRN 0.1 0.6039 0.9102 0.934 
 1 0.4654 0.8799 0.2424 
 10 0.5346 0.5909 0.5909 
 
Table 3.4-2 Comparison of integrated signals in the presence and absence of 
inhibitors against autocatalytic signal amplification pathways 
P Values comparing the integrated calcium signal in the presence of various inhibitors 
(columns 3, 4 and 5) with no added inhibitor at various agonist doses (column 2). *s 
indicate significant reductions in peak signal and were noted in 3 out of 45 conditions 
tested. 
 
Each experimental condition was tested in replicates of 6. The non-parametric Wilcoxon-
Mann-Whitney test was used to test whether the use of either Indomethacin/ Apyrase or 
both inhibitors added together resulted in a significant reduction in signal compared to 
the control experiment where no inhibitors were added. The tests were conducted at 5% 
significance level. Statistically significant reductions in signal were obtained with these 
added inhibitors in only ~5% of the conditions tested.  
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Lack of detectable secondary autocatalytic amplification is expected since diffusion 
would reduce platelet surface ADP levels by 1000-fold within 2 sec following release of 
all dense granules [200].  Also assuming release of  75%  of platelet dense granule ADP 
content of 1.74 μmoles/1011 platelets [201] into an instantaneously isotropic reaction 
volume of 50 μl containing 12% PRP results in a final ADP concentration of 494 nM, a 
concentration less than the EC50 levels of ADP.   In vivo, platelets are concentrated 5-10  
fold near the vessel wall due to drift caused by red blood cell accumulation at the vessel 
center [202].  Furthermore, during thrombosis, platelet concentrations in deposited 
aggregates can increase 10 to 50-fold over platlet-rich plasma levels. At such close 
confinement during thrombosis, autocatalytic amplifications caused by secreted ADP and 
TxA2 will become significant. However in the controlled, dilute (12% PRP), and 
unstirred environment inside the well plate containing EDTA which attenuates secretion, 
we observed only primary effects of receptor mediated calcium release from cell stores. 
3.4.3 Pairwise Agonist Scanning 
We tested all 135 pairwise combinations of low (0.1×EC50), moderate (1×EC50), 
and high (10×EC50) agonists concentrations (Figure 3.4-3 a). The pairwise agonist 
synergy score (Sij) is the scaled difference between the integrated calcium transient (area 
under the curve) for the combined response and the integrated area for the individual 
responses (Figure 3.4-3 b) (Sij>0, synergism; Sij=0, additivity; Sij<0, antagonism). 
    Neural network (NN) models are remarkable in learning patterns of inputs and 
predicting outputs by optimizing the weights of intermediate connections, akin to a 
platelet’s ability to respond to multiple thrombotic signals through coupled biochemical 
reactions. Motivated by the notion that a living cell is essentially a neural network whose 
connection weights have been selectively adjusted during evolution [203], we took a 
“top-down” approach [204] to model platelet signaling. A NN model was trained on these 
154 time-course traces (135 pairwise responses, 18 single agonist responses, 1 control) 
and captured both the time-course behavior (R=0.968 for correlation between time 
points) and the pairwise agonist synergy (R=0.884 for correlation between Sij scores 
(Figure 3.4-4) with excellent accuracy (Figure 3.4-3 a and b). 
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Figure 3.4-3 Pairwise Agonist Scanning (PAS) 
(a) Pairwise agonist scanning (PAS) All 154 binary combinations of the agonists CVX, 
ADP, U46619, SFLLRN, AYPGKF and PGE2 at concentrations of 0, 0.1, 1 and 10x 
EC50 were combined on the same plate (in replicates of 2) and the dynamic response of 
the platelet to each combination was recorded. The NN model was trained on this dataset. 
(b) Pairwise agonist synergy scores, which reflect the gain or loss in calcium response 
due to agonist cross talk, were calculated for both experimental and predicted time course 
traces. EC50: PGE2, 24.6 μM; AYPGKF, 112 μM; SFLLRN, 15.2 μM; U46619, 1.19 μM; 
ADP, 1.17 μM; CVX, 0.00534 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4-4 Predicted versus measured synergy scores for a PAS experiment 
Predicted versus measured synergy scores for the 135 conditions in a PAS experiment 
that contained binary agonist pairs (Figure 3.4-3). This fit is a measure of the “adequacy” 
of training of the NN on the binary interaction dataset. The strong correlation shows that 
the NN was suitably trained by the data, but does not yet demonstrate the predictive 
capability of the model. 
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3.4.4 Platelet responses to ternary agonist stimulation 
 
Figure 3.4-5 Ternary agonist stimulation 
Measurement and prediction of the platelet response to all 64 ternary combinations of 
ADP, SFLLRN and CVX at 0, 0.1, 1 and 10 × EC50. The neural network model was 
trained only on pairwise interactions but successfully predicted ternary interactions. 
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Figure 3.4-6 Predicted versus measured synergy scores for ternary stimulation 
Predicted versus measured synergy scores for the 27 conditions in the ternary experiment 
(Figure 3.4-5) that contained 3 agonist combinations. This fit is a measure of the de-novo 
predictive capacity of the NN model (trained exclusively on the binary interaction 
dataset) on ternary agonist space.  
 
Next, we measured all 64 ternary combinations of the agonists ADP, SFLLRN, 
and CVX at 0.1, 1, and 10×EC50 concentrations (Figure 3.4-5). A CVX response requires 
GPVI multimerization [180] and is characterized by a slow rise to a large peak signal 
followed by a slow decline.  In contrast, Gq–coupled responses (ADP or SFLLRN) 
produce rapid bursts that are quickly brought down to baseline. Increasing CVX for a 
fixed ADP level resulted in a steady increase in calcium concentrations on longer 
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timescales. In contrast, increasing ADP for a fixed CVX level bolstered early calcium 
release. A moderate dose of both ADP and CVX (for 0 and low SFLLRN) produced a 
response that almost instantaneously plateaued at a steady level above baseline.  
The NN model, trained exclusively on the pairwise interaction data set (Figure 
3.4-3 a), successfully predicted all experimentally observed trends in the ternary 
interactions among the three agonists studied. Both the time-course behavior (R = 0.844) 
and ternary agonist synergy scores (R = 0.881) (Figure 3.4-6) were accurately 
reproduced for the 27 unique ternary conditions in this experiment that were not present 
in the training set. Thus, the pairwise interaction data presented in Figure 3.4-3 captured 
additional information about the interactions amongst 3 agonists. 
3.4.5 Sequential addition of the platelet agonists ADP, SFLLRN, CVX 
We also explored the effect of adding the agonists ADP, SFLLRN and CVX in 
various sequential combinations (Figure 3.4-7). Several interesting behaviors were 
accurately predicted by the NN model.  Preceding a large dose of ADP with prior 
treatment with low dose of ADP (Figure 3.4-7, panel 12) desensitized the calcium signal 
expected from a large dose of ADP (as in Figure 3.4-7, panel 1). This behavior has been 
observed previously [205] and is attributed to the internalization of P2Y1. The temporal 
sequence ADP-SFLLRN-CVX (Figure 3.4-7, panel 1) produced three distinct calcium 
bursts, whereas the ADP response was completely abolished in the sequence SFLLRN-
ADP-CVX (Figure 3.4-7, panel 3). This behavior points to mechanisms of cross-down 
regulation of the ADP signaling cascade by component(s) of the PAR1 cascade. 
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Figure 3.4-7 Measured and predicted platelet responses to sequential additions of 
ADP, SFLLRN and CVX. 
The effect of ADP, SFLLRN and CVX added in various temporal sequences was tested. 
The NN model trained exclusively on binary interactions could predict several of the 
experimentally observed trends of cross down regulation and desensitization between the 
ADP, SFLLRN and CVX cascades. 
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Prior addition of CVX abolished detectable responsiveness to both ADP (Figure 
3.4-7, panel 5) and SFLLRN (Figure 3.4-7, panel 6) again pointing to a mechanism 
where components of the GPVI signal are able to down regulate the Gq-coupled ADP or 
SFLLRN signal. Additions of any two of these agonists in combination followed by the 
third agonist confirm the observation that any mixture containing CVX down-regulates 
responsiveness to both ADP (Figure 3.4-7, panel 9) and SFLLRN (Figure 3.4-7, 
panel 8). CVX-mediated calcium mobilization events were unaffected by pretreatment 
with either ADP (Figure 3.4-7, panel 2) or SFLLRN (Figure 3.4-7, panels 4 and 3), or a 
binary combination of these agonists (Figure 3.4-7, panel 7). Activation of GPVI or 
thrombin receptors phosphorylates the ITIM domain of platelet PECAM [206]. ITIM 
phosphorylation inhibits response via phosphatases like SHP-2 [207]. Such inhibitory 
mechanisms, or even the existence of agonist selective stores [208], may explain the lack 
of ADP/SFLLRN response after prior CVX stimulation and the lack of ADP response 
after prior SFLLRN stimulus. Simulation traces containing CVX did not decay as 
observed experimentally after ~260s (Figure 3.4-7, panels 2, 4-10). Such a limitation 
was expected because the NN was trained on measurements spanning only 260s (Figure 
3.4-3 a) and not the entire duration (upto 900s). Importantly, the NN captured such cross-
talks of sequential additions despite being trained on purely synchronous interactions.  
3.4.6 Sequential additions mimicking the in vivo thrombotic 
environment 
Platelets at the site of injury are likely to encounter specific sequences of 
thrombotic signals. These are illustrated in Figure 3.4-8 A. The effects of thrombin can 
be approximated by considering SFLLRN+AYPGKF to be its equivalent in simulation.  
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Figure 3.4-8 Sequential additions mimicking the in vivo thrombotic environment 
(A) Various sequences of thrombotic signals likely to be encountered by platelets during 
in vivo thrombosis. (B) Comparisons between experiment and simulations studying 
sequential additions of CVX, ADP and thromin (or SFLLRN + AYPGKF) 
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In a realistic thrombotic setting, the platelet is likely to first get activated upon an 
exposed collagen surface. Subsequently, platelets adhered to collagen will encounter 
either thrombin (formed on the active platelet surface downstream of the coagulation 
cascade) or ADP (released from activated platelets).Platelets that do not directly adhere 
to the exposed collagen surface might get activated by thrombin or ADP (or sequences of 
these agonists) and subsequently stick on to collagen adhered platelets or form larger 
aggregates in solution. These conditions are illustrated in Figure 3.4-8 A. We mimic 
these 4 conditions by making selective sequential additions (similar to Figure 3.4-7) of 
the collagen analogue CVX, the physiological agonist thrombin as well as preassembled 
mixtures of SFLLRN and AYPGKF peptides all at 10x EC50 in  Figure 3.4-8 B. We 
show that the signals generated by thrombin for these selective additions are similar to 
those generated by a mixture of high dose PAR1+PAR4 peptides.  A PAS trained NN for 
donor A, qualitatively reproduces these sequential additions of PAR1+PAR4 peptides (to 
approximate the function of thrombin). The results we obtained are similar to those 
already reported (Figure 3.4-7). Prior GPVI activation abolishes detectable 
responsiveness to ADP or thrombin. Thrombin (or PAR1+PAR4) abolishes subsequent 
response to ADP (presumably by cross down regulation of the ADP cascade by PAR1 as 
was already reported in Figure 3.4-7). In contrast, prior ADP stimulation does not 
abolish subsequent detectable responsiveness to thrombin (or PAR1+PAR4).  We note 
that the NN was not trained using thrombin as an agonist and peptides have weak μM 
affinity to PARs compared to the intramolecular signaling that is generated by thrombin 
cleavage of the PARs. Differences between thrombin and preassembled mixtures of 
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SFLLRN and AYPGKF were noted when a CVX stimulus followed these inputs. These 
effects are discussed in Section 4.2. 
3.4.7 Predicting the global 6 dimensional human platelet response 
To fully test and utilize the predictive power of the NN model, we made in silico 
time-course and synergy predictions for the complete 6-dimensional agonist space 
consisting of 4077 unique agonist combinations of 2 to 6 agonists at 0.1, 1, or 10×EC50 
concentrations. For comparison, the full distribution of synergy predictions for all 4077 
agonist combinations is shown as a vertical heat map in Figure 3.4-12. Based on these 
predictions (Figure 3.4-9), we selected 45 combinations of 4, 5 or 6 agonists that 
displayed a range of predicted synergy scores from strong synergy to strong antagonism 
and tested them experimentally (Figure 3.4-10). To prevent any bias in the selection we 
selected conditions that had maximal dissimilarity in the types and concentrations of 
agonists.  
 
Figure 3.4-9  Predicted distribution of synergies scores. 
The complete distribution of predicted synergy scores in all 4077 conditions that 
comprise the 6 dimensional agonist space of  the agonists PGE2, AYPGKF, SFLLRN, 
U46619, ADP and CVX. This space was probed at the indicated positions to sample both 
ends of the synergy spectrum. 
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Figure 3.4-10 Measurement and prediction of response in the full agonist space. 
45 conditions (containing 4-6 agonists) spanning the entire synergy spectrum were 
chosen from amongst the NN model’s predictions of the complete experimental space. 
These were tested experimentally along with 19 controls. 
 
We found strong agreement between both predicted and measured calcium 
transient shapes (R=0.845) in Figure 3.4-10 and Figure 3.4-11, as well as between 
predicted and measured Sij scores (R=0.883, slope=1.08) (Figure 3.4-12).  
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Figure 3.4-11 Probing the complete agonist space. 
Experimentally observed mean (blue) and NN predicted (red) [Ca2+]i time courses for 45 
out of  the 4077 possibilities (shown in Figure 3.4-9) in the complete 6 dimensional 
agonist space. Each experiment was done in replicates of 6. Experimental error bars 
corresponding to standard deviations are shown at only 17 points along a time course for 
the sake of visual clarity.  The 45 conditions tested were chosen to span antagonism, 
additive interaction and positive synergy. 
 
Conditions containing high levels of all agonists showed especially low measured 
synergy due to saturation of calcium release. The highest synergy was observed for 
agonist combinations that contained high levels of the thromboxane analog U46619 with 
no PGE2 present (Figure 3.4-12, orange bar).  
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Figure 3.4-12 Predicted versus measured distribution of synergies for conditions 
containing 4-6 agonists and spanning the complete agonist space. 
Predicted versus measured synergy scores for the 45 conditions in Figure 3.4-10 (upper 
left). Distribution of synergy scores for all 4,077 possible experimental conditions (upper 
right). Experimental conditions for the 45 sampled combinations of agonists, arranged in 
order of increasing synergy (bottom). The orange bar denotes the three most highly 
synergistic conditions, which all contained high U46619, no PGE2 and low levels of other 
agonists. 
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Given that only 8 of 45 conditions had maximal U46619/PGE2 ratio, this ordering 
of the top 3 conditions was highly significant (p <0.004), considering there are 14,190 
possible ways to order the first 3 conditions of which only 56 combinations would 
contain high U46619 and low PGE2. Thus, the NN model trained on pairwise data 
facilitated discovery of a high dimensional synergy that occurs at high U46619/PGE2 
ratio (at low levels of ADP, SFLLRN and submaximal levels of  AYPGKF) consistent 
with the known cardiovascular risks of COX2 inhibitors that prevent endothelial 
production of prostacyclin without affecting platelet production of thromboxane [209]. 
This points to a ‘high-dimensional’ COX2 inhibition risk of high concentrations of 
thromboxane, in the absence of PGI2, potentiating the effects of other agonists. 
 
 
Figure 3.4-13 Effect of input silencing on predictive ability 
The NN model’s predictive ability of response to multiple agonists does not amount to 
prediction of the response to a dominant pair in the input set of agonists. To illustrate the 
ability of the model to integrate all of the inputs in its prediction and not just rely on 
certain input species, we systematically silenced each input to the model. Single inputs 
were silenced first, followed by pairs, triples, etc. The performance of such models that 
considered only smaller input sets (comprised of a lower number of input species) was 
evaluated across all high dimensional input sets tested.  
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The results of this analysis are presented above. Presence of a particular agonist is 
indicated by a black fill in a respective input set. In all but two cases, the overall 
predictive power decreased as inputs were silenced.  This shows that the NN model 
utilizes information from all inputs to gain accuracy. Any suppression of 1, 2, 3, 4, or 
more inputs drives down the accuracy.  In fact, deletion of data down to only 2 inputs (if 
a pair is often able to predict as well as the full input set) shown in red reduces the 
predictive power severely to zero correlation between experiment and the NN.  This data 
demonstrates that no single pair embedded in the experiment that predicts all the tested 
outputs better than the full input test. 
We note that there were two smaller subsets that yielded better prediction than the 
complete input set. Also there were cases where reducing the number of inputs markedly 
(for instance even up to two inputs for the two left most red columns) does not make 
much difference to the overall prediction. It is generally impossible however, to have a 
priori knowledge of which input to exclude to get better predictive ability than the full 
input set. Given that there is a strong trend for predictions to do better when given 
multiple inputs (despite these few exceptions) we conclude that the NN integrates 
information from all input species.  
 
To investigate whether smaller subsets of inputs, such as dominant pairs, could 
account for the network’s predictive accuracy, we retrained the neural network on 
different subsets of inputs. This typically, but not always, reduced predictive accuracy 
(Figure 3.4-13), suggesting that the neural network does not exclusively rely on smaller 
subsets of inputs.  
3.4.8 Donor specific platelet responses 
To investigate the reproducibility of the PAS procedure and to investigate the 
potential for using it to stratify individuals’ platelet responses, PAS was performed twice 
within two weeks of each other (with 2 replicates of every condition in an individual 
experiment) for 10 healthy male donors to construct donor specific synergy maps (Figure 
3.4-14). Donors (Ages: 22-30 years) spanned several ethnic groups (3 Western 
Europeans, 2 Asians, 2 Indians, 1 Caribbean, 1 African American and 1 African).  
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Figure 3.4-14 Donor specific platelet agonist synergisms. 
PAS was performed twice for 10 healthy male donors to construct 135 parameter donor 
specific synergy maps 
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Figure 3.4-15 Donor specific PAS clustering patterns 
Ten healthy donors were phenotyped for platelet calcium response to all pairwise agonist 
combinations. Repeat experiments were conducted within 2 weeks. Donors (ages, 22–30 
years) spanned several ethnic groups (three Western Europeans, two Asians, two Indians, 
one Caribbean, one African American and one African). The magnitudes of synergy in 
each of the 20 donor-specific synergy maps were arranged as columns of the synergy 
matrix. These vectors were clustered according to similarity using a distance-based 
clustering algorithm. 
 
The 135 conditions containing pairs of agonists in a single PAS experiment make 
up the synergy map for each donor experiment (Figure 3.4-14) and individual columns of 
the synergy matrix (Figure 3.4-15). To demonstrate reproducibility and donor specificity, 
a simple hierarchical cluster tree was generated using the Euclidean distances between 
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donor experiments (columns of the synergy matrix). A total of 7 out of the 10 donor pair 
vectors (Donor pairs D, C, A, H, E, F and I) self clustered, demonstrating that in spite of 
intra donor variations in synergy, pronounced inter donor variations allow us to 
distinguish donors. This pattern of clustering was found to be highly significant (p < 
8×10-7) by randomizing observed donor synergies (Figure 3.4-16) considering the fact 
that 5 donor pairs (the highest number of donor pair clusterings by random chance) self 
clustered in only 8 out of 10 million random permutation tests. 
  
 
Figure 3.4-16 Randomization of donor specific synergisms. 
The synergy scores for each donor (values in the columns of the synergy matrix shown in 
Figure 3.4-15 were randomized to test whether the clustering of the ‘observed’ donor 
specific synergy vectors was significant. We found that the experimentally observed 
clustering of 7 donor pairs (red line) out of 10 was highly significant. A P-Value less than 
8×10-7, under the null hypothesis that the donor clustering pattern was by chance alone, 
was obtained. 
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  Donors separated into at least 2 major subgroups with the cluster of donor 
experiments D1, D2, J2, C1, C2, B1 and B2 characterized by relative lack of synergy 
(red) in comparison to other experiments. The cluster of experiments A1, A2, H1, H2, J1, 
E1, E2, F1, F2, G1, I1, I2 and G2 had marked synergy between moderate doses of 
SFLLRN and all doses of U46619/ADP, as well as marked synergy for moderate U46619 
and high CVX. Mild positive synergisms such as those between low doses of SFLLRN 
and U46619/ADP, as well as those between ADP and CVX further classify this latter 
cluster into smaller sub clusters comprising of donors A1, A2, H1, H2 and J1; and donors 
E1, E2, F1, F2, G1, I1 and I2 . PGE2 was found to be antagonistic to all Gq-coupled 
agonists (ADP, U46619, SFLLRN and AYPGKF) for all donors, in accordance with the 
known ability of PGE2 to raise cAMP levels [210]. Experiments A1, A2, J1 and I1, I2 
were distinguished by positive synergisms at high dose PGE2 and moderate to high dose 
CVX; positive synergy was also noted between low dose PGE2 and high dose CVX for 
experiments A1, A2, H1, H2, E1, E2, F2 and G1 possibly via  EP3 mediated signals [211] 
which are known to mediate pro-aggregatory actions.  
In a single PAS experiment there are 135 conditions containing 2 agonists. These 
were tested in duplicate on the same plate giving 2 measurements of the 135 synergy 
scores (using the mean single agonist integrated areas in a plate to calculate synergy). 
PAS experiments were repeated twice within two weeks for an individual donor, giving 
us 4 measurements of an experimental synergy score. The standard errors in synergy 
scores across all 135 conditions were uncorrelated with the magnitude of synergy and are 
measures of the experimental uncertainty and day-to-day fluctuations in mean synergy 
values at these conditions. The mean uncertainty for a representative donor (donor A) 
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was ± 0.0523 for Sij ranging from –1 to 1 (uncertainties across all 135 conditions are 
shown in Figure 3.4-17). The mean standard error in synergy scores for all ten donors 
ranged from ±0.0347 to ±0.0627 (Table 3.4-3).  
 
Figure 3.4-17 Experimental uncertainty in mean synergy score (Donor A). 
Shown above are the mean synergy scores ± standard errors for all 135 conditions for 
both donor A experiments. The mean standard error across all 135 conditions for each 
donor was 0.0523. These values were calculated for all the 10 donors studied and are 
reported in Table 3.4-3.  
 
Since all experiments were performed in diluted platelet rich plasma and not 
‘pure’ platelet suspensions, we tested whether the observed clustering patterns were 
dependent on platelet independent plasma components. We performed two separate PAS 
scans of platelets from a donor (separate from the donors reported in Figure 3.4-15). In 
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the first experiment for donor K (experiment K1), a PAS scan was performed identically 
to the procedure described in the manuscript using autologous plasma (as in Figure 
3.4-3). In experiment K2, platelet rich plasma from donor K was supplemented with an 
equal volume of plasma (platelet free) from donor E (whose PAS scans have been 
reported in Figure 3.4-15).  Both donor K experiments yield very similar PAS scans, and 
as shown above, both donor K experiments self clustered. Importantly K2 does not 
cluster with donor E replicates. This demonstrates that the PAS profiles are platelet cell 
autonomous and not dependent on plasma components. 
 
Donor Mean standard error in synergy scores 
A 0.0523 
B 0.0627 
C 0.0331 
D 0.0432 
E 0.0347 
F 0.0356 
G 0.0498 
H 0.0494 
I 0.0443 
J 0.0469 
 
Table 3.4-3 Mean standard error in synergy scores. 
The mean standard error in synergy score was calculated as explained in Figure 3.4-17. 
These values are a measure of the experimental uncertainty in determining donor specific 
synergisms.  
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Figure 3.4-18 Platelet cell autonomous clustering pattern. 
The observed pattern of self-clustering was platelet signaling dependent (and not related 
to donor plasma), as the PAS scans of an individual donor’s platelets with autologous 
(Experiment K1) or heterologous plasma (Experiment K2) self-clustered. 
 
3.4.9 Dose dependence of binary synergies 
To evaluate the dependence of binary synergy scores on the doses of the both of 
the agonists present in the binary mixture, we plotted the distributions of synergy at each 
dose combination (Figure 3.4-19). All experimentally observed pairwise synergy scores 
(4 synergy scores per condition per donor × 10 donors) at the 9 possible binary 
concentration pairs (at 0.1, 1 and 10 × EC50) were binned according to their binary 
synergy values. 
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Figure 3.4-19 Dependence of synergy scores on agonist pair concentrations. 
Shown above are the probability distributions of binned synergy scores at each 
concentration pair. Responses with synergy scores less than -0.1 were classified as 
antagonistic, those greater than 0.1 were classified as synergistic and scores between -0.1 
and 0.1 were classified as additive. Shown in the top left is a summary of the cumulative 
probabilities of antagonism, additive responsiveness and synergy at each condition. 
Highest probabilities of synergy were observed when both agonists were at moderate 
doses. At low doses of both agonists, responses were generally additive. When high doses 
of both agonists were present the synergy distributions were skewed towards antagonism 
in accordance with the notion of saturation of signaling pathways. 
 
In general across all conditions and donors, the highest probability of pairwise 
synergy was observed when moderate doses of both agonists were used. Low doses of 
both agonists produced additive responses, whereas high doses of both agonists skewed 
synergy distributions toward antagonism. 
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3.4.10 Intra and inter donor variability of phenotype 
 
 
Figure 3.4-20 Intra and inter donor variability of phenotype 
Variations in synergy scores both within the same donor and across donors were 
evaluated. (A) Intra-donor variability was calculated as the mean of the standard error 
in synergy scores across all conditions and (B) Inter-donor variability was calculated as 
the standard error of mean synergy scores across all conditions. 
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We have conducted an analysis of intra-donor and inter-donor variability (Figure 
3.4-20).  We found that the source of intra-donor variability was similar, but not identical 
to the source of inter-donor variability.  For example, ADP-CVX interactions were a 
strong source only of intra-donor variability.  In contrast, high PAR4 agonist in 
combination with ADP, U4619, and SFLLRN were sources of only inter-donor variation. 
To calculate intra-donor variability (panel A), the standard errors at each of the 
135 conditions containing binary mixtures was first evaluated. Next the means of these 
standard errors were calculated across all 10 donors. The conditions were plotted on the 
binary synergy map with the color indicating the magnitude of the relative variability. To 
calculate inter-donor variability (panel B), the mean synergy at each of the 135 
conditions (across all 4 replicates) was first calculated. The standard error of this mean 
synergy measurement at a particular condition was then calculated across all 10 donors. 
This gives us an indication of the spread of measured values for a particular condition in 
the donor cohort. The conditions were again plotted on the binary synergy map.  
Conditions containing PGE2  in general had the lowest intra donor variability. 
Conditions containing moderate CVX had the highest intra donor variability. Such 
variability is a measure of the likelihood of experimental noise at a particular condition. 
Conditions containing PGE2 had the least inter donor variability as well, thus pointing to 
highly conserved modes of interaction. Conditions that were identified to have high inter 
donor variability inspite of low intra donor variability are the most useful in 
distinguishing the two major donor clusters (Figure 3.4-15). Some of these conditions 
were (i) high AYPGKF, low/moderate ADP; (ii) high AYPGKF, moderate/high U46619; 
(iii) moderate SFLLRN, high U46619.     
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3.4.11 Synergy between thrombin and thromboxane pathways 
 
Figure 3.4-21 Synergism between thrombin and thromboxane. 
Noting marked synergism between SFLLRN and U46619, and some synergisms between 
AYPGKF and U46619, for all donors, we tested for synergism between the physiological 
agonist thrombin and U46619. A complete binary interaction map spanning 7 
concentrations of either agonist was studied. for 2 separate donors. All conditions were 
tested in replicates of 6 and mean responses were used to calculate synergy scores. 
Experiments were conducted in EDTA and also included 15 μM Indomethacin, 2 units/ml 
Apyrase and 100 μM GGACK to prevent autocatalytic amplification by thromboxane, 
ADP or Xa. 500 μM GPRP was included to prevent fibrin formation with added 
thrombin. It should be noted that our experiments were conducted in 12% ‘unwashed’ 
platelet rich plasma in the presence of ~300 nM concentration of the physiological 
thrombin inhibitor antithrombin III. This might account for the fact that relatively high 
levels of thrombin (greater than ~10 nM) were required to observe detectable response to 
thrombin. Such an experimental design has no effect on receptor mediated pathways but 
produces a right shift in thrombin dose response. As anticipated, we observed synergisms 
between low and moderate doses of these agonists prior to saturation of their receptor 
signaling pathways.  
 
All donors showed some synergism between low and moderate doses of SFLLRN 
and U46619. Except for experiment B2, synergy was also found between AYPGKF and 
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U46619 for all donors. Moreover, synergistic/additive interactions were noted also 
between low and moderate doses of SFLLRN and AYPGKF. These results strongly 
suggested a mechanism of synergy between thrombin and thromboxane. To test this, 
binary synergy maps of the physiological agonist thrombin and U46619 were constructed 
for donors A and E (Figure 3.4-21) over 7 doses spanning the active concentration 
ranges. Marked synergisms were noted at low and moderate doses of these agonists as 
expected from conserved synergy between SFLLRN/AYPGKF and U46619 (Figure 
3.4-15). High doses saturated signaling pathways abolishing synergism. To our 
knowledge, this is the first report of conserved synergy between thrombin and 
thromboxane mimetics. 
3.4.12 Dominance of pairwise effects in platelets 
The PAS approach works because individual and binary interactions dominate, 
and they are sampled across the full dose range of inputs. We expect the method to break 
down when ternary interactions in excess of summing binary interactions become strong. 
We show that the residual ternary synergy (∆(ABC) = SABC – SAB – SBC – SAC) was ~0 in 
each of 27 responses of platelets to different ternary combinations of CVX, ADP and 
SFLLRN and was minimized in the neural network model training (Figure 3.4-22). 
The PAS approach works because unitary and binary interactions dominate and 
they are no feedbacks, which would otherwise expand the repertoire of participating 
factors. With these “pure inputs” (which are not broad intracellular perturbations like 
ionophores or phosphodiesterase inhibitors), the network architecture (Figure 3.2-1) 
necessitates rapid convergence to a common second messenger. Because of the speed of 
signaling and the known cell circuitry, it is difficult to envision realization of greater than 
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second order synergies in such a situation. Thus observed ternary synergies appear to be 
well approximated by the linear superposition of the individual pairwise synergies. Since 
residual ternary interactions were undetectable, even higher ordered residuals are likely 
very small and potentially difficult to evolutionarily select. This exact result of unitary 
and binary interactions dominating with few detectable ternary interactions was reported 
for multiple cytokine stimulation of RAW264.7 cells [212].  
In general, knowledge of pairwise interactions alone cannot be expected to predict 
response to several simultaneously present stimuli (>2). However, certain characteristics 
of platelets and the conditions under which they were studied made such an approach 
feasible in this instance. These include (i) the relative abundance of binary interactions in 
signaling systems with minimized ternary interactions (ii) the efficient utilization of 
system history (Figure 3.4-23); (iii) the dense sampling of interactions across a full dose-
response range; (iv) known intracellular wiring that rapidly converges on Ca2+, without 
the possibility of higher order effects from genetic regulation or other interactions on 
long time scales; and (v) choice of well-characterized extracellular ligands and careful 
design to avoid autocatalytic feedback.  
Thus, the PAS approach is powerful for training NN models of signaling systems 
that accommodate multiple binary interactions where ∆(ABC) or higher ordered residuals 
are small. In systems where third order interactions are important “ternary” agonist 
scanning might be necessary, however this will require added experimental complexity. 
“Pairwise” agonist scanning is the bare minimum that can be expected to quantify 
interactions between multiple simultaneously acting signaling pathways over and above 
the strictly additive interactions between pathways.  
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Figure 3.4-22 Minimization of residual ternary synergy. 
The PAS trained NN model has complete knowledge about all unitary and binary 
interactions that occur in the platelet, since these conditions were exhaustively sampled in 
the experimental training set. However, information about higher order interactions are in 
general unknown, and thus successful predictions can be made in a system only if such 
higher order interactions are relatively unimportant.  
Our experiment with ADP/CVX/SFLLRN measured platelet response to simultaneous 
activation of two GPCRs and an immune receptor homologue (GPVI).   Above, we 
investigate the binary synergy score (SAB=AB-A-B), the trinary synergy score (SABC = 
ABC-A-B-C), and the “residual” ternary synergy which measures the synergy in excess 
of the binary synergies [∆(ABC) = SABC-SAB-SBC-SAC].   We show that the 
experimentally measured residual ternary synergy ∆(ABC) is essentially zero in 27 
different tests of platelet response to the 3 agonists used at 0.1, 1, and 10X EC50.  By 
determination of SAB, SABC, and ∆(ABC) from the predicted calcium responses obtained 
from the neural network, we show that ∆(ABC)NN is also minimized during the NN 
training.  If ∆(ABC) ~ 0, then it is highly unlikely that higher ordered residuals such as 
∆(ABCD..) are large.  In such a situation, sampling the pairwise interactions 
experimentally and using this data to train the NN allows the NN to make accurate 
prediction of n-tuples. 
Multiple signals acting simultaneously in vivo is not unique to platelets. Hsueh et. al. 
recently reported the binary to quintinary interactions between 5 ligands (IFN-β, TGF-β, 
IL-6, ISO and 8 Br-cAMP) of a single receptor (TLR4), resulting in secretion of 4 
cytokines (G-CSF, IL-6, IL-10, and TNF-α) in macrophage like RAW 264.7 cells [212]. 
They found that almost all pairwise interactions result in non-additive interactions (akin 
to Figure 3.4-3 and Figure 3.4-15 in the present study).  Instances of higher order 
interactions resulting in unique outcomes that not captured by “binary interactions” were 
less common (~33% of total combinations with the majority being explicable by ternary 
interactions). Hsueh et. al. made no consideration of dose dependence of the input 
signals, nor was any attempt made to distinguish between the responses of the same type 
originating from different human individuals.  
Thus the two actual biological systems tested to date (human platelets and cultured 
RAW264.7 cells) satisfy the requirement that response to combinatorial agonists is build 
upon unitary and binary interactions.  Since ternary interactions can be easily measured 
experimentally, this guides the use of PAS in other systems.  This approach can be 
expected to work in systems where residual third or higher order interactions are 
minimal.  
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3.4.13 Utilization of system history in making output predictions 
 
Figure 3.4-23 Use of system history in making output predictions. 
 
The importance of history on predictive ability was evaluated by systematically 
decreasing the length of system history utilized in making predictions about the current 
instant. 
 
The NARX model utilizes system history in making predictions of the output 
value [Ca2+]i at the current instant. Without any history, there is no notion of “dynamics”, 
and the system can at best predict outputs proportional to the magnitude of input.  
However these outputs are constant over the duration of the experiment, unlike the actual 
calcium transients experimentally observed. With very little history (2 s), the model does 
not “remember” its unperturbed steady state value (0) and hence calcium traces 
continually rise to a peak value, but never decrease.      The NN performs reasonably well 
with as little as 8 s of calcium concentration history, although  oscillations are produced, 
as the network progressively utilizes less information about its initial steady state, and 
heavily relies on just its “short term memory”,  repeatedly replicating the initial trend. As 
additional delay lines were removed from the network, the frequencies of these 
oscillations were decreased and the network gradually captured experimentally observed 
dynamics. Thus the long-term system history inputs (e.g., 32, 64, 128 s) dampen these 
short-term oscillations. 
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3.5 Discussion 
Studying the combinatorial effects of pairs of agonists in low, moderate and high 
concentrations allowed a rapid, donor-specific phenotypic scan that was predictive of 
responses to 6 multiple agonists. Importantly, a single 384-well plate of data was 
sufficient to train a NN model (Figure 3.4-3) that was capable of making accurate 
predictions of the global 6-dimensional agonist reaction space (Figure 3.4-9), which is 
difficult to probe experimentally but fundamental to the processes of thrombosis.
 Synergies between platelet agonists are dependent not just on agonist pairs and 
doses, but also vary from donor to donor (Figure 3.4-15). The synergistic effects of 
epinephrine on other platelet agonists is well documented [213, 214]. Synergy has also 
been reported between ~EC50 levels of SFLLRN-AYPGKF, AYPGKF-ADP and 
SFLLRN-ADP [215].  Such unique patterns of synergisms could be used to distinguish 
donors and be correlated with certain risk factors. In contrast, certain synergisms, such as 
those observed between U46619 and thrombin receptor agonist peptides, were consistent 
across donors and suggest conserved modes of interaction amongst these cascades.  
We note that in multi-dimensional agonist space emblematic of the thrombotic 
milleu, highest synergy was observed for combinatorial mixtures containing high U46619 
and no PGE2 (Figure 3.4-12). This points to the “high dimensional risk” of large 
concentrations of thromboxane, in the absence of PGI2, potentiating the effects of other 
agonists. Aspirin is approximately 170-fold selective to COX-1 mediated thromboxane 
production, compared to endothelial COX-2 mediated  PGI2/PGE2 synthesis. Thus, 
selective inhibition of thromboxane, without affecting prostacyclin may account for its 
efficacy in protecting against thrombotic events when diverse platelet activators are 
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present [216]. In contrast Rofecoxib (Vioxx), by a selective inhibition of COX-2 
mediated prostacyclin production, increases cardiovascular risk [217]. 
This study also introduces the use of neural network models for predicting 
dynamic cellular signaling data. This application of neural networks offers several unique 
benefits as a modeling strategy. First, NNs are “dense” modeling structures (few 
parameters) that do not require a detailed knowledge of the kinetic structure of a system. 
By comparison, a detailed ordinary differential equation (ODE) model of ADP-
stimulated calcium mobilization via P2Y1 in the platelet required almost 80 reactions and 
over 100 kinetic parameters to describe just this one single pathway [168]. We estimate 
that an ODE model that describes the signaling mechanisms of the 6 agonists (Figure 
3.2-1) in this study on a similar level of detail would require over 500 parameters, most 
of which are currently unavailable. Second, NN models may be trained to match an 
individual donor’s signaling response. We have demonstrated in Figure 3.4-15 the subtle 
but consistent variation in the platelet calcium response among healthy donors. This 
offers a predictive capability that may be used to assess risks associated with an 
individual’s platelets. A major goal of blood systems biology is to predict patient specific 
risks and to simulate thrombus formation under realistic hemodynamic conditions of flow 
[96, 218]. Platelet activation in prior simulations has been course grained by assuming 
discrete states of activation or arbitrary rules governing transitions between states. The 
speed of NN calculations of [Ca2+]i will allow large scale, donor-specific simulations 
with 103 to 105 activating platelets under conditions of flow. Such a model can be 
incorporated into lattice kinetic Monte Carlo simulations of particle motion in convective 
and dispersive flow fields [219] (Section 3.7). 
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Figure 3.5-1 ODE model of platelet calcium mobilization following an ADP stimulus 
An ODE based molecular signaling model (77 reactions, 132 rate constants, 70 species) 
of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 
activation was developed (top) [168]. This model was able to simulate experimentally 
obtained calcium dose response to ADP (bottom). 
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Clinically, we anticipate PAS profiles to depend on such variables as ancestry, 
age, sex, pharmacology, and cardiovascular state, all of which requires further testing.  In 
contrast to PAS, other current measurements of platelet phenotype provide the coarsest 
measure of differences among healthy donors. For instance, platelet aggregometry for 
359 subjects could classify them as “hypo  and hyper” reactive  to platelet agonists [220]; 
and flow cytometry of 26 individuals was able to classify them as high, medium or low 
responders. A combination of genetic variations may underlie differences in platelet 
phenotype, however linking genotype (1327 SNPs) to phenotype (flow cytometric 
measurement of P-Selectin exposure and fibrinogen binding) in 500 individuals [221] 
demonstrated weak association probabilities.    
Platelets are ideal “reduced” cellular systems for quantifying the effects of 
multiple signaling pathways because they are anucleate, easily obtained from donors, 
amenable to automated liquid handling, and biochemically well-characterized.   In spite 
of the distinction from the in vivo platelet environment, the simplified in vitro conditions 
using EDTA were useful for the dissection of signaling pathways ‘decoupled’ from 
confounding autocrine effects of soluble mediators that are highly dependent on local 
platelet concentrations and prevailing transport processes. However, the operational 
advantages of using EDTA prevent direct prediction of important physiologic phenomena 
like granule release, integrin activation, and outside-in signaling. 
Further expansion of the PAS set to include epinephrine, soluble CD40L, 
serotonin, and nitric oxide donors would essentially map a major portion of the entire 
platelet response space. The use of PAS with orthogonal pharmacological agents 
(indomethacin, P2Y12 inhibitors, selective PAR antagonists, quanylate cyclase or 
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adenylate cyclase inhibitors) would allow further assessment of individual clinical risk or 
sensitivity/resistance to therapy. The PAS method demonstrates that sampling all dual 
orthogonal "axes" (every agonist pair) can successfully predict the dynamic responses 
and cross-talks of a higher dimensional system (6 agonists in this case). 
3.6 Extension 1: Phenotyping of female donors 
  All of the donors shown in Figure 3.4-15 were male donors. To test for 
correlations between the gender of the donor and PAS clustering pattern, we carried out 
pairwise agonist scans for 10 female donors (donors L to U) and compared the clustering 
patterns of all donors (male and female) together Figure 3.6-1.  All female donors were 
between the ages of 20 and 26, were from either Asian or Caucasian ancestry; and 
affirmed before phlebotomy that they had not consumed alcohol for 3 days prior to the 
blood draw, were not under any medications, and were not currently using birth control 
hormone. Similar to the experiments with male donors a repeat experiment for every 
female donor was carried out within a period of two weeks.   
 All of the experiments beyond donor K were conducted with the same stocks of 
reagants for the 6 inputs tested. We also tested a male donor (donor V) with these same 
stocks. Donor V did not consent to a second blood draw, thus only a single experiment 
(V1) is shown for this donor in Figure 3.6-1.  
 3 of the 10 female donors self clustered (donors R, M and O). The number of 
male donors self clustering remain unaltered (7 out of 10). The comparatively reduced 
magnitude of self clustering for female donors can probably be explained by the fact that 
the female donors tested did not have as diverse a genetic background as the male donors. 
Moreover, the likelihood of self clustering can be expected to drop sharply as the number 
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of donors tested (columns in the synergy matrix) goes on increasing, for an unchanged 
number of conditions at which phenotypes were tested (the 135 conditions at which 
synergy between platelet agonists were measured comprising the rows of the synergy 
matrix). The probability of donor experiment self clustering can be expected to improve 
if the number of experimental conditions tested increases (either testing of ternary and 
higher order synergies in addition to the pairwise interactions, or the testing of the binary 
interactions amongst more signaling pathways). However this will require added 
experimental complexity, and is limited by technological limitations of current automated 
liquid handling protocols. The total number of donors self clustering (male and female) 
still remains highly significant (11 of 21) and to our knowledge PAS shows the most 
promise in “stratifying” individual donor platelet phenotypes amongst other currently 
available platelet phenotyping approaches (aggregometry or flow cytometry). 
 We did not observe a clear pattern in Figure 3.6-1 where female donors clustered 
separately from male donors. Because hierarchical clustering was inadequate in 
distinguishing platelet phenotypes on gender, we determined the principal components of 
the synergy matrix. Principal component analysis (PCA) is a method of dimensionality 
reduction where an orthogonal basis set of “principal components” is identified 
(consisting of linear combinations of the original variables), such that much of the 
variance in the original data is explained by variation along the first few principal 
components. We deteremined the principal components of the 135 dimensional synergy 
matrix and plotted up donor phenotypes along the first two principal components for ease 
of visualization (Figure 3.6-2). The first 2 principal components account for the most 
variation in the original data (PC-1 accounts 20.74 % of the variance and PC-2 13.98 %). 
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Figure 3.6-1 Dependence of synergy clustering pattern on donor gender 
10 healthy female donors (donors L to U) were tested twice each within a period of two 
weeks. Their PAS synergy profiles were arranged in columns of the synergy matrix (in 
addition to those for all male donors), and the columns of this matrix were clustered.  
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Figure 3.6-2 Scatter of donor phenotypes along first two principal components of 
synergy matrix. 
The columns of the synergy matrix in Figure 3.6-1 correspond to donors of varying 
gender and ethnicity. To determine whether the experimentally measured synergy 
profiles were correlated with any of these factors, we determined the principal 
components of the 135 dimensional synergy matrix. Donor phenotypes were projected 
along the first two principal components.  
 
Although the first two principal components account for only about 35% of the 
variance of the original synergy phenotypes  in the synergy matrix, the second principal 
component showed remarkable promise in distinguishing phenotypes on gender. 15 of the 
20 female donor phenotypes had negative values of the second principal component and 
21 out of 23 male phenotypes had positive values of the second principal component.  
The first principal component is correlated with donor ethnicity (phenotypes with large 
positive values of PC1 were Caucasian, whereas large negative values of PC1 were 
obtained for donors of African descent).  
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3.7 Extension 2: Platelet activation module in patient specific 
multiscale models of thrombosis under flow 
The process of thrombosis involves discrete particles (platelets) moving in a 
convective field. At the site of the growing thrombus these particles can attach to the wall 
(exposed collagen). Such platelets that attach to the wall will eventually activate fully and 
release autocatalytic activators like ADP and TXA2, as well as contribute catalytic 
surface for thrombin formation. This sets up a boundary layer around the growing clot 
where released species like ADP, TXA2 exist at appreciable concentrations. Unactivated 
platelets can activate in this layer around the growing thrombus according to the 
prevailing local concentrations of agonists. Two activated platelets in the viscinity of the 
growing clot can aggregate together either in solution, or an activated platelet in solution 
can deposit onto anto an activated platelet on the growing thrombus (Figure 3.7-1 A). 
Flamm et al have a developed Lattice Kinetic Monte Carlo (LKMC) algorithm 
that is capable of simulating convection and diffusion of particles in complex flow fields 
[219], as well as particulate aggregation for defined rates [222].  Kinetic Monte Carlo 
algorithms are efficient at predicting system evolution given the rates of governing 
stochastic processes involved [219]. For the problem at hand, the spatial and temporal 
growth of the thrombus can be simulated from the rates of convection, diffusion, platelet 
activation, and activated platelet aggregation/disaggregation. This is the basis for a 
multiscale model of thrombosis (Figure 3.7-1 B): where (i) the velocity field is obtained 
by either a Lattice Boltzman solution, or from solution of the full Navier Stokes equation 
using commercial CFD packages, (ii) the local concentrations of agonists can be obtained 
from finite element or finite difference solution of the convection-diffusion equation. 
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Figure 3.7-1 Multiscale systems model of thrombosis: Contribution of the platelet 
activation module 
(A) The process of thrombosis involves discrete platelet particles moving in a flow flow 
field that can attach to the exposed injury, activate in the growing cloud of active 
agonists, or bind to other active platelets in solution or at the thrombus site.  
(B) Multiscale model of thrombosis: An LKMC algorithm is able to simulate the 
evolution of the growing clot given rates of all events involved in the process 
(convection, diffusion, activation, aggregation and disaggregation). The rates of platelet 
activation are supplied by donor specific PAS trained NN models for calcium 
mobilization.  (Image courtesy Matt Flamm) 
ADP, TXA2, IIa
vv
Activation 
Deposition 
B 
A 
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 Given the local concentration of agonists at any position and time, a PAS trained 
neural network model can predict the level of calcium mobilization in the platelet. 
Integrated platelet calcium can be used as a measure of the activation status of the platelet 
and governs the “stickiness” of a given platelet for other platelets, as well as its potential 
to release autocrine activators. The advantage of this approach is that neural network 
models can be trained on an individual donor’s PAS dataset, thus yielding donor specific 
models of thrombosis.  
For initial comparisons between in vitro experiments studying platelet thrombus 
formation and their corresponding LKMC simulations, we do not consider the effects of 
thrombin. In the absence of thrombin, or endothelium produced prostacyclin, the effects 
of three of the inputs in the original PAS set: the PAR peptides SFLLRN and AYPGKF, 
and the prostacylin mimic PGE2 can be ignored. For the 3 remaining inputs (ADP, CVX 
and U46619) complete testing of all single and pairwise mixtures requires testing of 37 
conditions. We tested these conditions in replicates of 4, both for regular platelets and for 
platelets treated with the antiplatelet pharmacological agents MRS2395 (P2Y12 inhibitor) 
(Figure 3.7-2 for donor W) and Illoprost (prostacyclin analogue) (Figure 3.7-3 for 
donor D). All experiments in this section were conducted in the presence of 2 mM 
extracellular calcium, and contained 28 µM Indomethacin to prevent autocatalytic 
amplification by secreted thromboxane. Since the platelet suspensions contained external 
calcium in these experiments, the level of signal (and background) was higher. This 
permitted us to use a lower concentration of 6 % PRP as opposed to 12 % PRP used for 
PAS experiments (Figure 3.4-3). Autocatalytic amplification by released ADP at such 
dilute concentrations of PRP will be minimal (See Section 3.4.2).  
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These datasets were used to train donor specific neural network models of regular 
platelet phenotypes as well as models of patient specific therapy in response to these drug 
treatments. The structure of the neural network used for training was identical to the one 
previously described (2 processing layers with 8 and 4 neurons respectively and an output 
layer) (Figure 3.3-2). Training was continued until the performance of the trained models 
(mean squared error between experimental and simulated transients) was ~ 1×10-5. (Also 
see Section 3.3.6 for details about model construction and training) 
Maloney et al have developed an 8-channel microfluidic flow assay where blood 
drawn into PPACK (to inhibit thrombin), and labeled with AlexaFluor 647 conjugated 
anti-CD41 (αIIb) antibody to identify platelets, is perfused over focal zones of collagen at 
an average wall shear of 210 s-1 [223]. For comparison between experiment and LKMC 
simulation, this assay was used by Tom Colace to simultaneously measure platelet 
deposition on collagen coated surfaces using the same samples of blood that were used 
for calcium phenotyping in Figure 3.7-2 and Figure 3.7-3. Either untreated blood; blood 
treated with indomethacin; MRS2395 (Figure 3.7-2) or Illoprost (Figure 3.7-3); or 
combinations of Indomethacin and the respective inhibitor were used in each channel of 
the device and every condition was tested in replicates of two on the same device. Each 
condition was tested in replicates of 6 (on 3 separate devices). The total fluorecense after 
5 minutes of perfusion was used as a measure of platelet accumulation. All values were 
normalized to the mean value of the control (untreated blood sample) (Figure 3.7-4). The 
LKMC simulations of thrombosis will attempt to simulate such flow experiments using 
predictions of each platelet’s activation state (integral calcium levels) from corresponding 
PAS trained neural network models. 
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Although P2Y12 inhibition using MRS2395 has a pronounced effect in decreasing 
platelet deposition on collagen surfaces (Figure 3.7-4), we note that there was no 
appreciable effect of P2Y12 inhibition on calcium mobilization (Figure 3.7-2). The fact 
that calcium transients were unaffected by P2Y12 inhibition can be explained by the fact 
that the P2Y12 receptor is not Gq coupled (See Section 1.2), and contributes to 
aggregation independently of calcium pathways. Thus, neural network model predictions 
of calcium alone will be inadequate to simulate the effect of this inhibitor. Further 
experiments using readouts other than calcium mobilization (like flow cytometry), to 
quantify the diminution of integrin activation by ADP signaling in the presence of this 
inhibitor are underway. Corrections to activation levels predicted by integral calcium 
need to be incorporated into the LKMC model to predict the effect of this inhibitor.  
In contrast, Illoprost has a pronounced effect in decreasing both calcium 
mobilization (Figure 3.7-3) as well as platelet deposition onto an exposed collagen 
surface (Figure 3.7-4). Thus LKMC simulations of platelet deposition without or with 
Illoprost treatment can be generated using activation state predictions solely obtained 
from the PAS trained neural network values of integral calcium. We also note a more 
pronounced effect of thromboxane synthesis inhibition (Indomethacin treatment) for 
donor W in comparison to donor D for platelet deposition on collagen (Figure 3.7-4). 
This correlated with heightened levels of calcium synergy between the thromboxane 
analogue U46619 and ADP for donor W (compare ADP-U46619 pairs between Figure 
3.7-2 and Figure 3.7-3). We are currently confirming this correlation for a larger donor 
sampling. Use of either MRS2395 or Illoprost in conjunction with Indomethacin does not 
provide any statistically significant improvement in inhibitory capacity (Figure 3.7-4).    
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Figure 3.7-2 Pairwise scan of Donor W for ADP, U46619 and CVX for platelets 
treated without or with the P2Y12 inhibitor MRS2395 
Calcium mobilization for all pairwise combinations of ADP, U46619 and CVX were 
measured for donor W under regular conditions (red) and with the P2Y12 inhibitor 
MRS2395 (blue). All conditions were tested in replicates of 4.  
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Figure 3.7-3 Pairwise scan of Donor D for ADP, U46619 and CVX for platelets 
treated without or with the prostacyclin mimic Illoprost 
Calcium mobilization for all pairwise combinations of ADP, U46619 and CVX were 
measured for donor D under regular conditions (red) and with the IP receptor stimulant 
Illoprost (blue). All conditions were tested in replicates of 4.  
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Figure 3.7-4 Concurrent experiments studying platelet deposition phenotypes on 
collagen coated surfaces in microfluidic flow devices 
Blood was drawn into the thrombin inhibitor PPACK, and platelets were labeled with 
AlexaFluor 647 conjugated anti-CD41 (αIIb) antibody. These samples were perfused over 
a strip of patterned collagen in an 8 channel microfluidic device [223]. Each channel 
contained either regular blood; blood treated with Indomethacin to limit synthesized 
thromboxane; blood treated with MRS2395 to inhibit ADP signaling via P2Y12 (panel A 
for donor W) or treated with the antiplatelet drug Illoprost to raise intracellular cAMP 
levels via IP signaling (panel B for donor D); or with mixtures of Indomethacin and the 
respective inhibitor. These samples of blood were perfused for 5 minutes over collagen 
coated surfaces at an average wall shear of 210 s-1 and the level of platelet accumulation 
was quantified by measuring the final levels of fluorescence. Shown above are the 
fluorescence intensities scaled to the mean value of the control (untreated blood sample). 
All conditions were tested in replicates of 6 and blood from the same phlebotomy 
samples that were used for calcium phenotyping (Figure 3.7-2 for donor W and Figure 
3.7-3 for donor D) were used in these flow experiments (panel A and panel B 
respectively).  (Experiments and analyses courtesy Tom Colace) 
 
Donor W 
Donor D 
 
A 
B 
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Chapter 4  
Future Work 
4.1 Studying the contribution of store operated calcium entry 
Calcium exists at concentrations of ~100 nM in the platelet cytoplasm, at 
concentrations of ~10 µM in the platelet stores (Dense Tubular System (DTS)), and at 
levels of ~1.5mM outside the cell. Following agonist stimulation, there are 4 fluxes of 
calcium that regulate net cytoplasmic levels. 1) PLC activation leads to the generation of 
IP3 downstream of receptor activation (see Section 1.2). This leads to the opening of IP3 
gated calcium channels within the platelet DTS, and a sharp increase in cytoplasmic 
calcium levels. 2) The emptying of the intracellular stores is conveyed to the cytoplasmic 
membrane by the calcium sensor STIM-1 [224] and opens up Orai-1 [225] channels on 
the plasma membrane causing a dramatic influx of calcium with the steep concentration 
gradient that exists across the cytoplasm. This component of the signal is called “Store 
Operated Calcium Entry” (SOCE). There are also pumps that actively transport calcium 
against concentration gradients back to regions of higher concentration. 3) Sacro 
Endoplasmic Reticulum Calcium ATPase (SERCA) pumps transport calcium back from 
the cytosol into the DTS and 4) Plasma Membrane Calcium ATPases transport calcium 
back from the cytosol to the extracellular milieu. Most of the PAS experiments reported 
thus far were conducted in the presence of EDTA (except those in Section 3.7). Chelation 
of extracellular calcium allows us to study the component of the net calcium signal 
resulting directly from intracellular release from the DTS, but ignores the contribution of 
SOCE.  
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4.1.1 Dissecting the calcium signal resulting from agonist stimulation 
Separating these components of the net calcium signal (in particular to study the 
contribution of store operated calcium entry) requires selective recalcification protocols 
into a medium where activation proceeds initially in the absence of external calcium 
(using EDTA), as well as judicious use of inhibitors of platelet pumps (Thapsigargin to 
inhibit SERCA, and Carboxyeosin to inhibit PMCA) (Figure 4.1-1). Some initial 
experiments utilizing these approaches to isolate individual components of the calcium 
signal are presented below. These approaches could be explored further. 
 
Figure 4.1-1 The platelet machinery regulating calcium mobilization 
Intracellular calcium concentrations downstream of receptor activation are regulated by 
1) Release of calcium from IP3 gated channels on the DTS, 2) SOCE across the Orai-1 
channels on the plasma membrane after store emptying has been communicated to the 
membrane by the intracellular calcium sensor STM-1, 3) Pumping of calcium back into 
the DTS using SERCA (inhibited by Thapsigargin) pumps and 4) pumping of calcium 
out of the cell using PMCA pumps (inhibited by Carboxyeosin).  
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4.1.2 Recalcification protocols to study biphasic calcium signaling 
Simultaneous study of the net calcium signal in the absence (using EDTA) or 
presence of external calcium allows us to determine the contribution of store operated 
calcium entry. Inclusion of exogenous calcium beyond a certain instant during the time 
course of calcium mobilization, to a medium that previously contained no external 
calcium allows us to study the extent of the SOCE component of the signal for a 
particular duration of the total response. This approach is demonstrated in Figure 4.1-2 
Platelet Rich Plasma was treated with EDTA (first addition). CVX (left) or TRAP 
(right) were then added (second addition) either in the absence of calcium (red) or 
presence of calcium (blue). The difference in integrated area between the blue and red 
curves (before the third addition of calcium in the red transient) represents the total 
difference resulting from the contribution of SOCE in either case. We also note an 
increase in intracellular calcium levels by mere recalcification of agonist untreated 
platelets at t=7 min (green). Calcium can also be added at an intermediate point along the 
complete transient to gauge the level of SOCE resulting for a given state of “emptiness” 
of the DTS. This is shown in the recalcification step at t=7 min for the red transients. In 
contrast to the CVX signal at t=7 min, where a large amount of calcium has been 
released from the store (large integrated area below the transient before recalcification), 
the TRAP stimulus empties a much smaller proportion of the store. This accounts for the 
relatively minor amount of SOCE observed for TRAP in comparison to CVX. 
This experiment can be extended such that recalcification is carried out not just at 
t=7 min, but at several points along the transient. Also, the dependence of SOCE on the 
concentration of agonist used can be established by carrying out such experiments across 
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a wide range of agonist concentrations. Moreover, the driving force for SOCE can be 
controlled by merely adjusting the final level of calcium after recalcification. Finally 
phenotyping of mice with deletions in either STIM1 or Orai-1 [226] would allow one to 
quantify the contributions of these molecules to the overall signal. The ODE based model 
of the platelet developed by Purvis et al [168] does not include the contribution of SOCE 
to the overall calcium signal resulting from ADP stimulation. Experiments such as these 
will be useful to calibrate sub-models of SOCE for inclusion in the existing model.   
 
 
Figure 4.1-2 Recalcification protocols to isolate Store Operated Calcium Entry 
Calcium mobilization in response to CVX (left) and SFLLRN (right) were studied in the 
absence (red) or presence (blue) of external calcium. For experiments carried out in the 
absence of external calcium, recalcification at a certain instant during the time course of 
calcium mobilization allows us to determine the contribution of SOCE beyond that 
instant. Even addition of external calcium without any prior agonist addition (green) 
causes some increase in cytoplasmic due to basal activity of calcium channels on the 
plasma membrane. 
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4.1.3 Use of pharmacological agents to study components of the 
calcium flux that attenuate the overall signal 
The use of the inhibitors for the PMCA and SERCA pumps (Carboxyeosin and 
Thapsigargin), in various sequential cominations allows us to explore the ability of these 
two pumps to attenuate the calcium signal. This approach was utilized to identify 
differnces between TRAP (Figure 4.1-3) and CVX (Figure 4.1-4) signaling. These 
experiments were carried out in EDTA to exclude the possibility of SOCE (and thus 
simplify the analysis of these transients). 
We note that addition of Thapsigargin (Figure 4.1-3) causes calcium levels to 
increase as the SERCA pumps are gradually inhibited (green transient after the first 
addition). This is because the ability of SERCA to compensate for constitutively open IP3 
channels on the DTS is lost. However the platelet’s PMCA pumps are able to compensate 
and the platelet readjusts to a higher steady state of basal calcium. In contrast, inhibition 
of the PMCA pumps (red transient after the first addition) causes an uncontrolled 
increase in cytosolic calcium. Thus the PMCA is the most important controller of the 
constitutive leak out of the DTS, and possible upregulation of SERCA after PMCA 
inhibition cannot compensate. The effect of constitutively open channels on the plasma 
membrane could not be explored in this experiment, because there is no calcium outside 
the cells. Store refilling must constantly occur from extra-cellular calcium to keep the 
platelet at a steady state of 100 nM calcium. 
TRAP treatment after either of these inhibitions causes a spike in calcium.  This 
spike is brought down to basal levels by the unaltered PMCA (green transient after the 
second addition) or the uninhibited SERCA (red transient after the second addition). We 
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note however, that the rate of reduction in signal is faster for the red transient in 
comparison to the green transient after the second addition. This suggests faster kinetics 
for the SERCA pumps (which remain operational in the red transient after the second 
addition) in comparison to the PMCA pumps (which remain operational in the green 
transient after the second addition). The ability of the SERCA pumps is however 
overwhelmed by the continual leak out of the stores in the absence of PMCA activity and 
calcium levels continue to steeply rise (red transient after the second addition). When 
both PMCA and SERCA are inhibited (dark blue transient after the second addition), the 
subsequent addition of TRAP (third addition), causes a brief spike (barely noticeable at 
the high concentations that already exist at the time of TRAP addition because of the 
continuous leak that has occurred previously). This spike is not diminished at all with 
both pumps inhibited, thus confirming that PMCA and SERCA mediated pumping are 
the only mechanisms that attenuate the calcium spike following TRAP stimulation. 
SERCA or PMCA inhibition after prior TRAP stimulation (pink and light blue transients 
respectively after the second addition) cause either the platelet to adjust to a higher steady 
state or an uncontrolled leak out of the DTS as was noted before. Very similar results 
were also obtained for ADP stimulation (results not shown). 
In comparison to the results obtained with TRAP, a CVX signal is regulated 
differently by the PMCA and SERCA pumps (Figure 4.1-4). The CVX signal is not 
diminished as the PMCA is inhibited (red transient after the second addition). This is in 
contrast to the TRAP stimulus where the SERCA is able to compensate atleast to some 
degree for the loss of PMCA (red transient after the second addition in Figure 4.1-3). In 
a separate experiment (results not shown) inhibition of SERCA by thapsigargin causes no 
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change in the rate at which the CVX stimulus is downregulated (Compare this to the 
green transient after the second addition in Figure 4.1-3, where inhibition of SERCA 
causes a slower decay of the calcium spike in comparison to uninhibited platelets 
following TRAP stimulation). These results suggest that the CVX signal is 
downregulated predominantly by the slower PMCA pumps (and not the faster SERCA 
pumps). This is in contast to the Gq coupled ADP or SFLLRN responses which appear to 
be downregulated by both PMCA and SERCA pumps. This could account for the fact 
that a Gq coupled response is quickly brought down to baseline levels, whereas a CVX 
response is long lived. 
 
Figure 4.1-3 Studying the components of the SFLLRN induced calcium signal 
Buffer, the SERCA inhibitor Thapsigargin, the PMCA inhibitor Carboxyeosin and the 
PAR1 activating peptide SFLLRN (TRAP) were added in various sequential 
combinations as indicated in the legend to study the components of the calcium flux 
resulting from TRAP stimulation. All of these experiments were carried out in EDTA (0 
SOCE) and dispenses were made at the instants indicated (20s, 15 min and 30min). These 
experiments demonstrated that the TRAP mediated signal is attenuated by both the 
PMCA and SERCA pumps, and that the PMCA pumps are the predominant controller of 
a steady leak of calcium out of the stores in the absence of refilling via external calcium.  
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Figure 4.1-4 Studying the components of the CVX induced calcium signal 
Buffer, CVX, Thapsigargin and Carboxyeosin were added in varying sequences as 
indicated in the legend to study the components of the calcium flux resulting from CVX 
stimulation. These experiments demonstrated that the CVX mediated signal is attenuated 
predominantly by the slower PMCA pump (in contrast to the TRAP signal which utilizes 
both PMCA and SERCA pumps). 
 
These experiments can be extended further to aid in the calibration of mechanistic 
models of platelet metabolism. The experiments reported have utilized only single doses 
of agonists / pump inhibitors. Studying the effects of different extents of pump inhibition 
or the responses to different doses of agonists will provide a rich dataset for model 
calibration as well as mechanistic insight into the process of calcium metabolism. There 
are reports in literature that suggest the existence of agonist sensitive calcium pools 
within platelets [227]. Using experiments similar to the ones outlined in this section, it 
should be possible to distinguish between these different stores. Finally combinations of 
the selective recalcification protocols (Section 4.1.2) and the use of pump inhibitors 
would allow one to study how SOCE is regulated by the SERCA and PMCA pumps. 
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4.2 Downregulation of collagen signaling by prior thrombin 
stimulation: Differences between thrombin and PAR1+ 
PAR4 peptides 
ADP, thrombin and CVX were added in various sequential combinations where 
the agonists were either added individually, 2 agonists were added followed by a third or 
all three agonists were added together (Figure 4.2-1). Many of the conclusions obtained 
were similar to those in Section 3.4.5  for ADP, the PAR1 peptide (SFLLRN), and CVX. 
However, differences were noted particularly with regard to inhibition of a CVX signal.  
Prior stimulation with ADP, does not affect the ability of thrombin (Figure 4.2-1, 
panel 1) or CVX (Figure 4.2-1, panel 2) to signal (Similar to the effect of prior ADP 
stimulation on the SFLLRN or CVX signals in Figure 3.4-7).  Both thrombin (Figure 
4.2-1, panel 3) and CVX (Figure 4.2-1, panel 5) however cross down regulate the ADP 
signal (Similar to the effect of prior SFLLRN or CVX signals on subsequent ADP 
response in Figure 3.4-7). Also prior stimulation with CVX cross-downregulates 
thrombin response in Figure 4.2-1, panel 6 (Again similar to the ability of CVX to 
downregulate the SFLLRN response in Figure 3.4-7). One of the most intersing 
observations in this experiment however, was the fact that prior stimulation with 
thrombin cross down regulates the CVX response (Figure 4.2-1, panel 4) (In contrast 
SFLLRN does not inhibit the CVX signal in Figure 3.4-7). These observations were also 
observed when a third agonist is added to a well that had received two previous agonists 
in Figure 4.2-1 panels 1-6, or when two agonists are added together followed by a third 
in Figure 4.2-1 panels 7-9, or when all three agonists are added simultaneously 
producing a single burst in calcium in Figure 4.2-1 panels 10.  
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Figure 4.2-1 Sequential additions of ADP, thrombin and CVX 
The agonists ADP, thrombin and CVX were added in various sequential combinations to 
platelet suspensions. In addition to the trends noted in (Figure 3.4-7), we also noticed 
inhibition of the CVX signal by prior thrombin stimulation. Also the thrombin response 
was inhibited by prior CVX stimulation. 
 
We expected initially the responses of thrombin to be identical to those of 
mixtures of the two PAR peptides (SFLLRN and AYPGKF). Indeed several of the 
conditions involving thrombin which are likely to occur in a realistic thrombotic 
environment are very well approximated by mixtures of the PAR peptides (Figure 3.4-8). 
However, to test the distinction between thrombin and mixtures of the PAR peptides over 
a broad range of conditions we tested the effects of additions of sequential mixtures of 
ADP, (SFLLRN+AYPGKF) and CVX (Figure 4.2-2); and compared these to the results 
obtained by adding sequences of ADP, thrombin and CVX (Figure 4.2-2). 
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Figure 4.2-2 Sequential additions of ADP, PAR1+PAR4 peptide mixtures, and CVX 
To distinguish between the responses to thrombin and mixtures of the thrombin receptor 
peptides (SFLLRN and AYPGKF), we added various sequential combinations of ADP, 
(SFLLRN + AYPGKF) and CVX. Trends noted in Figure 3.4-7 remained unchanged, as 
was the ability of CVX to downregulate the (SFLLRN + AYPGKF) response. In contrast 
to thrombin however, mixtures of the PAR peptides do not inhibit CVX signaling. 
 
The results obtained with sequential additions of ADP, PAR1+PAR4 peptides and 
CVX (Figure 4.2-2) were identical to those noted in Figure 3.4-7. However quite 
unexpectedly, an important difference was noted between thrombin and mixtures of the 
PAR peptides. The cross down regulation of the CVX stimulus that was obtained by prior 
thrombin stimulation (Figure 4.2-1, panel 1) was not obtained with mixtures of the PAR 
peptides (Figure 4.2-2, panel 1). This conclusion was consistently observed throughout 
all of the conditons tested across Figure 4.2-1 and Figure 4.2-2 (panels 1, 3, 4 and 7).   
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Thus there is some property of the intact enzyme thrombin that is not reflected by 
synthetic mimics of PAR ligands (cleaved sections of thrombin receptors). One 
possibility is that the enzyme thrombin is able to cleave off GPVI from the platelet 
surface and thus downregulate signaling via this receptor. In contrast synthetic mixtures 
of PAR peptides that do not contain thrombin’s proteoytic activity will not downregulate 
the CVX signal.  This hypothesis is being explored further by looking for cleaved 
fragments of the GPVI receptor using flow cytometric detection of this receptor’s levels. 
Another possibility is that prior thrombin treatment causes the GPVI receptor to be 
internalized or downregulated via receptor pathways not yet identified. Confirmation of 
this hypothesis too requires further experimentation. 
4.3 Incorporating donor specific descriptions of platelet 
function into models of coagulation 
The Platelet-Plasma model developed in Chapter 2, includes a coarse grained 
description of platelet function where unbinding rates of platelet dependent reactions are 
decreased by two orders of magnitude via the ε function as the platelet’s activate with 
thrombin. As a next step ε can be obtained from PAS trained donor specific Neural 
Networks (Chapter 3). In addition to donor specificity, this will allow us to account for 
the combinatorial effects of the autocatalytically released agonists ADP and 
thromboxane. Eventually, a heterogenous model of platelet activation dependent 
enzymatic conversion will be developed; incorporating mass transfer of zymogens from 
the bulk onto the active platelet surface, coagulation factor assembly on discrete binding 
sites provided by the platelet, catalytic conversion of zymogens to active enzymes at 
these sites, and finally the release and diffusion away of these enzymes. 
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Appendix A: Phenotyping of murine platelets 
The high throughput calcium phenotyping protocol that we have developed is 
useful not just to study human platelets but can also be used to study murine platelets. 
This is especially useful for murine platelets, because very low volumes of blood can be 
obtained from mice (about 1 ml from a cardiac puncture for each mouse). Our assay 
allows the simultaneous testing of phenotypes across multiple conditions with several 
replicates in the same plate, using very small volumes of blood. Moreover experiments 
can be designed to compare both wildtype and genetically modified murine platelet 
phenotypes side by side on the same plate, and this allows for the rapid identification of 
genotype-phenotype linkages. 
A.1 Experimental protocol for murine platelet phenotyping 
Blood was drawn from the inferior vena cava of anasthetized mice (100 mg/kg 
Nembutal) using a heparinized syringe (1000 U/ml, 1:100 dilution with blood), diluted 
1:1 with HEPES-Tyrodes buffer, and spun at 800 rpm for 6 min to isolate platelet rich 
plasma (PRP). PRP was diluted with HEN buffer (10 mM HEPES pH 6.5, 1 mM EDTA, 
150 mM NaCl). The HEN buffer was supplemented with 1 µM PGE1 during the wash 
steps to prevent unwarranted platelet activation during rapid sedimentation. Platelets 
were sedimented at 1300 rpm for 15 min and then resuspended in HEPES-Tyrode’s 
buffer to the desired platelet counts. 
Washed platelets pooled from two mice of each genotype (either regular or 
genetically modified) were resuspended in 1.5 ml of HEPES-Tyrode’s buffer containing 
1 U/ml apyrase and 1 µM PGE1 and incubated with 25 µl of Fura-2AM in DMSO (1 
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mg/ml) for 45 min in the dark. Afterwards the platelets were washed with HEN buffer 
and resuspended in HEPES-Tyrode’s buffer at 2×108 platelets/ml. A 384 well microtiter 
plate containing platelet agonists was prepared on a Perkin Elmer Janus. A separate 
microtiter plate containing diluted platelet suspension (1×106 platelets/well) was prepared 
on a Perkin Elmer Evolution. Agonists were dispensed on a Molecular Devices 
FlexStation. Fura 2 fluorescence was measured at excitation 340/380 nm and emission 
510 nm for 4 minutes in every column of the plate. The 340/380 fluorescence ratio R(t) 
was scaled to the mean baseline values for each well R0(t) and relative calcium 
concentrations were quantified as R(t)/ R0(t). All conditions were tested in replicates of 8. 
A.2 Mice with substitution in Gi2α rendering resistance to RGS 
signaling 
This study explored one of the intrinsic mechanisms that prevent overly robust 
platelet activation following vascular injury (in contrast to extrinsic regulators of platelet 
function such as NO and PGI2). To study the role of RGS (Regulators of G Protein 
Signaling) proteins in platelets, mice with a G184S substitution in Gi2α that blocks 
RGS/Gi2 interactions were phenoyped. This allows us to examine the consequences of 
lifting constraints on Gi2 dependent signaling without altering receptor effector coupling. 
The results showed that the Gi2α (G184S) allele enhances platelet aggregation in vitro and 
increases platelet accumulation following vascular injury. These changes occur in concert 
with an attenuated rise in cAMP levels in response to PGI2 and a substantial increase in 
basal Akt activation.  
Because of suggestions in literature that Gi derived Gβγ can activate phospholipase 
Cβ, we explored the effect of the Gi2α (G184S) substitution on changes in cytosolic Ca++ 
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concentration when Gi2α (+/G184S) and matched control platelets were incubated with 
ADP, AYPGKF, U46619 or convulxin. Each agonist tested caused an increase in 
cytosolic Ca++, but the extent of the increase was unaffected by the presence of the Gi2α 
(G184S) substitution (Figure A.2-1).  This finding was consistent with the unperturbed 
timing and extent of Rap1b activation in response to ADP (one of the critical steps 
leading to αIIbβ3 activation in platelets downstream of Gq mediated increases in cytosolic 
calcium). It suggests that in this context, there is no crosstalk between Gi2 and Gq 
mediated pathways in the presence of the G184S mutation.  (The calcium phenoyping 
experiments in this section were done in collaboration with Rachel Signarvic). 
These experiments collectively 1) demonstrated an active role for RGS proteins in 
regulating platelet responsiveness, and 2) suggested that RGS proteins help to prevent 
unwarranted platelet activation and limit the magnitude of haemostasis [228]. 
 
Figure A.2-1 Comparison between platelet calcium mobilization phenotypes of 
wildtype and Gi2α knockin mice 
Gi2α (+/G184S) and matched control platelets were loaded with Fura-2 and stimulated 
with several concentrations of each of the indicated agonists. Ca++ dependent Fura-2 
fluorescence over time for each agonist was measured for wild type and Gi2α (+/G184S) 
platelets. A comparison of average maximal fluorescence over the range of agonist 
concentrations studied for each genotype is shown above. Each curve represents the 
average of 8 replicates. The experiment was performed twice with similar results 
obtained. Blood obtained from 2 mice of each genotype was used for each experiment.  
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A.3 ESAM-/- mice 
Endothelial cell Specific Adhesion Molecule (ESAM), normally found in the 
alpha granules of quiescent platelets, is expressed in abundance on the cell surface 
following activation. ESAM localizes to the junctions between adjacent platelets 
following platelet activation, suggesting a role for this protein in contact dependent 
events that regulate thrombus formation. This study explored the role of ESAM by 
phenotyping ESAM deleted platelets. 
In vivo, ESAM-/- mice achieved more stable hemostasis than wild-type mice 
following laser injury of cremaster muscle arterioles. In vitro, ESAM-/- platelets 
aggregated at lower concentrations of G protein-dependent agonists than wild type 
platelets, and were more resistant to disaggregation. 
To examine whether ESAM regulates early platelet signaling events downstream 
of agonist stimulation, calcium mobilization was measured in ESAM null platelets and 
this phenotype was compared to that of wildtype platelets. Calcium mobilization in 
response to either a PAR-4 agonist peptide or ADP was the same in ESAM-/- platelets as 
in wild type controls (Figure A.3-1). (The calcium phenoyping experiments in this 
section were done in collaboration with Tim Stalker). 
Similarly integrin activation measured by flow cytometry using an antibody 
selective for the active conformation of αIIbβ3 (or by measuring FITC-labeled fibrinogen 
binding) did not differ between ESAM-/- and wild type platelets.  Neither was there any 
appreciable difference in platelet spreading or alpha granule secretion phenotypes 
between wildtype and ESAM-/- platelets. These observations suggest that the gain of 
function observed in the absence of ESAM for aggregation or in vivo thrombosis were 
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not because of inside out signaling events but were rather dependent on post- aggregation 
signaling. 
To understand the molecular mechanism by which ESAM regulates platelet 
activity, a PDZ domain array was used to identify the scaffold protein NHERF-1 as an 
ESAM binding protein, and further experiments were carried out to demonstrate that this 
protein associates with ESAM in both resting and activated platelets. 
Taken together, these findings support a model in which ESAM localizes to 
platelet contacts following platelet activation in order to limit thrombus growth and 
stability so that the optimal hemostatic response occurs following vascular injury [33]. 
 
 
Figure A.3-1 Comparison between platelet calcium mobilization phenotypes of 
wildtype and ESAM knockout mice 
Calcium mobilization in response to ADP (left panel) and the PAR4 agonist AYPGKF 
(right panel) were measured using the fluorescent calcium indicator Fura-2. Values are 
mean ± SD and are representative of two independent experiments. ESAM did not have 
any effect in regulating calcium mobilization in isolated mouse platelets. 
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